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Physical Assessment
1
BASICS
Name: Room: Age: 
Diagnosis:
Surgeries/Past Hx:
Activity: Diet: DNR/DNI:
Allergies:
Neurological/MS:
ICP:
Cardiac:
VS/A-line:
ECG:
Hemodynamics: PAD PAS PCWP CVP
IABP:
Respiratory:
Ventilator:
ABGs/SpO2:
GI:
GU:
Wounds/Incisions:
Drainage Tubes:
Treatments:
Special Needs:
Other:
Reusable Assessment Form
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Acid-Base Disorder pH PCO2 HCO3
Respiratory acidosis ↓ if compensating
Respiratory alkalosis ↓ ↓ If compensating
Metabolic acidosis ↓ ↓ if compensating ↓
Metabolic alkalosis if compensating
2
BASICS
Normal Arterial and Venous Blood Gases
Blood Gas 
Components Arterial Venous
pH 7.35–7.45 7.31–7.41
PO2 80–100 mm Hg 35–40 mm Hg
PCO2 35–45 mm Hg 41–51 mm Hg
HCO3 22–26 mEq/L or mmol/L 22–26 mEq/L or mmol/L
Base Excess (BE) –2 to +2 mEq/L or mmol/L –2 to +2 mEq/L or mmol/L
O2 saturation 95%–100% 68%–77%
↓
Arterial Venous
pH
PO2
PCO2
HCO3
Base Excess (BE)
O2 saturation
Full or total compensation: pH will be within normal limits
Blood Gas Results
Quick Blood Gas Interpretation
↓
↓
↓↓↓
↓
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Compensation:
■ Respiratory problem → the kidneys compensate by conserving or
excreting HCO3

■ Metabolic problem → the lungs compensate by retaining or blowing
off CO2
Also look for mixed respiratory and metabolic problems.
PaCO2 or HCO3
 in a direction opposite its predicted direction or not close
to predictive value.
Common Causes of Acid-Base Imbalances
3
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Respiratory acidosis COPD, asthma, head injury, pulmonary 
edema, aspiration, pneumonia, ARDS, pneu-
mothorax, cardiac arrest, respiratory depres-
sion, CNS depression, or head injury
Respiratory alkalosis Hyperventilation, anxiety, fear, pain, 
fever, sepsis, brain tumor, mechanical 
overventilation
Metabolic acidosis Diabetes mellitus, acute and chronic renal
failure, severe diarrhea, alcoholism, starva-
tion, salicylate overdose, pancreatic 
fistulas
Metabolic alkalosis Loss of gastric acid (vomiting, gastric 
suction), long-term diuretic therapy 
(thiazides, furosemide), excessive NaHCO3
administration, hypercalcemia
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4BASICS
Pulse Oximetry
SpO2 monitoring: Monitoring saturation of peripheral O2
False readings may occur because of anemia, CO poisoning, hypothermia,
hypovolemia, peripheral vasoconstriction caused by disease or medications.
Lactic Acidosis
Lactic acid is a byproduct of anaerobic metabolism. Increased levels indi-
cate inadequate perfusion of vital organs with resultant tissue hypoxia.
May result from inadequate perfusion and oxygenation of vital organs;
post cardiac or respiratory arrest; cardiogenic, ischemic, or septic shock;
drug overdoses, seizures, cancers, or diabetes mellitus.
Critical values: Blood pH, <7.35, and lactate >5–6 mEq/L or >45 mg/dL.
Treat with sodium bicarbonate IV if acidosis is readily evident.
Capnography
Capnography is the measurement, display, and monitoring of the concen-
tration or partial pressure of CO2 (PETCO2) in the respiratory gases 
at the end of expiration. The capnogram displays the maximum inspirato-
ry and expiratory CO2 concentrations during a respiratory cycle, which
indirectly reflect the production of CO2 by the tissues and the transport of
CO2 to the lungs. Sudden changes in CO2 elimination should be moni-
tored in selected cardiorespiratory patients and postoperatively after
major cardiothoracic surgeries. Capnography can also be used to verify
ETT position and monitor the effectiveness of CPR.
SpO2 Level Indication
>95% Normal
91%–94% May be acceptable, provide O2 as necessary, encourage
C&DB or suction prn
85%–90% Provide O2 as necessary, encourage C&DB or suction prn,
may be normal for COPD patient
<85% Prepare for possible intubation
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5BASICS
Causes of    PETCO2 Causes of ↓ PETCO2
Fever Hypothermia
Hypertension Hypotension
Increased cardiac output Decreased cardiac output
Hypoventilation Hyperventilation
Hypovolemia Hypervolemia
Airway obstruction Airway obstruction
Bronchial intubation Accidental extubation
Pulmonary embolus
Cardiac arrest
Apnea
Normal range of ETCO2 is 35–45 mm Hg
RR (hyperventilation) → ↓ CO2 → ETCO2 < 35 = respiratory alkalosis
↓ RR (hypoventilation) → CO2 → ETCO2 > 45 = respiratory acidosis
There are five characteristics of the capnogram that should be evaluated:
frequency, rhythm, height, baseline, and shape.
Normal Capnogram
↓
↓
Phases I, II, and III represent expiration, the bolded lines represent inspira-
tion. Long periods of a flat wave form indicate apnea, dislodged endotra-
cheal tube, esophageal intubation, or patient disconnect from ventilator.
↓
I
II
III
Expiration Inspiration
m
m
 H
g
Time
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6BASICS
Artifical Airways and Mechanical Ventilation
Artifical Airways
Endotracheal Tube
■ Adult oral tube sizes: Males 8.0–8.5, I.D. (mm); females 7.0–8.0. 
I.D. (mm) (internal diameter).
■ Placement is 2 cm above the carina. Verify by auscultating for breath
sounds bilaterally, uniform up-and-down chest movement, CXR, and
checking end-tidal CO2 immediately after intubation.
■ Cuff pressure: 20–25 mm Hg.
Tracheostomy Tube
■ Size will vary.
■ Cuff pressure: 20–25 mm Hg.
Minimal leak technique or minimal occluding volume verifies that an ETT
or tracheostomy tube is at its lowest inflation point. Attach a 10-mL syringe
to the balloon of the inflated cuff. Position your stethoscope on the
patient’s neck at the area of the carotid pulse. Inflate balloon cuff to a point
where no leak is heard. Slowly remove air from the inflated cuff until you
hear a slight leak at the height of inspiration. Then add 1 mL of air back into
the cuff.
Cuff pressure can also be monitored via a calibrated aneroid manome-
ter device. Connect manometer to cuff. Deflate cuff. Reinflate cuff in 0.5
mL increments until desired cuff pressure is achieved. Check cuff pressure
every 8–12 hrs or per agency protocol.
Mechanical Ventilation
Classification of Ventilators
Positive Pressure Ventilation
■ Volume-Cycled Ventilator: Delivers a preset constant volume of air
and preset O2.
■ Pressure-Cycled Ventilator: Produces a flow of gas that inflates the
lung until the preset airway pressure is reached.
■ Time-Cycled Ventilator: Programmed to deliver a volume of gas over
a specific time period through adjustments in inspiratory-
to-expiratory ratio.
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■ High-Frequency Jet Ventilator (HFJV): Delivers 60–100 bpm with low
tidal volumes under considerable pressures.
Negative Pressure Ventilation
Uses the old iron lung principle by exerting a negative pressure on the
chest wall to cause inspiration. No intubation required. Custom fitted
“cuirass” or “turtle” shell unit that fits over the chest wall. May be utilized
at night for patients who require assistance during sleep.
Modes of Ventilation
■ Controlled Mechanical Ventilation (CMV): Machine controls rate of
breathing. Delivery of preset volume (TV) and rate regardless of
patient’s breathing pattern. Sedation or paralyzing agent (e.g.,
Pavulon) usually required.
■ Assist Controlled Ventilation (ACV): Patient controls rate of breathing.
Inspiratory effort triggers delivery of preset volume.
■ Intermittent Mandatory Ventilation (IMV): Patient breathes sponta-
neously (own tidal volume) between ventilator breaths of a preset
volume and rate. 
■ Synchronized Intermittent Mandatory Ventilation (SIMV): A form of
pressure support ventilation. Administers mandatory ventilator breath
at a preset level of positive airway pressure. Monitors negative inspira-
tory effort and augments patient’s spontaneous tidal volume or inspira-
tory effort. Synchronized with patient’s breathing pattern.
■ Positive End-Expiratory Pressure (PEEP): Increases oxygenation by
increasing functional residual capacity (FRC). Keeps alveoli inflated
after expiration. Can use lower O2 concentrations with PEEP; decreas-
es risk of O2 toxicity. Ordered as 5–10 cm H2O.
■ Continuous Positive Airway Pressure (CPAP): Maintains positive
pressure throughout the respiratory cycle of a spontaneously breath-
ing patient. Increases the amount of air remaining in the lungs at the
end of expiration. Less complications than PEEP. Ordered as 5–10 cm
H2O. 
■ Bilevel Positive Airway Pressure (BiPAP): Same as CPAP but settings
can be adjusted for both inspiration and expiration.
■ Pressure Support Ventilation (PSV): Patient’s inspiratory effort is
assisted by the ventilator to a certain level of pressure. Patient initiates
all breaths and controls flow rate and tidal volume. Decreases work of
breathing. 
7
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8BASICS
■ Inverse Ratio Ventilation (IRV): All breaths are pressure limited and
time cycled. Inspiratory time usually set longer than expiratory
time.
IMV, SIMV, CPAP, BiPAP and PSV can all be used in the weaning process.
Weaning
Sample Criteria for Weaning: Readiness
■ Alert and cooperative
■ FIO2 < 40%–50% and PEEP <5–8 cm H2O
■ Hemodynamically stable
■ pH >7.34
■ PaO2 >80 mm Hg
■ PaCO2 <45 mm Hg
■ PaO2/FIO2 ratio >200
■ Vital capacity 15 mL/kg and minute ventilation <10
■ Hemoglobin >7–9 g/dL and serum electrolytes within normal limits
■ Spontaneous respirations >6 b/min. or <35 b/min.
■ Negative inspiratory pressure –30 cm H2O
■ Relatively afebrile with limited respiratory secretions
■ Inotropes reduced or unchanged within previous 24 hrs
■ Sedation discontinued
Weaning Methods
■ T-tube weaning: Place patient on T-tube circuit on same FIO2 as on
ventilatory assistance. Monitor ABGs after 30 min. Provide a brief rest
period on the ventilator as needed and continue to monitor ABGs
until satisfactory. Extubate when patient is rested, good spontaneous
respiratory effort, and ABGs within acceptable parameters.
■ IMV/SIMV weaning: Decrease IMV rate every 1–4 hrs. Monitor spon-
taneous breaths. Obtain ABGs within 30 min. of ventilator change.
Allows for gradual change from positive-pressure ventilation to spon-
taneous-pressure ventilation.
■ PSV: Use low levels of PSV (5–10 cm H2O). Decrease in 3–6 cm of H2O
increments. Useful in retraining respiratory muscles due to long-term
ventilation.
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■ CPAP/BiPAP: Provides expiratory support, maintains positive intratho-
racic pressure. BiPAP adds inspiratory support to CPAP. Prevents res-
piratory muscle fatigue.
Nursing assessment during weaning
■ Vital signs and hemodynamics (PAS, PAD, PCWP, CO, CI)
■ Dysrhythmias or ECG changes
■ Oxygenation/Efficiency of gas exchange
■ CO2 production and elimination
■ pH level
■ Bedside pulmonary function tests
■ Work of breathing including use of accessory muscles
■ Level of fatigue
■ Patient discomfort
■ Adequate nutrition 
Ventilator Alarms
Ventilator alarms should never be ignored or turned off. They may be
muted or silenced temporarily until problem is resolved.
Checklist of Common Causes of Ventilator Alarms
Patient causes:
■ Biting down on endotracheal tube
■ Patient needs suctioning
■ Coughing
■ Gagging on endotracheal tube
■ Patient “bucking” or not synchronous with the ventilator
■ Patient attempting to talk
■ Patient experiences period of apnea
Mechanical causes:
■ Kinking of ventilator tubing
■ Endotracheal tube cuff may need more air
■ Leak in endotracheal tube cuff
■ Excess water in ventilator tubing
■ Leak or disconnect in the system
■ Air leak from chest tube if present
■ Malfunctioning of oxygen system
■ Loss of power to ventilator
9
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Pathophysiological causes:
■ Increased lung noncompliance, such as in ARDS
■ Increased airway resistance, such as in bronchospasm
■ Pulmonary edema
■ Pneumothorax or hemothorax
Nursing Interventions
■ Check ventilator disconnects and tubing.
■ Assess breath sounds, suction as needed.
■ Remove excess water from ventilator tubing.
■ Check endotracheal cuff pressure.
■ Insert bite block or oral airway.
If cause of the alarm cannot be found immediately or cause cannot be
readily resolved, remove patient from ventilator and manually ventilate
patient using a resuscitation bag.
Call respiratory therapy stat.
Continue to assess patient’s respiratory status until mechanical ventila-
tion is resumed.
Ventilator Complications
Complication Signs & Symptoms/Interventions
• High peak inspiratory and mean airway
pressures
• Diminished breath sounds
• Tracheal shift
• Subcutaneous crepitus
• Hypoxemia
Insert chest tube or needle thoracostomy.
• Absent or diminished breath sounds in 
left lung
• Unilateral chest excursion
Reposition ETT.
Barotrauma or 
volutrauma—acute lung
injury, may result in pneu-
mothorax or tension pneu-
mothorax, pneumomedi-
astinum, pneumoperi-
toneum, subcutaneous
crepitus
Intubation of right main-
stem bronchus
Continued
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Ventilator Complications—Cont’d
Complication Signs & Symptoms/Interventions
• Absent or diminished breath sounds
Note location of tube at the lip (21–22 cm).
Reposition ETT or reintubate.
Restrain only when necessary.
• Blood in sputum when suctioning
• Frequent ventilator alarm
Monitor ETT cuff pressure every 4–8 hrs.
Perform minimal leak technique.
Ensure minimal occluding volume.
• Skin breakdown or necrosis to lips,
nares, or oral mucous membranes
Reposition tube side-side of mouth every
day.
Apply petroleum jelly to nares.
Provide oral care with toothbrush every 
2 hrs.
• Feeding viewed when suctioning
• If blue dye is used, sputum is blue in color
Use blue dye with enteral feedings if 
aspiration suspected. 
Keep head of bed 30–45 degrees.
Administer proton pump inhibitors or his-
tamine H2-receptor antagonists.
• Refer to section on VAP
Assess color and odor of sputum.
Monitor temperature, WBC count, ESR.
• Hypotension
• Decreased CVP, RAP, and preload
Monitor vital signs and hemodynamics.
Endotracheal tube out of
position or unplanned extu-
bation
Tracheal damage due to
excessive cuff pressure
(>30 cm H2O)
Damage to oral or nasal
mucosa
Aspiration
Tracheo-esophageal 
fistulas
Ventilator-assisted 
pneumonia
Respiratory infection
Increased risk of sinusitis
Decreased venous return
→ decreased cardiac out-
put due to increased
intrathoracic pressure
Continued
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Ventilator Complications—Cont’d
Complication Signs & Symptoms/Interventions
• Blood in nasogastric drainage
• Hematemesis and/or melena
Hematest nasogastric drainage, emesis,
feces.
Administer proton pump inhibitors or his-
tamine H2-receptor antagonists.
• Absence of diminished bowel sounds
Provide nasogastric drainage with 
intermittent suction.
Turn and position patient frequently. 
• Refer to section on nutrition.
Start enteral feedings if appropriate.
Start total parenteral nutrition if GI tract
nonfunctional or contraindicated. 
• Changes in level of consciousness
• Unable to follow commands
Assess neurological status frequently.
Assess for edema.
Administer diuretics.
Drain ventilator tubing frequently.
Turn and position patient frequently.
Assess skin for breakdown.
Assist patient out of bed to chair unless
contraindicated.
Keep skin clean and dry, sheets wrinkle-
free.
Keep communication simple.
Obtain slate or writing board. 
Use letter/picture chart.
Communicate using sign language.
Stress ulcer and 
GI bleeding
Paralytic ileus
Inadequate nutrition, loss
of protein
Increased intracranial 
pressure
Fluid retention due to
increased humidification
from ventilator, increased
pressure to baroreceptors
causing a release of ADH
Immobility
Skin breakdown
Communication difficulties
Continued
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Ventilator Complications—Cont’d
Complication Signs & Symptoms/Interventions
• Urine becomes cloudy, concentrated,
odorous
Change/remove Foley catheter.
Ensure adequate hydration.
Administer antiinfectives.
• Painful, swollen leg; pain may increase
on dorsiflexion
Assess for pulmonary embolism. See 
respiratory section.
Administer heparin or enoxaparin.
• Anxious
• Difficulty sleeping
• Poor pain control
Administer anxiolytics, sedatives, 
analgesics.
Cluster activities to promote periods of
sleep.
Allow patient to make choices when
appropriate.
Allow for frequent family visits.
Keep patient and family informed.
Urinary tract infection
Deep vein thrombosis
Psychosocial concerns:
fear, loss, powerlessness,
pain, anxiety, sleep distur-
bances, nightmares, loneli-
ness
Hemodynamic Monitoring
Hemodynamic Parameters
Arteriovenous oxygen difference  . . . . . . . . . . . 3.5–5.5 vol% or 4–8 L/min
Aortic pressure:
■ Systolic  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .100-140 mm Hg
■ Diastolic  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .60–80 mm Hg
■ Mean  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .70–90 mm Hg
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Cardiac output (CO = HR X SV)  . . . . . . . . . . . . . . . . . . . . . . . . . . .4–8 L/min
Cardiac index (CO/BSA)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2.5–4 L/min
Central venous pressure (CVP)  . . . . . . . . . . . . . . . . . . . . . . . . .2–8 mm Hg
** Same as right atrial pressure (RAP)
Cerebral perfusion pressure (CPP)  . . . . . . . . .2–6 mm Hg or 5–12 cm H2O
Coronary artery perfusion pressure (CAPP)  . . . . . . . . . . . . .60–80 mm Hg
Ejection fraction (Ej Fx or EF)  . . . . . . . . . . . . . . . . . . . . . . . . . . . .60%–75%
Left arterial mean pressure  . . . . . . . . . . . . . . . . . . . . . . . . . . .4–12 mm Hg
Left ventricular systolic pressure  . . . . . . . . . . . . . . . . . . . .100–140 mm Hg
Left ventricular diastolic pressure  . . . . . . . . . . . . . . . . . . . . . . .0–5 mm Hg
Left ventricular stroke work index (LSWI)  . . . . . . . . . . . .30–50 g/beats/m2
Mean arterial pressure (MAP)  . . . . . . . . . . . . . . . . . . . . . . .70–100 mm Hg
Oxygen consumption (VO2)  . . . . . . . . . . . . . . . . . . . . . . . .200–250 mL/min
Oxygen delivery (Do2)  . . . . . . . . . . . . . . . . . . . . . . . . . . . .900–1100 mL/min
Pulmonary artery pressure (PAP): 
■ Systolic  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .20–30 mm Hg
■ Diastolic  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .10–20 mm Hg
■ Mean . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .10–15 mm Hg
Pulmonary capillary wedge pressure (PCWP) . . . . . . . . . . . . .4–12 mm Hg
Right arterial mean pressure  . . . . . . . . . . . . . . . . . . . . . . . . . . .2–6 mm Hg
Right ventricular pressure: 
■ Systolic  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .20–30 mm Hg
■ Diastolic  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .0–8 mm Hg
■ End Diastolic  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2–6 mm Hg   
Right ventricular stroke work index (RSWI) . . . . . . . . . . . . .7–12 g/m2/beat
Pulmonary vascular resistance (PVR)  . . . . . . . . . . .20–130 dynes/sec/cm-5
Pulmonary vascular resistance index (PVRI)  . . . . . . . .200–400 dynes/sec/
cm5/m2
Pulmonary ventricular stroke index  . . . . . . . . . . . . . . . . . . .5–10 g/beat/m2
Right atrial pressure (RAP)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2–6 mm Hg
Stroke index (SI)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .30–650 mL/beat/m2
Stroke volume (SV = CO/HR)  . . . . . . . . . . . . . . . . . . . . . . . . .60–100 mL/beat
Systemic vascular resistance (SVR)  . . . . . . . . . .900–1,600 dynes/sec/cm-5
Systemic vascular resistance index  . . . . . .1,360–2,200 dynes/sec/cm-5/m2
Systemic venous oxygen saturation (SvO2)  . . . . . . . . . . . . . . . . .60%–80%
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Pulmonary Artery Catheter
The purpose of the pulmonary artery catheter, also known as the Swan-
Ganz catheter, is to assess and monitor left ventricular function and can
determine preload, assess contractility, and approximate afterload.
PCWP approximates left atrial pressure and left ventricular end diastolic
pressure. 
Increases in PCWP, LAP, or LVEDP indicates heart failure, hypervolemia,
shock, mitral valve insufficiency, or stenosis. Decreases in PCWP, LAP, or
LVEDP indicate hypovolemia.
PA Catheter Waveforms
The pulmonary artery catheter is threaded through the right atrium and
right ventricle and into the pulmonary artery. Insertion is done via fluo-
roscopy or monitoring waveform changes.
15
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Preload Contractility Afterload
PaO2 SaO2 Hemoglobin (Hgb)
Right atrial pressure Stroke volume Pulmonary vascular resistance
Central venous Cardiac output Systemic vascular resistance
pressure
Left ventricular Tissue perfusion Blood pressure
end diastolic
pressureP
m
m
 H
g
Time
Right atrium10
0
20
30
40
Balloon catheter
Catheter advanced 
to right atrium, 
balloon is 
inflated. Pressure 
is low, usually 
2–5 mm Hg.
Cardiac Output Components
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Pulmonary
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Pulmonary
artery wedge
m
m
 H
g
Time
10
0
20
30
40
Balloon
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Catheter is floated 
to right ventricle 
with the balloon 
inflated. Wave-
forms indicate a 
systolic pressure 
of 25–30 mm Hg 
and a diastolic 
pressure of 
0–5 mm Hg.
As the catheter 
moves into the 
pulmonary artery, 
the systolic pres-
sure remains the 
same but the dia-
stolic pressure ele-
vates to 10–15 
mm Hg.
The catheter is 
moved until it can 
be wedged in a 
smaller vessel. 
When the balloon 
is inflated, the 
pressure recorded 
is that pressure in 
front of the 
catheter. It is an 
approximate 
measure of the 
left ventricular 
end diastolic 
pressure.
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Complications of Pulmonary Artery Catheters
■ Risk for infection
■ Altered skin integrity
■ Air embolism
■ Pulmonary thromboembolism
■ Cardiac tamponade
■ Dysrhythmias
■ Altered cardiopulmonary tissue perfusion due to thrombus formation;
catheter in wedged position leading to pulmonary infarction 
■ Catheter displacement/dislodgement
■ Loss of balloon integrity or balloon rupture
■ Pneumothorax
■ Hemothorax
17
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Problems with Pulmonary Artery Catheters
Problem Check For/Action
No waveform • Loose connections
• Tubing kinked or compressed
• Air in transducer
• Loose/cracked transducer
• Stopcock mispositioned
• Occlusion by clot: Aspirate as per policy
Overdamping (smaller • Air bubble or clot in the system
waveform with slow • Catheter position: Reposition patient or 
rise, diminished or have patient cough
absent dicrotic notch) • Kinks or knotting
• Clot: Aspirate as per policy
Catheter whip (erratic • Catheter position: Reposition patient or 
waveform, variable catheter; obtain chest x-ray
and inaccurate 
pressure)
Inability to wedge • Balloon rupture: Turn patient on left side; 
catheter (no wedge check catheter position for retrograde 
waveform after slippage
inflating balloon)
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■ Frank hemorrhage
■ Pulmonary artery extravasation
■ Pulmonary artery rupture
Intra-Arterial Monitoring
An arterial line (A-line) is used if frequent blood pressure and arterial
blood gas determinations are needed. It is especially useful
■ After surgery.
■ For patients with unstable vital signs.
■ For patients experiencing hypoxemia.
Perform Allen’s test prior to insertion. Elevate the patient’s hand with his
or her fists clenched. Release pressure over only the ulnar artery. Color
returns to the hand within 6 seconds if the ulnar artery is patent and ade-
quate collateral blood flow present.
Compressing the radi-
al and ulnar arteries
Observing for pallor Releasing pressure
and observing for
return of normal color
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Intra-Arterial Waveform
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Components of Waveform
■ Systolic peak: Ventricular ejection and stroke volume. Sharp rise and
rounded top.
■ Dicrotic notch: Aortic valve closure, end ventricular systole, start ven-
tricular diastole. Should be one-third or greater of height of systolic
peak. If lower → suspect ↓ C.O.
Tapering of down stroke following dicrotic notch
Important assessments: changes in capillary refill/blanching, sensation,
motion, or color that may indicate lack of perfusion to the extremity
systolic BP  (diastolic BP  2) 
3
Decreased tissue perfusion—decreasing urine output, elevation in
BUN:Creatinine ratio, altered mental status with decreasing level of
consciousness, restlessness, dyspnea,  cyanosis, dysrhythmias, abnor-
mal ABGs, weak or absent peripheral pulses, increased capillary refill
time (>3 sec), diminished arterial pulsations, bruits.
MAP  = 70–100 mm Hg
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Potential Complications of Intra-Arterial Monitoring
■ Hemorrhage
■ Air emboli
■ Equipment malfunction/inaccurate pressure
■ Dysrhythmias
■ Infection
■ Altered skin integrity
■ Impaired circulation to extremities
Nutrition Issues in Critical Care
Primary Concerns
■ Starvation and catabolism
■ Stress hypermetabolism
■ Fluid volume deficit
■ Fluid volume excess
Stress and Nutrition
Prolonged or continual stress depletes glycogen stores → hypermetabol-
ic state.
Metabolic rate increases with the release of catecholamines + glucagon
+ cortisol → hyperglycemia and “stress diabetes.”
Protein is lost via gluconeogenesis → decrease in serum protein 
(albumin).
Lipolysis → increase in free fatty acids.
Nitrogen excretion increases.
Body weight decreases.
1 kg body weight = 1 liter of fluid retained or lost.
Body Mass Index
BMI is a simple means of classifying sedentary (physically inactive) individ-
uals of average body composition and may indicate obesity. It is calculated
by the following: Body mass index (BMI) = weight (kg) ÷ height (meters)2
1 kg = 2.2 lbs Normal BMI = 20–25 kg/m2
20
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A BMI >30 kg/m2 indicates obesity, >40 kg/m2 indicates morbid obesity. An
increase in BMI has been associated with heart disease and diabetes.
A BMI <18.5 kg/m2 suggests a person is underweight. A BMI <17.5 may
indicate the person has anorexia or a related disorder.
BMI does not take into account factors such as frame size and 
muscularity.
Signs and Symptoms of Fluid Volume Deficit:
Hypovolemia
■ Dry mucous membranes; dry cracked tongue
■ Thirst
■ Poor skin turgor
■ Sunken eyeballs
■ Subnormal temperature
■ Decreased or orthostatic blood pressure
■ Weak, rapid heart rate and increased respiratory rate
■ Decreased capillary refill
■ Urine output decreased (<30 mL/hr)
■ Increased specific gravity of urine (<1.030)
■ Decreased central venous pressure
■ Increased hemoglobin and hematocrit
■ Increased BUN and serum osmolarity
■ Increased BUN:creatinine ratio
■ Lethargy, mental confusion
Signs and Symptoms of Fluid Volume Excess:
Hypervolemia
■ Crackles in lungs; dyspnea, shortness of breath
■ Decreased hemoglobin and hematocrit
■ Decreased specific gravity of urine
■ Distended neck veins and jugular venous pressure
■ Edema and decreased serum osmolarity
■ Full, bounding pulse; tachycardia
■ Increased BP, CVP, and PAP
21
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■ Mental confusion, restlessness
■ Moist mucous membranes
■ Pulmonary congestion or pleural effusion
■ Weight gain
Enteral Tube Feedings
Gastric Access
■ Nasogastric tube (NGT)
■ Oral
■ Percutaneous endoscopic gastrostomy (PEG)
■ Nasoduodenal tube (NDT)
■ Low-profile gastrostomy device (LPGD)
Small Bowel Access
■ Nasal-jejunal tube (NJT)
■ Percutaneous endoscopic jejunostomy (PEJ)
Types of Tube Feedings
■ Intermittent or bolus feedings: A set volume of formula is delivered
at specified times.
■ Continuous feedings: A set rate of formula is delivered over a 
period of time.
■ Cyclic feedings: Similar to a continuous feeding but the infusion is
stopped for a specified time within a 24-hour period, usually 6–10 hours.
Checking Tube Placement
■ Aspirate gastric contents and check pH.  
■ Gastric aspirate pH 1–4 but may be as high as 6 if patient is on med-
ication to reduce gastric acid (famotidine, ranitidine, pantoprazole). 
■ Small intestine aspirate pH >6.
■ Obtain chest x-ray.
■ Inject 20–30 mL of air into the tube while auscultating over the epi-
gastrium. Air in the stomach can be heard via a swooshing sound.
BASICS
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Feeding Tube Complications
Mechanical Complications Interventions
Nasopharyngeal discomfort • Reposition tube.
Esophageal ulceration or bleeding • Consider PEG or PEJ tube.
esophageal varices
Clogged tube • Flush with lukewarm water after
every feeding.
Hosp. Protocol:
Tube displacement • Reposition tube.
Extubation • Insert new tube.
• Consider PEG or PEJ tube.
Stomal leak or infection • Keep area around stoma clean 
and dry. 
Nonmechanical Complications Interventions
Nausea, vomiting, cramps, • Withhold or decrease 
bloating, abdominal distention amount, rate, and frequency 
of feedings.
• Change to low-fat formula.
Diarrhea • Withhold or decrease amount,
rate, and frequency of feedings.
Aspiration • Hold feedings. Check 
residuals.
• Keep HOB elevated 30°–45°
during feedings and 1 hr. after
bolus feedings.
Tube-Feeding Formulas
Standard Very High-Protein/Wound-Healing
Pediatric Fiber-Containing
Diabetic Elemental and Semi-Elemental
Pulmonary Immune-Enhancing or Stress Formulas
Renal Concentrated
23
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Checking for Residuals
1. Assess every 4–6 hrs for continuous feeding and prior to bolus 
feeding.
2. Using a 30- to 60-mL syringe, withdraw gastric contents from the
feeding tube. Note volume of formula.
Total Parenteral Nutrition (TPN)
TPN is an IV solution of 10%–50% dextrose in water (CHO), amino acids
(protein), electrolytes, and additives (vitamins, minerals, trace elements of
insulin, vitamin K, zinc, famotidine). Fat emulsions provide fatty acids and
calories. Solutions >10% dextrose must be infused via a central line.
■ 1000 mL 5% D/W contains 50 g sugar = <200 calories
■ 1000 mL 25% dextrose contains 250 g sugar = 1000 calories
Indications
■ Severe malnutrition
■ Burns
BASICS
Feeding Tube Complications—Cont’d
Nonmechanical Complications Interventions
Gastric reflux • Hold feedings. Check residuals.
• Keep HOB elevated 30°–45°.
Dumping syndrome: nausea, • Withhold or decrease 
vomiting, diarrhea, cramps, amount, rate, and 
pallor, sweating, HR frequency of feedings.
↓
Volume Indication
<50 mL Normal residual.
50-100 mL Repeat measurement of residual every 1–2 hrs.
>100 mL Stop feeding. Check residual after 3–4 hrs. When
residual is <100 mL, resume feeding at slower rate,
amount, or frequency.
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■ Bowel disorders (inflammatory disorders, total bowel obstruction,
short bowel syndrome)
■ Severe acute pancreatitis
■ Acute renal failure
■ Hepatic failure
■ Metastatic cancer
■ Postoperative major surgery if NPO >5 days
Nursing Care
■ Each bag of TPN should be changed at least every 24 hrs with tubing
change.
■ Monitor intake and output and weigh the patient daily.
■ Monitor glucose levels, including finger stick blood sugars every 4 to 
6 hours. Cover with regular insulin as necessary. If poor control of serum
glucose, consider adding insulin to TPN and continue rainbow coverage.
■ Monitor serum electrolytes including magnesium, phosphate, triglyc-
erides, prealbumin, CBC, PT/PTT, and urine urea nitrogen.
■ Assess IV site for redness, swelling, and drainage.
■ Change gauze dressing around IV site every 48 to 72 hours, as per
protocol. Transparent dressings may be changed every 7 days.
■ If TPN is temporarily unavailable, hang 10% D/W at the same rate as
TPN. Monitor for hypoglycemia.
■ Place TPN on infusion pump. Monitor hourly rate. Never attempt to
“catch up” if infusion not accurate.
■ Patients generally are taken off of TPN prior to surgery.
Complications
Complications from TPN may be catheter-related, mechanical, or metabolic.
Complications of TPN Signs and Symptoms
Infection, catheter-related Leukocytosis; fever; glucose intolerance;
sepsis, septicemia, catheter site red, swollen, tender; drainage
septic shock
Hypoglycemia Shaking, tachycardia, sweating, anxious, 
Blood glucose dizziness, hunger, impaired vision, 
<70 mg/dL weakness, fatigue, headache, irritability
Continued
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Infectious Diseases
Critical Care Risk Factors
■ Invasive devices
■ Immunocompromising conditions
■ Serious underlying illness
■ Prolonged stay in critical care unit
■ Colonization and cross-infection
Complications of TPN Signs and Symptoms
Hyperglycemia Extreme thirst, frequent urination,
Blood glucose dry skin, hunger, blurred vision, 
>200 mg/dL drowsiness, nausea
Prerenal azotemia BUN and serum Na+, signs of dehydra-
tion, lethargy, coma
Hepatic dysfunction serum liver function tests (SGOT, SGPT,
alkaline phosphatase)
Pneumothorax, SOB, restlessness, dyspnea, signs
hydrothorax of hypoxia, chest pain radiating
Subclavian/carotid to back, arterial blood in syringe,
artery puncture tachycardia, pulsatile blood flow, bleeding
from catheter site
Air embolus Respiratory distress, dyspnea, SOB, tachy-
cardia, ↓ BP, neurological deficits, cardiac
arrest
Dysrhythmias Atrial, junctional, and ventricular arrhyth-
mias; ↓ C.O., ↓ BP, loss of consciousness
Hypo-/hypernatremia Normal values: 135–145 mEq/L or 135–145
mmol/L
Hypo-/hyperkalemia Normal values: 3.5–5.0 mEq/L or 3.5–5.0
mmol/L 
Hypo-/hyperphosphatemia Normal values: 3.0–4.5 mg/100 mL or
1.0–1.5 mmol/L
Hypo-/hypermagnesemia Normal values: 1.5–2.0 mEq/L or  0.8–1.3
mmol/L
Hypo-/hypercalcemia Normal values: 8.5–10.5 mg/100 mL or
2.1–2.6 mmol/L
↓
↓
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■ Overuse of antibiotics
■ Elderly
Methicillin-Resistant Staphylococcus aureus (MRSA)
Etiology
Health-care associated bloodstream and catheter-related infections.
Transmitted by close contact with infected person. Health-care worker
may be colonized with MRSA strain with absence of symptoms. The
Staph. aureus bacterium is resistant to methicillin, amoxicillin, penicillin,
oxacillin, and other antibiotics.
Signs and Symptoms
■ Skin infection: Boil or abscess
■ Surgical wound: Swollen, red, painful, exudate (pus)
■ Bloodstream: Fever, chills
■ Lung infection/pneumonia: Shortness of breath, fever, chills
■ Urinary tract: Cloudy urine, strong odor
Diagnosis
■ Culture of infected area
Treatment
■ Vancomycin (Vanocin, Vancoled)
■ Linezolid (Zyvox)
■ Daptomycin (Cubicin)
Clostridium Difficile (C-diff)
Etiology
C. difficile is a common cause of antibiotic-associated diarrhea (AAD) and
is transmitted through the feces or any surface, device, or material that
has become contaminated with feces.
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Signs and Symptoms
■ Watery diarrhea (at least 3 BMs/day for 2 or more days)
■ Fever
■ Loss of appetite
■ Nausea
■ Abdominal pain and tenderness
Diagnosis
■ Stool culture
Treatment
■ Discontinue antibiotics. May give metronidazole (Flagyl) to treat 
diarrhea 
Revised CDC Guidelines 2007
■ Perform hand hygiene after touching blood, body fluids, secretions,
excretions, and contaminated items immediately after removing
gloves and between patient contacts.
■ Alcohol-based hand gels are the preferred method for hand decon-
tamination between patients. Decontamination should be performed
after contact with a patient and/or medical equipment.
■ Gloves and gown should be worn when in contact with clothing or
exposed skin with blood or body fluids, secretions, and excretions.
■ Mask, eye protection (goggles), and face shield should be worn dur-
ing procedures such as suctioning or endotracheal intubation if
splashes or sprays of body fluids or blood may occur. For patients
with suspected or proven infections transmitted by respiratory
aerosols, such as SARS, a fit-tested N95 or higher respirator should
also be worn.
■ For injected medications, single-dose vials are preferred to multiple-
dose vials.
During patient transport, masks are not necessary if the patient is wearing
a mask. Health-care workers should continue to wear masks when caring
for patients with droplet precautions. For more information: http://www.
cdc.gov/ncidod/dhqp/pdf/guidelines/Isolation2007. pdf
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Psychosocial Issues in Critical Care
Sensory Overload and Deprivation
■ Sensory Overload: A condition in which sensory stimuli are received at a
rate and intensity beyond the level that the patient can accommodate.
■ Sensory Deprivation: A condition in which the patient experiences a
lack of variety and/or intensity of sensory stimuli.
Types of Sensory Stimuli
■ Visual
■ Auditory
■ Kinesthetic
■ Gustatory
■ Tactile
■ Olfactory
Signs and Symptoms of Sensory Problems
■ Confusion
■ Hallucinations
■ Lethargy
■ Behavioral changes (combativeness)
■ Increased startle response
■ Disorientation
■ Anxiety
■ Restlessness
■ Panic
■ Withdrawal
■ Mood swings
■ Withdrawal
Near-Death Experience
The experience of patients that they have glimpsed the afterlife when
coming close to death. These perceptions may include:
■ Seeing an intense light
■ Seeing angels or departed loved ones
■ Traveling through a tunnel
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Out-of-Body Experience
The experience of being away from and overlooking one’s body. The
patient feels that the mind has separated from the body.
Family Needs of the Critical Care Patient
■ Relief of anxiety.
■ Assurance of competent care.
■ Timely access to the patient.
■ Accurate and timely information about the patient’s condition and
prognosis in easily understandable terms.
■ Early notification of changes in the patient’s condition.
■ Explanations regarding the environment, machinery, and monitoring
equipment.
■ Honest answers to questions.
■ Emotional support.
■ Regard for the spiritual needs of the family and patient.
Organ Donation
Transplantable organs include:
■ Kidneys
■ Heart
■ Lungs
■ Liver
■ Pancreas
■ Intestines
Corneas, the middle ear, skin, heart valves, bone, veins, cartilage, ten-
dons, and ligaments can be stored in tissue banks and used to restore
sight, cover burns, repair hearts, replace veins, and mend damaged con-
nective tissue and cartilage in recipients.
Healthy adults between the ages of 18 and 60 can donate blood stem
cells: marrow, peripheral blood stem cells, and cored blood stem cells.
Nursing Role in Organ Donation
■ Provide accurate information regarding donation.
■ Identify possible donors early.
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■ Work closely with the organ procurement organization and members
of the health team to illicit donations.
■ Provide emotional support to families considering donation, making
sure to respect their cultural and religious beliefs.
■ Become a donor advocate among colleagues and for patients and
their families.
General Criteria for Brain Death
■ Absence of purposive movement
■ Flaccid tone and absence of spontaneous or induced movements
■ Persistent deep coma
■ Absence of spontaneous respiration
■ Absence of brainstem reflexes:
■ Midposition or pupils fixed and dilated
■ No corneal, gag, or cough reflexes
■ Absence of spontaneous oculocephalic (doll’s eye phenomenon) reflex
■ No vestibular response to caloric stimulation
■ Isoelectric or flat electroencephalogram (EEG)
■ Absent cerebral blood flow
These criteria vary from state to state.
Hemodynamic management of potential brain-dead organ donors:
ensure adequate intravascular volume and adequate cardiac output to
ensure consistent perfusion to vital organs.
■ MAP >60 mm Hg
■ Urine output >1.0 mL/kg/hr
■ Left ventricular ejection fraction >45%
Nursing care
■ Fluid management—fluids or diuretics
■ Inotropic agents to correct low cardiac output
■ Vasopressors to correct vasodilatation
■ Thyroid hormone
■ Corticosteroids to reduce inflammation
■ Vasopressin to support renal function
■ Insulin to control glucose levels
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■ Regulate ventilator settings including use of PEEP
■ Suction frequently to promote adequate oxygenation
Specific organ donation protocols:
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
Sedation, Agitation, and Delirium Management
Purpose of sedation is to minimize use of neuromuscular paralysis agents.
This will ↓ ventilatory time, ↓ length of stay in ICU, ↓ costs, fewer tra-
cheostomies, and provide early intervention of neurological deterioration.
Sedatives should be titrated without impairing neurological assessment.
Analgesics should be titrated to keep pain  level <3 on 0–10 scale.
Assessment 
Prior to sedation, exclude and treat possible causes of agitation and 
confusion:
■ Cerebral hypoperfusion
■ Cardiac ischemia
■ Hypotension
■ Hypoxemia or hypercarbia (elevated blood CO2)
■ Fluid and electrolyte imbalance: acidosis, hyponatremia, hypo-
glycemia, hypercalcemia, hepatic or renal insufficiency
■ Infection
■ Drug-induced
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Use nonpharmacologic therapies such as massage, distraction, minimize
noise. Cluster activities to allow for uninterrupted periods of sleep.
Assess pain on 0–10 scale or faces scale and look for nonverbal cues.
Medications for Sedation, Pain, and Delirium
Benzodiazepines
■ Diazepam (Valium)
■ Lorazepam (Ativan)
■ Midazolam (Versed)
Keep antidote flumazenil (Romazicon) available.
Narcotics
■ Morphine sulfate ■ Hydromorphone (Dilaudid)
■ Codeine ■ Oxycodone (OxyContin)
■ Fentanyl ■ Remifentanil (Ultiva)
Alpha-adrenergic Receptor Agonists
■ Clonidine (Catapres)
■ Dexmedetomidine (Precedex)
Neuroleptics/Antipsychotics/Butyrophenones
■ Haloperidol (Haldol)
■ Droperidol (Inapsine)
Sedatives/Hypnotics
■ Propofol (Diprivan)
Physiological Responses to Pain and Anxiety
■ Tachycardia ■ Hypertension
■ Diaphoresis ■ Tachypnea
■ Sleep disturbance ■ Nausea
Signs of Sedative or Analgesic Withdrawal
■ Nausea, vomiting, diarrhea
■ Cramps, muscle aches
■ Increased sensitivity to pain
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Score Level of Sedation-Agitation Response
7 Dangerous agitation Pulling at endotracheal tube,
thrashing, climbing over bed
rails
6 Very agitated Does not calm, requires
restraints, bites endotracheal
tube
5 Agitated Attempts to sit up but calms to
verbal instructions
4 Calm and cooperative Obeys commands
3 Sedated Difficult to rouse, obeys simple
commands
2 Very sedated Rouses to stimuli; does not
obey commands
1 Unarousable Minimal or no response to 
noxious stimuli
Reprinted with permission from Riker, R. et al. Critical Care Medicine, 1994, 22(3), 433-440.
■ Tachypnea, HR, BP
■ Delirium, tremors, seizures, agitation
Medication Management
■ Monitor body and limb movements, facial expression, posturing,
muscle tension for signs of pain.
■ Monitor for acute changes or fluctuations in mental status, LOC, 
disorientation, hallucinations, delusions.
■ Evaluate arousability.
■ Monitor neurological status including pupillary response, response to
verbal commands and pain.
■ Monitor respiratory rate and respiratory effort, respiratory depression,
BP, HR.
Sedation Assessment Scales
Sedation-Agitation Scale (SAS)
↓↓
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Bispectral Index Monitoring (BSI) 
Physiological assessment of sedation: Examines the EEG and monitors
states of increased and diminished cortical arousal. Scoring: 
Pain Visual Analog Scale (VAS)
no pain 0  _____________________________________________ worst pain 10
no anxiety                                        5                                  severe anxiety
Delirium Assessment
Delirium has been associated with poor patient outcomes. Patients with
delirium have higher ICU and hospital stays along with a higher risk of
death.
It is characterized by an acute onset of mental status changes that
develop over a short period of time, usually hours to days. It may fluctu-
ate over the course of a day. It may be combined with inattention and dis-
organized thinking or altered level of consciousness. The DSM IV
describes three clinical subtypes: hyperactive, hypoactive, and mixed.
Hyperactive delirium may be confused with anxiety and agitation.
Benzodiazepines may cause or worsen delirium.
Haloperidol (Haldol) is the drug of choice to treat delirium in the ICU
patient.
The Confusion Assessment Method for the Intensive Care Unit 
(CAM-ICU) score has been used to screen for delirium in the ICU population.
0 Isoelectric brain activity (flat EEG)
40–60 General anesthesia
60–70 Deep sedation
70–80 Moderate (conscious) sedation
90–100 Awake state
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Complications of Sedation, Agitation, and Delirium
Therapy
■ Hypotension
■ Patient unresponsiveness
■ Respiratory depression
■ Delayed weaning from mechanical ventilator
■ Complications associated with immobility: pressure ulcers, throm-
boembolism, gastric ileus, hospital-acquired pneumonia
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Acute Coronary Syndrome (ACS)
ACS is the term used to denote any one of three clinical manifestations of
coronary artery disease:
■ Unstable angina
■ Non-ST elevation MI
■ ST elevation MI
Pathophysiology
Unstable angina represents the progression of stable coronary artery dis-
ease to unstable disease. Rupture of atherosclerotic plaque causes throm-
bus formation and partial occlusion in coronary arteries.
Clinical Presentation
ACS presents with chest pain, diaphoresis, SOB, nausea and vomiting,
dyspnea, weakness, and fatigue. Look for symptoms of MI—midsternal
chest pain, may be described as pressure, squeezing, fullness, or pain.
May radiate to jaw, neck, arms, or back and usually lasts more than 
15 minutes. 
Assessment for chest pain and associated symptoms of ACS include:
Use of PQRST method when assessing pain, physical exam, vital signs,
auscultate for S3 or S4 gallop, auscultate lungs for crackles, and assess
peripheral vessels for pulse deficits or bruits.
Diagnostic Tests 
■ ECG
■ Echocardiogram
■ Cycle cardiac markers (troponin I, CK, CK MB, myoglobin, C-reactive
protein)
Management  
■ Administer oxygen to maintain SaO2 >90%.
■ Establish IV access.
37
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■ Perform cardiac monitoring.
■ Administer SL nitroglycerin tablets or oral spray, every 5 minutes x 3
doses. If pain persists, IV nitroglycerin may be started.
■ Monitor for hypotension and headaches from vasodilatation.
■ Administer aspirin and have patient chew it, if not already on daily
dose.
■ Administer IV morphine, 2–4 mg every 15 minutes until pain is 
controlled.
■ Monitor for hypotension and respiratory depression.
■ Unless contraindicated, administer a beta blocker.
Unstable Angina
Unstable angina is the sudden onset of chest pain, pressure, or tightness
due to insufficient blood flow through coronary arteries.
Pathophysiology 
Atherosclerosis → obstruction of coronary arteries → decrease blood flow
through coronary arteries → decrease oxygen supply to myocardial
demand for O2 during exertion or emotional stress → angina.
Clinical Presentation 
Chest pain presents as substernal pain, tightness, dullness, fullness, heav-
iness or pressure, dyspnea, syncope, pain radiating to arms, epigastrium,
shoulder, neck, or jaw. 
Women may experience more atypical symptoms such as back pain; GI
symptoms, such as indigestion, nausea and vomiting, and abdominal full-
ness; whereas men may experience typical symptoms such as midsternal
chest pain radiating into the left arm.
Diagnostic Tests 
■ 12-lead ECG
■ Lab work: cardiac markers: creatine kinase (CK), creatine kinase-
myocardial band (CK-MB), troponin I (TnI), and myoglobin
■ Exercise or pharmacological stress test
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■ Echocardiogram
■ Nuclear scan 
■ Cardiac catheterization and coronary artery angiography
Management 
■ Bedrest.
■ Obtain ECG and lab work.
■ Assess chest pain for frequency, duration, cause that triggered pain,
radiation of pain, and intensity based on pain scale from 1 to 10, with
1 being no pain and 10 being worst pain.
■ Supply O2.
■ Pharmacological treatment:
■ Early conservative, for low-risk patient: Anti-ischemic, antiplatelet,
and antithrombotic drug therapy; stress and treadmill tests.
■ Early invasive: Same drug therapy as early conservative but fol-
lowed by diagnostic catheterization and revascularization.
■ Administer nitroglycerin (NTG): 0.4 mg (SL or spray) → IV infusion
start @ 10 mcg/hr, titrate for pain; check for contraindications such as
hypotension, or if taking the following meds: Viagra, Cialis, or Levitra.
■ Administer morphine sulfate IV if symptoms persist after receiving NTG
or in patients who have pulmonary congestion or severe agitation.
■ Administer beta blocker: metoprolol.
■ Administer ACE inhibitors in patients with LV dysfunction or CHF
with HTN, not recommended in patients with renal failure.
■ Administer calcium channel blockers: Verapamil (Calan, Isoptin) or
diltiazem (Cardizem) if patient not responding from beta blocker or
nitrates. 
*Use severe caution when combining blocking agents*
■ Administer antiplatelet: Aspirin 160–325 mg, chewed.
■ Administer GP IIb- IIIa inhibitor: Eptifibatide (Integrilin) or tirofiban
(Aggrastat) if no contraindications (i.e., bleeding, stroke in past
month, severe HTN, renal dialysis, major surgery within the past 
6 weeks, or platelet count <100,000 mm3 ).
■ Administer antithrombotic: Heparin.
■ Administer anticoagulant: Enoxaparin (Lovenox).
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Acute Myocardial Infarction (AMI)
AMI is the acute death of myocardial cells due to lack of oxygenated blood
flow in the coronary arteries. It is also known as a heart attack.
Pathophysiology
Injury to the artery’s endothelium → increases platelet adhesion → inflam-
matory response causing monocytes and T lymphocytes to migrate in the
intima → macrophages and smooth muscle distend with lipids, forming
fatty streaks and forming fibrous cap → thinning of cap increases suscep-
tibility to rupture or hemorrhage → rupture triggers thrombus formation
and vasoconstriction → result: thrombus with narrowing artery. If occlu-
sion lasts more than 20 minutes it leads to AMI.
Clinical Presentation
AMI presents with chest pain or discomfort lasting 20 minutes or longer.
Pain can be described as pressure, tightness, heaviness, burning, or a
squeezing or crushing sensation, located typically in the central chest or
epigastrium; it may radiate to the arms, shoulders, neck, jaw, or back.
Discomfort may be accompanied by weakness, dyspnea, diaphoresis,
or anxiety, not relieved by NTG. Women may experience atypical discom-
fort, SOB, or fatigue. Diabetic patients may not display classic signs &
symptoms of AMI. Elderly may experience SOB, pulmonary edema, dizzi-
ness, altered mental status.
ST-segment elevation MI: Look for tall positive T waves and 
ST-segment elevation of 1 mm or more above baseline. 
Non-ST segment elevation MI: May include ST-segment depression and
T-wave inversion.
Diagnostic Tests
■ ECG findings
■ Cardiac markers (CK, myoglobin, and troponins)
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Management
■ Focus on pain radiation, SOB, and diaphoresis.
■ Obtain a 12-lead ECG and lab draw for cardiac markers.
■ MONA: morphine, O2, NTG, and 160–325 mg aspirin, po. If allergic to
aspirin, give ticlopidine (Ticlid) or clopidogrel (Plavix). 
■ Administer supplemental O2 to maintain SpO2 >90%.
■ Administer SL NTG tablets or spray.
■ Administer IV morphine 2–4 mg every 15 minutes until pain is con-
trolled. (Monitor for hypotension and respiratory depression.)
Hypertensive Crisis
Hypertensive crisis is defined as a severe elevation in blood pressure (sys-
tolic BP >179 mm Hg, diastolic BP >109 mm Hg), which may or may not
lead to organ damage. There are two types of hypertensive crisis: 
■ Hypertensive emergency: Rapid (hours to days) marked elevation in
BP → acute organ tissue damage.
■ Hypertensive urgency: Slow (days to weeks) elevation in BP that usu-
ally does not lead to organ tissue damage.
Pathophysiology
Any disorder or cause (essential hypertension, renal parenchymal dis-
ease, renovascular disease, pregnancy, endocrine drugs, autonomic
hyper-reactivity, CNS disorder) → BP → vessel becomes inflamed →
leak fluid or blood to the brain → CVA → long-term disability.
Clinical Presentation 
Hypertensive crisis presents with
■ Chest pain
■ Dyspnea
■ Neurological deficits
■ Occipital headache
■ Visual disturbance
■ Vomiting
↓
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Diagnostic Tests
■ CT scan of chest, abdomen, and brain
■ 2-D echocardiogram or transesophageal echocardiogram
■ ECG
■ Lab draws: CBC, cardiac markers, BUN, creatinine, UA, urine toxicology
Management
■ Administer O2 to maintain PaO2 >92%.
■ Obtain VS-orthostatic BP every 5 min, then longer intervals.
■ First-line medical therapy: Labetalol (Trandate) and adrenergic-
receptor blocker with both selective alpha-adrenergic and nonselec-
tive beta-adrenergic receptor blocking actions.
■ Administer vasodilator: Nitroprusside (Nipride) and NTG.
■ Hypertensive emergency: IV route is preferred; reduce mean arterial
pressure (MAP) by no more than 25% in the first hour; if stable, ↓
diastolic BP to 100–110 mm Hg over the next 2–6 hours.
■ If pt has neurological complication, primary goal → maintain ade-
quate cerebral perfusion, control HTN, minimize cerebral edema; ↓ BP
by 10% but no more than 20%–30% from initial reading.
■ Hypertensive urgency: PO meds; ↓ BP in 24–36 hours; short-acting
agents: captopril (Capoten) or clonidine (Catapres).
Congestive Heart Failure (CHF)
CHF, which is sometimes referred to as “pump failure,” is a general term
for the inadequacy of the heart to pump blood throughout the body. This
deficit causes insufficient perfusion to body tissues with vital nutrients
and oxygen.
Pathophysiology 
There are two types of CHF failure: Left-sided failure and right-sided failure.
Both may be acute or chronic and mild to severe, caused by HTN, CAD, or
valvular disease, involving the mitral or aortic valve. CHF can also be divid-
ed into two subtypes: systolic heart function and diastolic heart function.
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■ Systolic heart function results when the heart is unable to contract
forcefully enough, during systole, to eject adequate amounts of blood
into the circulation. Preload increases with decreased contractility and
afterload increases as a result of increased peripheral resistance. 
■ Diastolic heart failure occurs when the left ventricle is unable to relax
adequately during diastole. Inadequate relaxation prevents the ventri-
cle from filling with sufficient blood to ensure adequate cardiac 
output.
Clinical Presentation
Left-sided CHF presents as:
■ Dyspnea
■ Diaphoresis
■ Orthopnea
■ Tachycardia
■ Tachypnea
■ Paroxysmal nocturnal dyspnea
■ Fatigue
■ Pulmonary crackles
■ Wheezes
■ S3 gallop
■ Frothy pink-tinged sputum
■ Weakness
■ Confusion
■ Restlessness
Right-sided CHF presents as:
■ Right upper quadrant pain
■ Peripheral edema
■ JVD
■ Hepatomegaly
■ Hepatojugular reflux and edema
■ HTN
■ Anorexia
■ Nausea
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Diagnostic Tests
■ B-type natriuretic peptide (BNP) level 
■ Chest x-ray
■ Echocardiogram
■ Pulmonary artery pressure catheterization
Management 
■ Primary goal in managing heart failure is to maintain cardiac output.
■ Secondary goal is to decrease venous (capillary) pressure to limit
edema.    
■ Diuretics (furosemide): Aimed at controlling fluid retention.
■ Beta blockers (metoprolol): Aimed at reducing cardiac workload.
■ Nitrates (NTG, nitroprusside): Aimed at enhancing myocardial con-
tractility.
■ Inotropes (dobutamine): Aimed at enhancing myocardial contractility.
Abdominal Aortic Aneurysm (AAA)
AAA is a localized, chronic abnormal dilation of an artery located between
the renal and iliac arteries, having a diameter at least 1.5 times that of 
the expected diameter with a natural history toward enlargement and 
rupture.
Pathophysiology 
There are just theories about the pathology of AAA because the etiology
is not completely understood. Theories suggest that atherosclerosis and
destruction of elastin and collagen fibers in the vessel walls contribute to
the development.
Pathophysiology for Atherosclerosis
Fatty streaks deposited in arterial intima → stimulates inflammatory response
that causes proliferation → proliferation causes blood vessel to form fibrous
capillaries → deposits build up as atheromas or plaques → plaques pile up,
obstructing the blood flow → outpouching of abdominal aneurysm.
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Pathophysiology Involvement with Elastin and Collagen  
Media thins → decrease in elastin fibers in vessel walls → collagen weak-
ens → leads to aneurysm growth → outpouching of abdominal aorta
Clinical Presentation 
AAA may present as asymptomatic or symptomatic. When asymptomatic,
look for a pulsatile, periumbilical mass with or without a bruit. When
symptomatic, symptoms include:
■ Early satiety
■ Nausea
■ Vomiting
■ Gastrointestinal bleeding
■ Back pain
■ Lower extremity ischemia
■ Venous thrombosis
■ Flank/groin pain
AAA can also mimic:
■ UTI infection
■ Renal obstruction
■ Ruptured disc
■ Diverticulitis
■ Pancreatitis
■ Upper gastrointestinal hemorrhage
■ Abdominal neoplasm
■ Peptic ulcer perforation
Diagnostic Tests
■ Abdominal ultrasound (first line of diagnostic testing)
■ CT scan of the abdomen
■ Abdominal x-ray
■ Aortogram
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Management
■ Administer beta blocker to lower arterial pressure to the lowest SBP
(120 mm Hg or less).
■ May use newer alpha-beta-blocker labetalol (Trandate) in place of
nitroprusside and a beta blocker; do not give direct vasodilators such
as hydralazine.
Postoperative Management
■ Goal of postoperative care is to reduce afterload and pressure at the
repair site.
■ Administer IV nitroprusside with esmolol (Brevibloc) or labetalol
(Trandate) and titrate the dosage to keep systolic BP below 120 mm
Hg as ordered.
■ Starting immediately after surgery, continuously monitor the patient’s
neurological status, cardiac rhythm, RR, hemodynamics, urine output,
core body temperature, fluid and electrolyte imbalance.
■ Provide analgesia.
■ Monitor for acute renal failure, ischemic colitis, spinal cord ischemia,
and aorto-enteric fistula.
■ Assess patient’s gastrointestinal function.
■ Report urine output less than 0.5 mL/kg/hr, which indicates dehydra-
tion, volume deficit, or decreased renal function.
Aortic Dissection
Aortic dissection is a tear (without hematoma or an intramural
hematoma) in the aortic wall, causing a longitudinal separation between
the intima and adventitia layers resulting in a diversion of blood flow from
its normal arterial pathway. Aortic dissection requires emergent surgery.
Pathophysiology 
Tear in aorta intima → blood flows into subintimal region → pulsatile
pressure creates a false channel between intimal and medial layers of
aorta → intimal and medial layer is separated → circulatory volume
decreases → channel expands and creates either an expanding mass or a
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hematoma (from blood coagulating) → lumen narrows and obstructs
blood flow, cardiac output decreases → results in end-organ failure, also
diverted blood can pool around heart, resulting in cardiac tamponade.
Clinical Presentation
Consider acute phase if diagnosed within first 2 weeks of onset of pain. 
Presenting Symptoms
■ Mimics inferior wall MI
■ CHF 
■ CVAP 
■ Standard type A aortic dissection: Severe chest pain, sometimes
sharp
■ Standard type B dissection: Severe chest pain radiating to the back;
described as “ripping or tearing” pain 
■ Pain can shift to the abdomen 
■ Increasing restlessness (sign of extending dissection)
■ Decrease in urine output
Diagnostic Tests 
■ Chest x-ray: Shows widening mediastinum
■ ECG
■ Transthoracic echocardiogram
■ Transesophageal echocardiogram
■ CT scan
■ Aortography
■ MRI
Management
■ Measure BP in both arms. Monitor HR, RR, and pain level.
■ Perform frequent peripheral pulse checks, ankle brachial index mea-
surements, and neurological assessments.
■ Administer beta blockers as first line of treatment; if hypertensive →
give nitroprusside IV.
■ Plan for emergency surgery.
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Pericardial Effusion
Pericardial effusion is the abnormal accumulation of more than 50 mL of
fluid (normal: 15–50 mL to serve as lubricant for the visceral and parietal
layers of pericardium) in the pericardial sac, which may lead to noncom-
pression of the heart, which interferes with heart function.
Pathophysiology 
Causes: chest trauma, accidents, stab wounds, gun shot wounds, rupture
of tumors, obstruction of lymphatic or venous flow → accumulate blood
in the pericardial sac → pressure → compresses or does not compress
the heart.
Clinical Manifestations 
Pericardial effusion can be asymptomatic with up to 2 L accumulated fluid
in the pericardial sac. 
■ Complaints of dull, constant ache in the left side of the chest  with
symptoms of cardiac compression. 
■ Muffled heart sounds. 
■ May or may not present with pericardial friction.
■ Dullness of percussion of the left lung over the angle of scapula
(Ewart’s sign). 
■ ECG shows ↓ voltage of complexes.
Diagnostic Tests 
■ Echocardiogram
Management 
■ Pain management.
■ Pericardiocentesis performed by a physician.
■ Position changes decrease SOB.
↓
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■ Wound care after pericardiocentesis, care of pericardial catheters.
■ Frequent assessments of VS, pulses, LOC, respiratory status, skin and
temperature changes, intake and output.
■ Prevent cardiac tamponade.
Cardiac Surgeries
Coronary Artery Bypass Graft (CABG)
CABG is an open-heart surgical procedure in which a blood vessel from
another part of the body, usually the saphenous vein from the leg, is grafted
below the occluded coronary artery so that blood can bypass the blockage.
Pathophysiology 
Surgery is performed on those patients with coronary artery disease,
causing blockage to the coronary arteries. Fatty streaks deposited in 
arterial intima stimulates an inflammatory response that causes prolifer-
ation. Proliferation causes blood vessels to form fibrous caps, and
deposits build up as atheromas or plaques. Plaques pile up obstructing
the blood flow.
Clinical Manifestations 
Ischemia: if ischemic episode lasts long enough can cause death to
myocardial cells → MI, angina, chest pain, somatic and visceral pain and
discomfort. Atrial fibrillation common complication of cardiac surgery.
Diagnostic Tests
■ Health history
■ Exercise treadmill testing
■ Gated SPECT imaging
■ Echocardiography
■ Electron Beam Computed Tomography (EBCT)
■ Lab work: lipid profile
Postoperative Care
■ Common postop care includes maintaining airway patency and moni-
toring the patient’s pulmonary status, vital signs, intake and output.
■ Perform peripheral and neurovascular assessments hourly for first 
8 hours.
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■ Monitor neurological status. 
■ Titrate drugs: vasopressor and inotropes to optimize cardiac function
and BP.
■ Monitor chest tube drainage and record amount.
■ Watch for signs of bleeding and monitor hemoglobin and hematocrit
every 4 hours.
■ Monitor patient’s pain and medicate as needed.
Coronary Stenting/Percutaneous Coronary Intervention
Percutaneous coronary intervention (PCI) is a common intervention for
angina. In a catheterization lab, a catheter equipped with an inflatable bal-
loon tip is inserted into the appropriate coronary artery. When the lesion is
located, the catheter is passed through the lesion, the balloon is inflated,
and the atherosclerotic plaque is compressed, resulting in vessel dilata-
tion. Intracoronary stents are usually inserted during PCI. Stents are used
to treat abrupt or threatened abrupt closure or restenosis following PCI.
Procedure 
Stents are expandable meshlike structures designed to maintain vessel
patency by compressing the arterial walls and resisting vasoconstric-
tion. Stents are carefully placed over the angioplasty site to hold the
vessel open.
Clinical Presentation 
■ Atypical or typical chest pain
■ SOB
■ Dyspnea
■ Symptoms of angina
Diagnostic Tests
■ ECG
■ Echocardiogram
■ Chest x-ray
■ Lab tests: cardiac markers
Management of Clinical Condition
■ Administer antiplatelet agents (aspirin, ticlopidine, clopidogrel).
■ Administer IV infusion of glycoprotein IIb IIIa inhibitors (eptifibatide).
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■ Monitor for signs and symptoms of bleeding at catheter site. 
■ Monitor for chest pain.
Stent Insertion
Stent Inflation and Expansion
Balloon Removal and Stent Implantation
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Cardiac Valve Replacement
Clinical conditions that require a surgical procedure to replace the valve
with either a mechanical valve or a porcine valve include:
■ Acquired valvular dysfunction
■ Mitral valve stenosis
■ Mitral valve regurgitation
■ Mitral valve prolapse
■ Aortic stenosis
■ Aortic regurgitation
The surgical procedure is the same as open-heart surgery except the heart
is not bypassed, only the valve is replaced. 
Pathophysiology 
Mitral stenosis: Usually results from rheumatic fever (which can cause
valve thickening), atrial myxoma (tumor), calcium accumulation, or
thrombus formation → valve becomes stiff. The valve opening narrows →
prevention of normal blood flow from left atrium to left ventricle → pul-
monary congestion → right-sided heart failure.
■ Mitral valve regurgitation: Fibrotic and calcific changes prevent mitral
valve from closing completely during systole → incomplete closure of
the valve → backflow of blood into left atrium when left ventricle con-
tracts → increased volume ejection with next systole → increased
pressure → left ventricular hypertrophy.
■ Mitral valve prolapse: The valvular leaflets enlarge and prolapse into
left atrium during systole → usually benign but may lead to mitral
valve regurgitation.
■ Aortic stenosis: Aortic valve orifice narrows and obstructs left ventri-
cle outflow during systole → increased resistance to ejection or after-
load → ventricular hypertrophy.
■ Aortic regurgitation: Aortic valve leaflets do not close properly →
regurgitation of aortic blood back into ventricle during diastole → left
ventricular hypertrophy.
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Clinical Presentation
■ Mitral stenosis: Fatigue, dyspnea on exertion, orthopnea, paroxysmal
nocturnal dyspnea, hemoptysis, hepatomegaly, JVD, pitting edema,
atrial fibrillation, apical diastolic murmur.
■ Mitral valve regurgitation: Fatigue, dyspnea on exertion, orthopnea,
palpitations, atrial fibrillation, JVD, pitting edema, high-pitched
holosystolic murmur.
■ Mitral valve prolapse: Atypical chest pain, dizziness, syncope, palpita-
tions, atrial tachycardia, ventricular tachycardia, systolic click.
■ Aortic stenosis: Dyspnea on exertion, angina, syncope on exertion,
fatigue, orthopnea, paroxysmal nocturnal dyspnea, harsh systolic
crescendo-decrescendo murmur.
■ Aortic insufficiency: Palpitations, dyspnea, orthopnea, paroxysmal
nocturnal dyspnea, fatigue, angina, sinus tachycardia, blowing
decrescendo diastolic murmur.
Diagnostic Tests 
■ Echocardiogram
■ ECG
■ Cardiac angiogram
■ Exercise tolerance test
Management
■ Routine postoperative care: maintain airway patency, monitor pul-
monary status.
■ Monitor vital signs and intake and output.
■ Perform peripheral and neurovascular assessments hourly for first 8
hours after surgery.
■ Monitor neurological status for first 8 hours postoperatively.
■ Titrate medications, pressors and inotropes to optimize cardiac func-
tion and BP. 
■ Monitor chest tube drainage.
■ Watch for signs of bleeding by monitoring hgb and hct every 4 hours.
■ Monitor for pain.
■ Start on anticoagulation therapy when approved by cardiac surgeon.
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Cardiac Transplant
Cardiac transplant is a surgical procedure to remove a diseased heart and
replace it with a healthy donor heart.
Causes That Lead to Cardiac Transplant
End-stage heart disease includes congenital heart disease (single ventri-
cle physiology, coronary sinusoids), cardiomyopathy (primary: idiopathic,
familial, secondary pregnancy, drug-induced), and acquired heart disease
(valvular disease).
Criteria for Heart Transplant
■ CHF
■ CAD with intractable angina symptoms, 
■ Ventricular dysrhythmias unresponsive to medical/surgery therapy 
■ Primary cardiac tumors with no evidence of spread to other body 
systems
Diagnostic Tests Prior to Transplantation
■ Echocardiogram
■ Right heart catheterization
■ Pulmonary function tests
■ Exercise treadmill test
■ Abdominal ultrasound
■ Chest x-rays
■ Coronary angiogram
■ Cardiac biopsy
■ Chromosome testing
■ Lab tests: chemistries, CBC, human leukocyte antigens (HLA) anti-
body screening, viral antibody screening (HIV, cytomegalovirus, 
herpes virus, varicella, Epstein- Barr)
Postoperative Care 
■ Admit to Cardio Thoracic ICU, 24–48 hours on ventilator until 
anesthesia cleared from system.
■ Foley catheter to gravity, monitor output closely.
■ Daily chest x-ray.
■ Monitor chest tube sites and drainage (generally will have 2–3 chest
tubes in place).
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■ Pulmonary toilet measures hourly, once extubated.
■ Perform and document complete nursing assessments frequently 
during first 12–24 hours after surgery. 
■ Watch for signs and symptoms of bleeding.
■ Treat dysrhythmias.
■ Prevention of right-sided heart failure.
■ Watch for early signs of rejection, infection, immunosuppressive issues.
■ Monitor for signs of drug toxicity.
■ ICU care for about 3–5 days post-op.
■ Treatment of rejection: treated with increased doses of cyclosporine,
azathioprine, high-dose corticosteroids, prednisone, monoclonal anti-
bodies or polyclonal antibodies.
■ Highest risk for infection: 1 week post-op.
Signs and Symptoms of Rejection
■ Low-grade fever
■ Fatigue
■ SOB
■ Peripheral edema
■ Pulmonary crackles
■ Pericardial friction rub
■ Arrhythmias
■ Decreased ECG voltage
■ Increased JVD
■ Hypotension
■ Cardiac enlargement on x-ray
■ Vascular degeneration
■ Tachycardia
■ Fatigue
■ Palpitations
■ Nausea and vomiting
Other Complications
■ Infection
■ CAD
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Carotid Endarterectomy (CE)
CE is a surgical procedure to remove plaque material from inside the
carotid artery, improving the carotid luminal diameter, allowing adequate
blood flow, therefore preventing stroke. The procedure is indicated in
symptomatic patients with carotid-territory TIA or minor strokes who
have carotid artery stenosis of 70%–99%.
Pathophysiology of the Disease Process Leading to CE
Surgery is performed on patients with symptomatic carotid artery steno-
sis. Fatty streaks are deposited in arterial intima → stimulates inflamma-
tory response that causes proliferation → blood vessels forming fibrous
caps → deposit buildup as atheromas or plaques → plaques build up
causing blood flow obstruction.
Clinical Presentation  
■ Signs and symptoms of TIA or stroke
■ Dizziness
■ Lightheadedness
Diagnostic Tests  
■ Ultrasound of carotid artery
■ Magnetic resonance angiography (MRA)
■ Contrast enhanced MRA (CEMRA)
■ Intra-arterial angiography (IAA)
Management of Clinical Condition 
■ Assess surgical site for bleeding.
■ Perform frequent neurological checks.
■ Administer antihypertensive medications.
■ Administer statins.
■ Administer antiplatelet agents. 
■ Administer aspirin (81–325 mg) before and after surgery.
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Infections of the Heart
Endocarditis
Endocarditis is the inflammation of the inner most layer of the heart. It can
include the heart valves, chordae tendinea, cardiac septum or the lining of
the chambers. It is caused typically by bacterial infections (Streptococcus
viridans or Staphylococcus aureus).
Pathophysiology 
Microbe invades the valve leaflets → infection occurs causing valve
leaflets to be deformed
Clinical Presentation 
Endocarditis presents as:
■ Acute onset of fever
■ Chills
■ Night sweats
■ Anorexia
■ Myalgia
■ Arthralgia
■ Extreme fatigue and malaise
■ Nausea and vomiting
■ Headache
■ Weight loss
■ SOB
■ Chest pain
■ Abdominal pain
■ Confusion
■ Pain in the muscles, joints, and back
Be suspicious if petechiae appears on the conjunctiva, neck, anterior
chest, abdomen, or oral mucosa. Look for Janeway lesions (nontender
macule) on patient’s palms and soles, Osler’s nodes (tender, erythema-
tous, raised nodules) on fingers and toe pads, and splinter hemorrhages
under fingernails.
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Diagnostic Tests 
■ Transthoracic echocardiogram
■ Abdominal computed tomography (CT) or MRI
■ Positive blood cultures
Management 
■ Antibiotic prophylaxis before certain invasive procedures.
■ Priorities include supporting cardiac function, eradicating the infec-
tion, and preventing complications, such as systemic embolization
and heart failure.
■ Do not give anticoagulants because of risk of intracerebral 
hemorrhage.
Pericarditis
Pericarditis is inflammation of pericardium that can cause fluid to accu-
mulate in the pericardial space due to idiopathic causes, infection, cardiac
complications, autoimmune reactions, certain drugs, or trauma.
Pathophysiology 
Primary illness of medical or surgical disorder can be the etiology → peri-
cardium becomes inflamed → can lead to excess fluid accumulation or
increased pressure on the heart leading to tamponade.
Clinical Presentation 
Sharp, constant chest pain that is located in the midchest (retrosternal) is
the most common symptom. A hallmark sign of pericarditis is if the
patient leans forward while sitting to relieve chest pain. Pain may radiate
to the neck, shoulders, and back; radiation to the ridge of the left trapez-
ius muscle is specific for pericarditis. 
Depending on the cause, patient may also have fever, malaise, tachy-
pnea, and tachycardia. Pericardial friction rub, heard in the lower sternal
border, is the most important physical sign.
Diagnostic Tests 
■ ECG
■ Echocardiogram
■ Chest x-ray
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■ Lab work: cardiac markers
■ Complete blood count
■ Urinalysis
■ Transesophageal echocardiogram (TEE)
Management
■ NSAIDs may be used for up to 2 weeks.
■ Monitor for cardiac tamponade.  
■ More severe pain can be controlled with morphine.
■ If cause is infectious, antibiotics or antifungal drugs may be adminis-
tered.
■ Treatment: Antibiotics specific to the pathogen for at least 6 weeks.
■ If a pericardiectomy is performed, continue assessments of VS, lab
work, and the appearance of wounds and insertion sites of invasive
lines. 
■ Monitor temperature and cardiac rhythm, assess for heart murmurs.
■ Perform neurological assessments, inspect skin surfaces, and monitor
drug peaks and troughs, and urine output.
Pacemakers/AICD
There are three types of pacemakers: 
■ Transcutaneous (external)
■ Percutaneous
■ Permanent
Transcutaneous Pacemakers
Transcutaneous pacemakers are used for noninvasive temporary pacing,
accomplished through the application of two large external electrodes.
The electrodes are attached to an external pulse generator, which can
operate on alternating current or battery. The generator emits electrical
pulses, which are transmitted through the electrodes and then transcuta-
neously to stimulate ventricular depolarization when the patient’s heart
rate is slower than the rate set on the pacemaker. Used as an emergency
measure, a transcutaneous pacemaker should be used for 48–72 hours
only. Electrodes should be changed every 24 hours minimally.
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Percutaneous Pacemakers
Percutaneous pacemakers are for invasive temporary pacing. An invasive
temporary pacemaker system consists of an external battery pulse gener-
ator and pacing electrodes, or lead wires. These wires attach to the gen-
erator on one end and are in contact with the heart on the other end.
Electrical pulses, or stimuli, are emitted from the negative terminal or the
generator, flow through a lead wire and stimulate the cardiac cells to
depolarize.
Permanent Pacemakers
Permanent pacing is performed for the resolution of nontemporary con-
duction disorders, including complete heart block and sick sinus syn-
drome. Permanent pacemakers are usually powered by a lithium battery
and have an average life span of 10 years. 
Automatic Implantable Cardioverter Device (AICD)
AICD is indicated for the patient who has experienced one or more
episodes of spontaneous sustained ventricular tachycardia (VT) or ven-
tricular fibrillation (VF) unrelated to MI or other causes amendable to 
correction.
Cardiac Tamponade
Cardiac tamponade is excessive fluid or blood from the heart in the peri-
cardial space that accumulates pressure in the pericardial sac and affects
the heart’s function.
Pathophysiology 
Causes: accidents, stab wounds, gun shot wounds, rupture of tumors, obstruc-
tion of lymphatic or venous flow → accumulate blood in the pericardial sac →
venous pressure → compress all four chambers of the heart → RA and RV
are compressed → ↓ RA filling during diastole → ↓ venous blood returns to RA
↓
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→ venous pressure → JVD, edema, hepatomegaly, DBP → continued
compression of the heart → ↓ diastolic filling of ventricles → ↓ SV, ↓ CO, ↓
tissue perfusion → body attempts to increase blood volume, increase SV →
workload of the heart → body compensation → tachycardia → all of these
complications last for a limited amount of time → shock, cardiac arrest, or
death if not immediately corrected.
Clinical Manifestations 
First Signs
■ Anxiety and restlessness
■ Cool, diaphoretic skin
Classic Signs
■ Beck’s triad: muffled heart sounds, increased JVD, and hypotension
■ Narrow pulse pressure (SBP and DBP)
■ Tachycardia
■ Weak, thready pulse
Late Signs
■ Pulsus paradoxus (↓ SBP of more than 10 mm Hg on inspiration)
■ Electrical alternans (alternating levels of voltage in the P waves and
QRS complexes in all leads and may occur in T waves)
Diagnostic Tests
■ Chest x-ray
■ Echocardiogram
Management 
■ Call MD stat.
■ Obtain Stat 2-D echocardiogram.
■ Obtain Stat chest x-ray.
■ Obtain Stat lab work.
■ MD to place PA catheter.
■ Place patient in supine position, HOB elevated 30°–60°.
■ Administer O2. 
■ Give sedatives, morphine for chest pain.
↓
↓↓
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■ Obtain ECG.
■ If on mechanical ventilation: No positive pressure used.
■ Inotropic drugs on standby.
■ Blood, plasma, volume expander on hand.
ACLS Algorithms: Cardiac/Respiratory Arrest
Ventricular Fibrillation (VF) or Pulseless Ventricular
Tachycardia (VT)
■ Shock: Biphasic: 200 J; monophasic: 360 J. Reassess rhythm.
■ CPR: Immediately perform 5 cycles of CPR (should last about 2 min).
■ Epinephrine: 1 mg IV or IO (2 to 2.5 mg, endotracheal tube) every 3–5 min
or Vasopressin: 40 units IV or IO, one time only. May use to replace 1st
or 2nd dose of epinephrine (given without interrupting CPR).
■ Shock: Biphasic: 200 J; monophasic: 360 J. Reassess rhythm.
■ Consider antiarrhythmics (given without interrupting CPR):
■ Amiodarone: 300 mg IV or IO, may repeat 150 mg in 3–5 min.
■ Lidocaine: 1.0–1.5 mg/kg IV or IO, may repeat 0.5 to 0.75 mg/kg
q5–10 min, max 3 mg/kg.
■ Magnesium: 1–2 g IV or IO for Torsade de Pointes.
Asystole or PEA (Pulseless Electrical Activity)
■ Resume CPR for 5 cycles (should last about 2 minutes).
■ Epinephrine: 1 mg IV or IO (2 to 2.5 mg ET) every 3–5 min or
Vasopressin: 40 units IV or IO, one time only. May use to replace 1st
or 2nd dose of epinephrine (given without interrupting CPR).
■ Atropine: 1 mg IV (2 to 3 mg endotracheal tube every 3–5 min) (maxi-
mum 3 mg) for asystole or bradycardic PEA.
Intra-Aortic Balloon Pump (IABP)
An IABP consists of a 30-cm polyurethane balloon attached to one end of
a large bore catheter. The device is inserted into the femoral artery at the
groin, either percutaneously or via arteriotomy, with the balloon wrapped
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tightly around the catheter. Once inserted, the catheter is advanced up the
aorta until the tip lies just beyond the origin of the L subclavian artery.
When in place, the balloon wrapping is released to allow periodic balloon
inflations.
Effects 
The intra-aortic balloon is inflated with helium at the onset of each dia-
stolic period, when the aortic valve closes. The balloon is deflated at the
onset of ventricular systole, just before aortic valve opens. Inflation of
the balloon increases the peak diastolic pressure and displaces blood
toward the periphery. Deflation of the balloon decreases the end-
diastolic pressure, which reduces impedance to flow when aortic valve
opens at onset of systole. This decreases ventricular afterload and pro-
motes stroke volume.
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IABP waveforms
Indications
■ Cardiopulmonary bypass
■ Cardiac transplant
■ AMI with cardiogenic shock
■ Acute mitral valve insufficiency
■ Unstable angina
Contraindications
■ Aortic regurgitation
■ Aortic dissection
■ Recently placed (within 12 months) prosthetic graft in thoracic aorta
m
m
 H
g
Time
Systole Diastolic augmentation
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ECGs
12-Lead ECG
Lead Placement
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I aVR V1 V4
II aVL V2 V5
III aVF V3 V6
Midclavicular
line
V1 V2
V3 V4
V5
V6
Anterior
axillary line 
Midaxillary
line
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Hemodynamics of Dysrhythmias
Atrial Dysrhythmias
Atrial dysrhythmias are caused by increased automaticity in the atria. The
patient may complain of palpitations or “heart racing.” Loss of atrial con-
traction → shortens diastole → loss of atrial kick (25%–30% of C.O.) → ↓
C.O. → ↓ coronary perfusion → ischemic myocardial changes.
Causes 
■ Amphetamines
■ Cocaine
■ Decongestants
■ Hypokalemia
■ Hyperthyroidism
■ COPD
■ Pericarditis
■ Digoxin toxicity
■ Hypothermia
■ Alcohol intoxication
■ Pulmonary edema
Ventricular Dysrhythmias
Ventricular dysrhythmias are caused by increased automaticity in the ven-
tricles. PVCs—patient complains of “heart skipping a beat.” This dys-
rhythmia can lead to bradycardia → ↓ C.O. → ↓ BP and eventually VT, VF,
and death. 
Bradycardia 
Bradycardia is defined as a heart rate less than 60 bpm. ↓HR → ↓ C.O. →
↓ BP → ↓ perfusion to brain, heart, kidneys, lung & skin.
Causes
■ Vomiting
■ Gagging
■ Valsalva maneuver
■ ETT suctioning
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Symptoms
■ Chest pain
■ SOB
■ Altered mental status
Treatment Considerations
■ Atropine
■ Epinephrine
■ Isoproterenol (Isuprel)
■ Pacemaker
■ Dopamine if hypotensive
Tachycardia 
Tachycardia is defined as a heart rate greater than 100 bpm. HR can
compromise C.O. by ↓ ventricular filling → ↓ SV → ↓ C.O. → workload
of the heart → O2 consumption.
Causes
■ Caffeine
■ Nicotine
■ Pain
■ Fever
■ Stress
■ Anxiety
Symptoms
■ Altered LOC
■ Chest pain or discomfort
■ Palpitations
■ SOB
■ Diaphoresis
■ Hypotension
■ Jugular venous distention
Treatment Considerations
■ Carotid massage 
■ Valsalva maneuver 
■ Cardiovert at 100 J–360 J
■ Radiofrequency ablation
■ Pacemaker 
↓
↓
↓↓
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■ If arrhythmia converts to pulseless VT or VF → defibrillate
■ Implantable cardioverter defibrillator (ICD), if indicated
Determining Rate and Measurement
To figure out rate (regular rhythms only), you can do one  
of the following: 
 
Count the number of QRS complexes 
(regular rhythms only) in a 6-sec strip  
and multiply by 10. 
Divide the number of large boxes 
between two R waves into 300. 
Remember the number sequence below and find an  
R wave that falls on a heavy line.  Starting from the  
next heavy line, count 300, 150, 100, and so forth,  
and whatever line the next R wave falls on is the  
heart rate (see below for example). 
Irregular 
rhythms 
should be 
counted for 
an entire 
minute. 
300 150 100 60 75 50 43 
    
 
1st R wave 
One big box represents  
0.20 sec and is 5 mm2. 
One small box 
represents  
0.04 sec and  
is 1 mm2. 
Inherent rates of different cardiac regions: 
SA Node ..................... 60– 100 bpm 
AV Node ....................... 40– 60 bpm 
Ventricles ..................... 20– 40 bpm 
Next R wave here 
would be 60 bpm.
Next R wave here 
would be 150 bpm.
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Normal Cardiac Cycle and Measurements
Normal Rate → 60 to 100 bpm
Normal P-R → 0.12 to 0.20 sec
Normal QRS → 0.08 to 0.12 sec
P wave → atrial depolarization; QRS → ventricular depolarization; 
T wave → ventricular repolarization
Quick Guide to Analyzing the ECG
■ Determine the overall rate: <60 bpm → bradycardia, >100 bpm 
→ tachycardia.
■ Determine the regularity: Regular or irregular. 
■ If irregular, is there any pattern? 
■ Examine the P waves.
■ Is there a P wave before each QRS? Is there more than 1 P wave? 
■ Are P waves absent?
■ What is the configuration of the P wave? Round? Saw toothed?
■ Do they look the same?
■ Do any occur earlier or later than expected?
■ Are any P waves located within the QRS or T wave?
■ Determine the PR interval. 
■ Is it normal, prolonged, or shortened?
■ Can it be measured?
■ Is it the same for each beat? Any pattern?
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■ Examine the QRS complex.
■ Is there a QRS after each P wave?
■ Do they look the same?
■ Do any occur earlier than expected?
■ Is there a pattern to QRS complexes occurring early?
Normal Cardiac Rhythm Parameters
NSR • 60 bpm–100 bpm
Bradycardia • <60 bpm; consider sinus bradycardia, AV block
Tachycardia • >100 bpm; consider atrial fibrillation, atrial flutter,
supraventricular tachycardia, ventricular tachycardia
PR interval • 0.12–0.20 sec
• >0.20 sec; consider AV block
• <0.12 sec; consider junctional rhythm
• Unable to determine; consider atrial arrhythmia, junc-
tional arrhythmia; examine QRS to determine if 
ventricular arrhythmia
P wave • Generally round
• Saw toothed → Consider atrial flutter
• Spiked, nonrounded; consider atrial fibrillation or PACs
QRS • 0.06–0.10 sec
• Wide, bizarre; consider PVC, VT
Baseline is grossly irregular with no discernible P waves; consider VT
Flat baseline, asystole; begin CPR for either dysrhythmia.
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Respiratory Disorders
Adult Respiratory Distress Syndrome (ARDS)
ARDS is defined as noncardiogenic pulmonary edema characterized by
severe refractory hypoxemic respiratory failure and decreased pulmonary
compliance.
Pathophysiology
capillary/alveolar membrane permeability → interstitial & alveolar leak
→ right-to-left intrapulmonary shunting → severe and refractory hypox-
emia, metabolic acidosis. Inactivation of surfactant → alveolar atelectasis,
↓ lung compliance → hypoventilation and hypercapnia.
Clinical Presentation
Symptoms of ARDS occur within 24 to 48 hours of cause and include: 
■ Increased respiratory rate, increased work of breathing, dyspnea,
cyanosis
■ Crackles, rhonchi or wheezes, dry cough
■ Intercostal and suprasternal retraction, retrosternal discomfort
■ Agitation, restlessness, anxiety, confusion
■ Diaphoresis
■ Abdominal paradox
■ Increased pressure to ventilate
■ Hypoxemia refractory to increased fractional concentration of 
oxygen in inspired gas (FIO2)
■ Increased peak inspiratory pressure
■ Decreased lung volume, decreased functional residual capacity, low
ventilation/perfusion (V/Q) ratio
■ Pulmonary capillary wedge pressure (PCWP) <18 mm Hg and/or no
evidence of CHF or left atrial hypertension
■ Acute respiratory alkalosis initially, which may progress to respiratory
acidosis
■ Worsening arterial blood gases (ABGs) with increased FIO2,, increased
crackles
■ Worsening partial pressure of arterial oxygen (PaO2)/FIO2 (P/F) ratio
■ Diffuse bilateral pulmonary infiltrates on chest x-ray (CXR) indicates
“whiteout”
■ Fluid and electrolyte problems
→
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Diagnostic Tests 
■ Arterial and venous blood gases
■ Mixed venous oxygen saturation
■ Continuous oxygenation monitoring via pulse oximetry
■ Pulmonary function tests
■ Pulmonary artery catheter
■ Serial CXRs
■ Chest computed tomography (CT)
■ CBC, metabolic panel, serum lactate (lactic acid)
Management 
■ Treat underlying cause.
■ Administer O2 mask or mechanical ventilation with positive end-
expiratory pressure (PEEP) and high FIO2. Consider oscillator ventilator—
used when difficulty oxygenating a patient on conventional setting
because of poor lung compliance (required neuromuscular blockade).
■ Refer to basics: mechanical ventilation, blood gases p. 6 and p. 2.
■ Provide continuous arteriovenous hemofiltration (CAVH).
■ Maintain hemodynamic stability.
■ Administer glucocorticosteroids.
■ Administer surfactant therapy.
■ Place patient in prone position.
■ Administer diuretic; fluid management.
■ Provide sedation or therapeutic paralysis if necessary.
■ Provide pain control.
■ Provide nutritional support.
■ Cluster activities to decrease fatigue.
■ Investigational management of ARDS includes inhaled nitrous oxide,
liquid ventilation, ECMO, alveolar surfactant, and vasodilators.
Extracorporeal Membrane Oxygenation (ECMO)
ECMO is a modified form of cardiorespiratory bypass. It provides oxy-
genation and pulmonary support for patients in severe respiratory failure,
particularly ARDS. Its purpose is to avoid high oxygen concentrations and
high peak inspiratory pressures, PEEP, and tidal volume, while allowing
the lung to rest and heal.
Venovenous (VV) ECMO 
The right internal jugular, saphenous, common iliac, or femoral veins
are cannulated. The patient’s blood is circulated through a membrane
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oxygenator in which O2 is infused and CO2 removed. ECMO can 
compensate for approximately 70% of the patient’s gas exchange
requirements.
Functional oxygen saturation (SpO2) and CO2 are monitored continu-
ously to maintain values of 50%–80% and 35–45 mm Hg, respectively.
Complications include infections and sepsis, bleeding, disseminated
intravascular coagulation (DIC) and intracranial bleeding, air emboli, renal
failure, decubitus ulcers, and heparin-induced thrombocytopenia.
Nursing care is aimed toward preventing complications.
Shunting
Anatomic shunt is defined as the diversion of blood flow from the right
side of the heart directly into the left side of the heart without coming into
contact with the alveoli.
Physiologic shunt (capillary shunt; or right-to-left shunt) is defined as
the flow of blood from the right side of the heart, through the lungs, and
into the left side of the heart without taking part in alveolar and capillary
diffusion. Pulmonary blood perfuses completely unventilated alveoli.
Absolute shunt (true shunt) is defined as a combination of the anatom-
ic and capillary shunt, and is generally refractory to oxygen therapy.
The V/Q ratio expresses the relationship of alveolar ventilation to 
pulmonary capillary perfusion:
■ Decreased ventilation plus increased perfusion represents a low V/Q
ratio.
■ Increased ventilation plus decreased perfusion represents a high V/Q
ratio.
Diagnostic Tests 
■ Alveolar-arterial (A-a) gradient (PAO2/PaO2)
■ PAO2 represents the partial pressure of alveolar O2 (mm Hg).
■ PaO2 represents the partial pressure of arterial O2 (mm Hg).
■ Value is used to calculate the percentage of the estimated shunt.
■ Value represents the difference between the alveolar and arterial
oxygen tension.
■ Normal A-a gradient value <15 mm Hg.
■ Value is increased in atrial or ventricular septal defects, pulmonary
edema, ARDS, pneumothorax, and V/Q mismatch.
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■ a/A ratio (PaO2/PAO2).
■ If ratio <0.60, shunt is worsening.
■ Estimation of shunt using PaO2/FIO2 (P/F) ratio:
■ P/F ratio 500 indicates a 5% shunt.
■ P/F ratio 300 indicates a 15% shunt.
■ P/F ratio 200 indicates a 20% shunt.
Ventilator-Assisted Pneumonia (VAP)
VAP is an airway infection that develops more than 48 hours after the
patient is intubated. It is associated with increased mortality, prolonged
time spent on a ventilator, and increased length of ICU/hospital stay. 
Pathophysiology
VAP is usually caused by gram-negative bacilli or Staphylococcus aureus
via microaspiration of bacteria that colonize the oropharynx and upper
airways or bacteria that form a biofilm on or within an endotracheal tube
(ETT). The presence of an ETT also impairs cough and mucociliary clear-
ance. Suctioning also contributes to VAP.
Clinical Presentation
VAP presents with:
■ Increased RR, HR, and temperature (>38.3°C or 101°F)
■ Increased WBC (>10,000/mm3)
■ Increased purulent tracheal secretions
■ Crackles
■ Worsening oxygenation, hypoxemia, PaO2/FIO2 changes
Diagnostic Tests 
■ CXR shows new or persistent infiltrate
■ Tracheal aspirate and blood cultures
■ Clinical Pulmonary Infection Score (CPIS) >6
■ Bronchoscopy or bronchoalveolar lavage
Management 
■ Monitor CXR and amount and color of tracheal secretions.
■ Give IV antibacterials to which the known causative bacteria are 
sensitive. Consider:
■ Piperacillin/tazobactam (Zosyn)
■ Gentamicin (Garamycin)
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■ Tobramycin (Nebcin) 
■ Vancomycin (Vancocin)
■ Ceftazidime (Fortax, Ceptaz)
■ Levofloxacin (Levaquin)
■ Imipenem/cilastatin (Primaxin)
■ Linezolid (Zyvox)
■ Ticarcillin (Ticar)
■ Daptomycin (Cubicin)
■ Ticarcillin (Ticar)
■ Ciprofloxacin (Cipro)
■ Amikacin (Amikin)
■ Aztreonam (Azactam)
Evidence-Based Practice Guidelines to Prevent VAP
(Ventilator Bundle):
■ Elevate head of bed 30–45 degrees.
■ Provide “sedation vacations”: Decrease amount and frequency of
sedation.
■ Assess readiness to extubate and extubate as soon as possible.
■ Provide peptic ulcer disease prophylaxis with H2-receptor inhibitors.
■ Provide deep venous thrombosis prophylaxis.
■ Use meticulous hand hygiene, use gloves appropriately. 
■ Use meticulous sterile technique when appropriate.
■ Use a continuous aspiration of subglottic secretion (CASS) ETT.
■ Provide meticulous oral care every 12 hours, including brushing the
teeth with a soft toothbrush, tap water, and toothpaste for 1–2 minutes;
brushing the tongue; and applying lip balm and moisturizing swabs.
Follow with 0.5 oz of 0.12% chlorhexidine gluconate rinse to tooth
enamel, gums, and posterior oropharynx.
■ Eliminate routine saline bronchial lavage during ETT suctioning.
■ Use continuous lateral rotation therapy (CLRT).
■ Drain condensation in ventilator tubing down and away from patient.
■ Suction every 4 hours and prn. Replace all suction equipment every
24 hours.
■ Feeding tubes should be placed beyond the pylorus of the stomach.
■ Discontinue mechanical ventilation as soon as possible. Consider
bilevel positive airway pressure (BiPAP) and continuous positive 
airway pressure (CPAP).
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Hospital-Acquired Pneumonia Risk Index †
Factor Points Patient Patient 
A B
Temperature (°C) >36.5 and <38.4 0
>38.5 and <8.9 1
>9 and <36 2
Blood leukocytes, μL >4,000 and <11,000 0
<4,000 or >11,000 1
Band forms >50% 1
Tracheal secretions None 0
Nonpurulent 1
Purulent 2
Oxygenation: 
PaO2/FIO2, mm Hg >240 or ARDS 0
<240 and no ARDS 2
Pulmonary 
radiography: No infiltrate 0
Diffuse (or patchy)  
infiltrate 1
Localized infiltrate 2
Progression of 
infiltrate*: None 0
Progression (heart 
failure and ARDS 
excluded) 2
Growth of pathogenic 
bacteria on tracheal No, rare, or light
aspirate culture*: growth 0
Moderate or heavy 1
growth
Same bacteria as on 
Gram stain 1
Total
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Community-Acquired Pneumonia (CAP)
CAP is pneumonia or inflammation of the lung parenchyma that develops
in the community setting or within 48 hours of hospitalization. There are
two types of CAP: 
■ Typical or bacterial: Infection by bacteria in the alveoli that cause
inflammation.
■ Atypical or nonbacterial: “Patchy” inflammatory change in the alveo-
lar sputum and the interstitium of the lungs with less severe symp-
toms than typical pneumonia.
Pathophysiology
Bacteria (Streptococcus pneumoniae, Haemophilus influenzae, Staph-
ylococcus aureus) → aspirated to lung → trapped by mucus producing
cells → alveolar macrophages fail → activation of inflammatory media-
tors, cellular inflation, immune activation → damage bronchial mucous
membrane and alveocapillary membrane → fill acini and terminal bron-
chioles with infectious debris and exudates → edema.
Clinical Presentation
CAP presents with:
■ Rapidly rising temperature (101°F–105°F or 38.5°C–40.5°C)
■ Chest tightness or discomfort
■ Diaphoresis, chills, general malaise
■ Tachycardia
■ Tachypnea (25–45 breaths/min), shortness of breath (SOB), dyspnea
■ Cough with or without sputum
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PaO2/FIO2 = ratio of arterial O2 pressure to fraction of inspired O2; ARDS = acute respiratory dis-
tress syndrome.
*Criteria applicable 72 hours after initial diagnosis.
Score >6 suggests hospital-acquired pneumonia.
Score <6 suggests alternative process.
†Adapted from Singh N, Rogers P, Atwood CW, et al: Short-course empiric antibiotic therapy for
patients with pulmonary infiltrates in the intensive care unit. American Journal of Respiratory
and Critical Care Medicine 162:505–511, 2000 In Beers, MH: The Merck Manual, 18th edition. 
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■ Inspiratory and expiratory crackles
■ Diminished breath sounds
■ Hypoxia
Diagnostic Tests 
■ CXR
■ Sputum and blood cultures
■ CBC, erythrocyte sedimentation rate (ESR)
■ ABGs or O2 saturation
Management 
■ Monitor CXR and amount and color of tracheal secretions.
■ Provide oxygenation and ventilation: O2 by cannula/mask, mechanical
ventilation. Assess oxygenation status by ABGs or pulse oximeter.
■ Provide adequate hydration and nutrition.
■ Administer mucolytics and encourage effective coughing and deep
breathing. Provide chest physiotherapy.
■ Change patient’s position frequently to enhance clearance of secretions
and improve ventilation. Place in semi-Fowler position.
■ Give antibacterials to which the known causative bacteria are sensitive.
Consider:
■ Uncomplicated CAP: clarithromycin (Biaxin), azithromycin
(Zithromax), erythromycin, doxycycline (Vibramycin).
■ Complicated CAP: clarithromycin (Biaxin), azithromycin
(Zithromax), erythromycin, moxifloxacin (Avelox), levofloxacin
(Levaquin), gemifloxacin (Factive), gatifloxacin (Tequin).
Pneumothorax
Pneumothorax is defined as air entering the pleural space and interrupt-
ing the negative pressure, which results in partial or total lung collapse. 
Types of pneumothorax include:  
■ Spontaneous pneumothorax: Rupture of subpleural bleb with
unknown cause that may be related to smoking and connective tissue
disorder. Patients with chronic lung disease (COPD) have a higher
incidence.
■ Traumatic pneumothorax: Caused by blunt chest trauma, penetrating
injury, pulmonary contusion → rib fracture or puncture directly to the
lung → penetrates parietal and visceral pleura → punctures the lung
parenchyma → lung air pressure from positive to negative pressure
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environment (inside the lung) → pneumothorax. If pneumothorax
remains confined → air in pleural space on inspiration → air cannot
exit on expiration → pressure . 
■ Tension pneumothorax: Due to increased pressure in the pleural
space causing the lung to collapse. The increase in pressure may
impair circulation by compressing the heart and vena cava.
Pneumothorax can also be categorized by size: 
■ Small pneumothorax (<15%)
■ Moderate pneumothorax (15%–60%)
■ Large pneumothorax (>60%)
Clinical Presentation
Pneumothorax presents with:
■ Shortness of breath, dyspnea.
■ Sharp pleuritic chest pain that increases with deep inspiration and
cough on the ipsilateral side. Pain may radiate to the shoulder, neck,
or epigastrium.
■ Decreased breath sounds, hyperresonance to percussion, absent 
tactile fremitus on the affected side.
■ Hypoxemia, decreased SpO2 or SaO2.
■ Tachycardia, hypotension.
■ Subcutaneous emphysema → swelling in affected area with crepitus
upon auscultation.
Can develop into tension pneumothorax → severe respiratory distress,
cyanosis, absent breath sounds on the affected side, sinus tachycardia
>140 bpm → tracheal deviation → midline shift, hypotension, changes in
mental status
Diagnostic Tests 
■ CXR
■ CT scan
■ ECG
Management 
■ Assess vital signs, skin color, breathing pattern, pain level, and 
oxygenation.
■ Keep patient upright.
■ Administer O2 as needed by nasal cannula or mask, and monitor O2
saturation.
→
→
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■ Use needle aspiration to remove accumulating air.
■ Insert chest tube.
■ In the case of a small pneumothorax (no symptoms and uncomplicat-
ed), observe and monitor the patient for pneumothorax resolution at
1.25% every day.
Pulmonary Edema
Pulmonary edema is defined as abnormal accumulation of fluid in the
alveoli, lung tissues, or airway.
Pathophysiology
Inadequate LV function → blood backs up into the pulmonary venous sys-
tem → pressure in the pulmonary vasculature → forces intravascular
fluid into alveoli and interstitial spaces of lungs → impaired gas exchange
→ respiratory distress.
Risk factors include: 
■ Excess fluid in pulmonary capillaries (e.g., HF) 
■ Cocaine-induced pulmonary vasoconstriction 
■ Leakage of pulmonary capillary membrane (e.g., ARDS, pneumonia)
Clinical Presentation
■ Weak peripheral pulses
■ Capillary refill >3 seconds
■ Peripheral cyanosis
■ Tachycardia
■ Tachypnea
■ Decreased SpO2 or PaO2 with dyspnea
■ Decreased cardiac output 
■ Pallor, diaphoresis
■ Vasoconstriction
■ Arrhythmias
■ Respiratory distress: SOB, decreased respiratory rate, crackles at lung
base
■ Decreased urine output
■ Cough
■ Pink, foamy, and frothy sputum
■ Change in mental status
→
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Diagnostic Tests 
■ CXR
■ ABGs and/or pulse oximetry
■ ECG
■ Plasma B-type natriuretic peptide (BNP) level
■ Normal level: 34–42 pg/mL (11.0–13.6 pmol/L)
■ Serum cardiac markers 
■ Two-dimensional transthoracic echocardiogram
■ Transesophageal echocardiogram
Management 
■ Maintain sitting position if BP reading permits.
■ Start IV and obtain ABGs.
■ Administer O2 of 5–6 L/min by simple face mask or 1–15 L/min by
nonrebreather mask with reservoir and keep SpO2 >90%. 
■ Increase O2 concentration if needed. If unable to resolve respiratory
distress, intubation or mechanical ventilation is needed. Consider
PEEP.
■ Monitor patient with cardiac monitor and pulse oximeter. 
■ If systolic BP >100, administer nitroglycerin.
■ Administer diuretic: IV furosemide (Lasix) 0.5–1 mg/kg.
■ Administer morphine slowly if BP is stable.
■ Treat the underlying cause.
Pulmonary Arterial Hypertension (PAH)
PAH is defined as a mean pulmonary artery pressure (PAPm) ≥25 mm Hg
and a PCWP <15 mm Hg as measured by cardiac catheterization, with a
resultant increased pulmonary vascular resistance.
Pathophysiology
PAH is seen in preexisting pulmonary or cardiac disease, familial pul-
monary or cardiac disease, chronic obstructive pulmonary disease
(COPD), obesity, alveolar hypoventilation, smoke inhalation, high altitude,
collagen vascular disease, and congenital heart disease.
Hypoxemia → hypertrophy of smooth muscle in pulmonary arteries → ↓
lumen vessel size → vasoconstriction → narrow of artery vessels → resist-
ance to blood flow → right ventricle pumps harder to move blood across the
resistance→ pulmonary vascular resistance→ right ventricle  workload→→
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→ smooth muscle proliferated → vascular obliteration → luminal obstruc-
tion → pulmonary artery pressure and PVR → right ventricle hypertrophy,
right heart dilation, ↓ RV cardiac function. 
Clinical Presentation
■ Increased mean right atrial pressure, decreased cardiac index,
increased PAPm
■ ECG: Increased P-wave amplitude (lead II), incomplete right bundle-
branch block (RBBB), tall right precordial R waves, right axis devia-
tion, and right ventricular strain
■ Hypoxemia, central cyanosis
■ Labored and painful breathing, crackles, wheezing
■ Jugular venous distention (JVD), hepatomegaly  
■ Atrial gallop, narrow splitting of S2 or increased S2 intensity, ejection
click
■ Heart palpitations, angina-like chest pain
■ LVF: SOB, hypoventilation, tachypnea, coughing, fatigue, syncope,
hypotension, decreased urinary output, decreased cardiac output,
shock
■ RVF: Peripheral edema, tricuspid regurgitation, prominent heave over
right ventricle palpated
■ Hoarseness if pressure on left recurrent laryngeal nerve
Diagnostic Tests 
■ Electrocardiogram
■ Two-dimensional echocardiogram with Doppler flow
■ CXR or CT
■ Polysomnography for PAH sleep-disordered breathing
■ V/Q scan—Contraindicated in patients with primary pulmonary 
hypertension
■ Pulmonary angiography with right-sided heart catheterization
■ Pulmonary function tests
■ ABGs, CBC
Management 
■ Therapy is dependent upon the stage of the disease.
■ The aim is to decrease pulmonary pressure, remove excessive fluid,
and decrease the risk of clotting.
■ Hemodynamic monitoring.
■ Oxygen therapy: Cannula, mask, ventilator.
→
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■ Stand-by therapeutic phlebotomy if Hct >60%.
■ Low-sodium diet and fluid restrictions.
■ Vasodilators, digoxin (Lanoxin), anticoagulants, judicious use of
diuretics.
■ Administer calcium channel blockers (not for patients with cor pul-
monale): nifedipine (Procardia), diltiazem (Cardizem), amlodipine
(Norvasc); avoid verapamil (negative inotropic effects).
■ Administer prostanoids: treprostinil (Remodulin), iloprost.
■ Administer endothelin-receptor antagonists: bosentan (Tracleer),
sitaxsentan, ambrisentan.
■ Administer phosphodiesterase type 5 (PDE5) inhibitors: sildenafil
(Viagra).
■ Surgury (optional): Atrial septostomy, pulmonary thromboendarterec-
tomy.
■ Lung or heart-lung transplant.
Pulmonary Embolism
Pulmonary embolism is defined as an obstruction of the pulmonary artery
or its branch (pulmonary vasculature) by a thrombus or thrombi (blood
clot) that originates in the venous circulatory system or the right side of
the heart.
Pathophysiology
Usually the result of deep vein thrombosis (DVT) in the legs. Also femoral,
popliteal, and iliac veins. Other types: air, fat especially due to long bone
fractures, amniotic fluid, tumors, bone marrow, septic thrombi, vegetations
on heart valves.
Risk factors include: 
■ Venous stasis 
■ Surgery (GYN, abdominal, thoracic, orthopedic) 
■ Pregnancy 
■ Estrogen therapy (BCP, HRT) 
■ Obesity 
■ Advanced age 
■ Carcinomas 
■ Immobilization 
■ Trauma 
■ Heart failure 
93
RESP
20841_Tab03_081-100.qxd  1/15/09  6:05 PM  Page 93
RESP
94
■ Stroke 
■ Sepsis
Thrombus obstructs the pulmonary artery or branch → ↓ blood flow to
lungs → impaired/absent gas exchange → ventilation /perfusion mis-
match (dead space ventilation) → platelets accumulate around thrombus
→ release of endotoxins → constrict regional blood vessels + bronchioles
→ pulmonary vascular resistance → pulmonary arterial pressure →
↓ right ventricular work to maintain pulmonary blood flow → right ventric-
ular failure → ↓ cardiac output → ↓ systemic blood pressure → shock
Clinical Presentation
Symptoms, which depend on size of the thrombus and areas of the occlu-
sion, may include:
■ Dyspnea, tachypnea, crackles, cough 
■ Chest pain (sudden, pleuritic, sharp), angina pectoris, myocardial
infraction (MI)
■ Mental confusion, restlessness
■ Leg cramps
■ Nausea and vomiting
■ Hemoptysis, syncope
■ Cardiac arrhythmias, palpitations, hypotension, S3 or S4 gallop
■ Anxiety, apprehension
■ Fever (>37.8°C), diaphoresis, chills
■ Acute cor pulmonale
■ Hypoxemia with PaO2 <80 mm Hg and SaO2 <95%
Diagnostic Tests 
■ CXR
■ ECG (tall, peaked P wave; tachycardia; atrial fibrillation; RBBB)
■ ESR, WBC
■ ABGs (low PaO2)
■ D-dimer assay
■ Venous ultrasonography and impedance plethysmography
■ Ventilation-perfusion V/Q scan
■ Pulmonary angiography 
■ Contrast-enhanced spiral chest CT scan
■ High-resolution helical CT angiography
→→
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Management 
■ Provide oxygen by cannula, mask, or ventilator.
■ Start heparin infusion.
■ Administer sodium bicarbonate if acidotic.
■ Monitor prothrombin time (PT), partial thromboplastin time (PTT),
international normalized ratio (INR).
■ Administer pain medication if needed.
■ Administer heparin bolus.
■ Elevate head of bed; elevate lower extremities if DVT present.
■ Assess vital signs and lung sounds frequently.
■ Prepare for surgical embolectomy–intracaval filter
■ Administer thrombolytic drug therapy: Recombinant tissue plasmino-
gen activator (TPA), reteplase, streptokinase, urokinase, alteplase.
■ Administer morphine to manage pain and anxiety.
■ Administer inotropic agents if heart failure present.
■ Prevention: 
■ Enoxaparin (Lovenox) 30–40 mg daily.
■ Dalteparin (Fragmin) 2,500–5,000 units presurgery and 
postoperatively.
■ Heparin 5,000 units every 8 hours. 
■ Leg exercises—dorsiflexion of the feet.
■ Frequent position changes, ambulation.
■ Antiembolism stockings.
Carbon Monoxide (CO) Poisoning
CO poisoning is defined as an abnormal level of CO in the bloodstream.
Normal carboxyhemoglobin (COHgb) level for nonsmokers is <2%; for
smokers it is 5% but may be as high as 13%.
Carboxyhemoglobin COHgb level >60% → cardiac toxicity, neurotoxicity,
systemic acidosis, respiratory arrest, death.
Pathophysiology
Carbon monoxide (CO) affinity for Hgb is 300 times that of O2. CO binds
with Hgb → ↓ O2 binding sites → more CO binds → carboxyhemoglobin
forms → CO changes structure of Hgb molecules → more difficult for O2
to bind → tissue ischemia and hypoxemia → acute respiratory failure,
ARDS, end organ dysfunction and death.
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CO as an inflammatory mediator → tissue damage with capillary leak-
age and edema → tracheal and bronchial constriction.
CO → ↓ activity of nitric oxide → (1) peripheral vasodilation → ↓ cere-
bral blood flow and systemic hypotension; (2) formation of free radicals
→ endothelial damage and oxidative damage to brain; myocardial depres-
sion and arrhythmias → ↓ cardiac output → impaired tissue perfusion.
Clinical Presentation
Early signs 
■ Headache 
■ Nausea 
■ Vomiting 
■ General fatigue 
■ Difficulty staying focused 
■ Flu-like symptoms
Later signs 
■ Chest pain 
■ Palpitations 
■ Dysrhythmias 
■ MI 
■ Pulmonary edema
■ Throbbing headache, weakness, fatigue, dizziness, memory loss, 
ataxia, confusion, inability to concentrate
■ Skin pale to reddish purple (not a reliable sign)
■ Blurred vision, retinal hemorrhages
■ Tachypnea, dyspnea, respiratory alkalosis
■ Nausea, vomiting, lactic acidosis, rhabdomyolysis
■ Upper airway obstruction—hoarseness, dry cough, labored breathing,
stridor, difficulty swallowing
■ Brassy cough with carbonaceous (soot or carbon) sputum
■ Wheezing, bronchospasm
Diagnostic Tests 
■ COHgb and myoglobin concentration, CBC, CK
■ ABG (pulse oximetry inaccurate)
■ ECG and CXR
■ Fiberoptic bronchoscopy and ventilation/perfusion (V/Q) scan
→
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Management 
■ Monitor COHgb levels until <10%.
■ Administer 100% O2 via rebreather mask or ETT (mechanical ventila-
tion) to increase PaO2 levels and decrease PaCO2 levels.
■ Assess loss of consciousness (LOC) using Glasgow Coma Scale.
■ Monitor pH level if lactic acidosis present.
■ Monitor cardiac status. Myocardial injury is a common consequence
of moderate to severe CO poisoning → higher risk of death.
■ Administer hyperbaric O2 therapy within 2–6 hours after exposure if
symptoms are severe or if COHgb levels >25% (controversial).
Thoracic Procedures
Thoracic Surgery
Segmental resection is the removal of the bronchus, a portion of the pul-
monary artery and vein, and tissue of the involved lung segment.
Lobectomy is the removal of an entire lobe of the lung.
Pneumonectomy is the removal of the entire lung, generally due to lung
cancer, bronchiectasis, TB, or lung abscess. Removal of the right lung is
more dangerous because of its larger vascular bed.
Management 
Pneumonectomy (postoperative; first 24–48 hours)
■ Patient should lie on back or operative side only. This prevents leak-
ing of bronchial stump, prevents fluid from draining into operative
site, and allows full expansion of remaining lung.
■ Perform CXR to check for deviation of trachea from midline →
mediastinal shift.
Patient may need chest tube or thoracostomy needle aspiration.
■ Assess for signs and symptoms: neck vein distention, HR, RR,
dyspnea, trachea displaced to one side. 
■ Note that remaining lung needs 2–4 days to adjust to increased blood
flow.
■ Monitor fluid and electrolyte balance to prevent fluid overload (e.g.,
crackles, increased HR, increased BP, dyspnea).
→→
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■ Provide oxygen therapy. Mechanical ventilation may be needed; mon-
itor level of oxygenation. Administer pulmonary function tests, such
as forced expiratory volume (volume of air patient can forcibly exhale
after a full inspiration).
■ Encourage coughing, deep breathing, and splinting.
■ Elevate head of bed 30°–45°.
■ Administer analgesia as needed.
■ Monitor ECG to detect cardiac arrhythmias.
■ Monitor vital signs to detect hypotension.
■ Monitor for pulmonary edema and subcutaneous emphysema.
COMPLICATIONS OF PNEUMONECTOMY
■ Atelectasis, pneumothorax, empyema, bronchopleural fistula
(increased temperature, cough, increased WBC, anorexia, purulent
sputum)
■ Excessive blood loss, hemorrhage
■ Respiratory distress and pulmonary edema
■ Cardiac dysrhythmias and hypotension
Chest Tubes
A chest tube is inserted into the pleural space to reestablish negative
intrapleural pressure or to remove air, fluid, or blood. It is inserted after
cardiac surgery, if needed, and to treat pneumothorax and hemothorax.
A mediastinal tube is inserted into the mediastinal space to provide
fluid and blood drainage after cardiac surgery. It is managed the same as
a chest tube.
Management 
■ Perform CXR immediately after insertion and every day thereafter.
■ Apply sterile occlusive gauze dressing to the chest tube site.
■ Attach chest tube to water seal drainage; use wall suction.
■ Monitor vital signs every 15 minutes until stable, then every 4 hours.
■ Monitor color and amount of drainage every 2 hours. Notify physician
if drainage >100–200 mL/hr.
■ Administer O2 via nasal cannula or mask; monitor oxygenation.
■ Reposition patient every 2 hours.
■ Make sure all connections are tight.
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■ Palpate for subcutaneous emphysema around insertion site and chest
wall.
■ Auscultate breath sounds; assess respirations.
■ Observe color and consistency of drainage; mark fluid level of
drainage.
■ Check water seal level; add sterile water if needed.
■ Avoid clamping the chest tube; can lead to tension pneumothorax.
■ Never clamp the chest tube to transport the patient.
Signs of air leak may include bubbles in water seal chamber during inspi-
ration, coughing, and large area of subcutaneous emphysema. Locate
source of air leak by gently clamping chest tube near insertion site. If bub-
bling stops → leak is at the insertion site or inside the patient. If bubbling
persists → leak in the system → replace chest tube, retape connections or
replace drainage system.
Suction control chamber should be set to 20-cm H2O level. Fluid level
regulates amount of suction → low → add sterile water to chamber.
Bubbling should be constant but gentle → “slow boil.”
Complications: 
■ Rapid and shallow breathing 
■ Cyanosis 
■ Hemorrhage 
■ Significant changes in vital signs 
■ Increased subcutaneous emphysema
Chest tube removal (when there is no air leak for 24 hr, drainage 
<100 mL/day, and CXR shows complete lung expansion):
■ Premedicate with analgesics 1⁄2 hour prior to removal.
■ Use Vaseline gauze on a sterile dressing and hold over chest tube
site. Have patient take a deep breath and perform Valsalva maneuver
→ chest tube is removed while rapidly covering the chest tube inser-
tion site with the gauzed dressing.
■ Perform follow-up CXR.
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Chest tube placement between ribs and pleural space of lung.
Chamber flow in a chest tube drainage system. 
Rib
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muscle
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Acute Renal Failure (ARF)
■ Chronic kidney disease develops slowly over months to years and
necessitates the initiation of dialysis or transplantation. Chronic kid-
ney disease is not a critical care issue. Although it is seen regularly in
an ICU setting, it is generally not the reason for admission to the ICU.
■ Acute renal failure (ARF) is a clinical syndrome characterized by rapid
decline in renal function → progressive azotemia and creatinine. It
is associated with oliguria which can progress over hours or days
with in BUN, creatinine, and K+ with or without oliguria.
Pathophysiology
The 3 types of acute renal failure include:
■ Prerenal failure: Caused by conditions such as hemorrhage, myocar-
dial infarction, heart failure, cardiogenic shock, sepsis, and anaphylax-
is → impaired blood flow to kidneys → hypoperfusion of kidneys →
retention of excessive amount of nitrogenous compounds → intense
vasoconstriction → ↓ glomerular filtration rate (GFR). Patient can
recover if fluid is replaced.
■ Intrarenal failure: Caused by burns, crush injuries, infections,
glomerulonephritis, lupus erythematosus, diabetes mellitus, malig-
nant HTN, nephroseptic agents → acute tubular necrosis → afferent
arteriole vasoconstriction → hypoperfusion of the glomerular appara-
tus → ↓ GFR → obstruction of tubular lumen by debris and casts,
interstitial edema, or release of intrarenal vasoactive substances. A
nonrecovery is common.
■ Postrenal failure: Caused by any obstruction such as bladder tumors,
renal calculi, enlarged prostate, or blocked catheter between the kid-
neys and urethral meatus → pressure in kidney tubules → ↓ GFR.
Clinical Presentation
ARF presents as:
■ Critical illness 
■ Lethargic 
■ Persistent nausea and vomiting 
→
→
→
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■ Diarrhea 
■ Dry skin and mucous membrane from dehydration 
■ Drowsiness 
■ Headache 
■ Muscle twitching 
■ Seizures
Signs of ARF include:
■ Urine <400 mL/24 hours
■ serum urea and creatinine
■ Peripheral and systemic edema
■ ↓ BP → fluid overload → pulmonary and peripheral edema
■ ↓ BP → dehydration/sepsis
■ Abnormal, irregular pulse → cardiac arrhythmia
■ Kussmaul’s respirations → metabolic acidosis
■ temperature → infection
■ ↓ level of consciousness (LOC)/seizures
■ Electrolyte imbalance (increased serum BUN, creatinine, K+, Na+,
phosphate; decreased serum calcium)
Diagnostic Tests 
■ Serum BUN, creatinine, electrolytes, CBC, coagulation studies
(PT/PTT), serum osmolarity, chemistry panel
■ Urinalysis with microscopic examination for protein and casts
■ Urine culture and sensitivity
■ Urine electrolytes and urine osmolarity
■ 24-hour urine for creatinine clearance
■ Renal ultrasound scanning
■ Chest x-ray
■ Renal biopsy
■ GFR rate
■ Kidney-ureters-bladder (KUB) x-ray 
■ Intravenous pyelogram (IVP)
■ CT scan or MRI of kidneys
■ Renal arteriogram
→
→
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Management
■ Monitor fluid and electrolytes. Assess for acid-base imbalances.
■ Assess respiratory status and monitor oxygenation. Administer O2 as
indicated.
■ Institute cardiac monitor and observe for arrhythmias.
■ Insert indwelling Foley catheter.
■ Restrict fluid intake and measure intake and output strictly. Assess for
edema.
■ Assess color, clarity, and amount of urine output. Check specific gravity.
■ Institute renal diet with adequate protein and low K+, Na+, and phos-
phorus. Protein may be restricted if BUN and creatinine greatly ele-
vated. Treat anorexia, nausea, and vomiting.
■ Monitor daily weight.
■ Insertion of a large-bore central line.
■ Administer medications, including calcium channel blockers, beta
blockers, and diuretics such as bumetanide (Bumex) and furosemide
(Lasix).
■ Administer iron supplement.
■ Monitor hemoglobin and hematocrit levels for anemia and O2-carrying
capacity of hemoglobin.
■ Administer blood products or erythropoietin products as needed.
■ Maintain meticulous skin care to prevent skin breakdown.
■ Ensure prevention of secondary infections.
■ Assess for gastrointestinal and cutaneous bleeding.
■ Assess neurological status for changes in LOC and confusion.
■ Administer dialysis (hemodialysis, peritoneal dialysis).
■ Provide patient and family support.
Treatment of Renal Disorders 
Renal Replacement Therapy
Renal replacement therapy (RRT) is a general term used to describe the
various substitution treatments available for severe, acute, and end-
stage chronic renal failure (ESCRF), including dialysis (hemodialysis and
peritoneal dialysis), hemofiltration, and renal transplant.
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Hemodialysis
Hemodialysis is one of several RRTs used in the treatment of renal failure
to remove excess fluids and waste products → restores chemical and
electrolyte imbalances.
Pathophysiology 
Hemodialysis involves passing the client’s blood through an artificial
semipermeable membrane to perform filtering and excretion functions
that the kidney can no longer do effectively.
Procedure 
Dialysis works by using passive transfer of toxins by diffusion (movement
of molecules from an area of higher concentration to an area of lower
concentration). Blood and dialysate (dialyzing solution) containing elec-
trolytes and H2O (closely resembling plasma) flow in opposite directions
through the semipermeable membrane. The patient’s blood contains
excess H2O, and excess electrolyte and metabolic waste. During dialysis,
the waste products and excess H2O move from blood → dialysate because
of the differences in concentrations. Electrolytes can move in or out of
blood or dialysate. This circulating pattern takes place over a preset
length of time, generally 3–4 hours.
Components 
The components of the hemodialysis system include:
■ Dialyzer 
■ Dialysate 
■ Vascular access 
■ Hemodialysis machine
Heparin is used to prevent blood clots from forming in the dialyzer or in
the blood tubing. The heparin dose is adjusted to client needs.
Hemodialysis Nursing Care
■ Many drugs are dialyzable.
■ Vasoactive drugs can cause hypotension → may hold until after 
dialysis.
■ Many antibiotics are given after dialysis and administered on days
patients receive dialysis.
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Postdialysis Care   
■ Monitor vital signs every hour x 4 hours, then every 4 hours (hypoten-
sion may occur secondary to hypovolemia requiring IV fluids; 
temperature may occur after dialysis secondary to blood warming
mechanism of the hemodialysis machine).
■ Weigh postdialysis.
■ Avoid all invasive procedures for 4–6 hours after dialysis if anticoagu-
lation used.
Continuous Renal Replacement Therapy (CRRT)
Continuous renal replacement therapy (CRRT) represents a family of
modalities that provide continuous support of severely ill patients in ARF.
It is used when hemodialysis is not feasible. CRRT works more slowly
than hemodialysis and requires continuous monitoring. It is indicated for
patients who are no longer responding to diuretic therapy, are in fluid
overload, and/or are hemodynamically unstable.
Procedure 
CRRT requires placement of a continuous arteriovenous hemofiltration
(CAVH) catheter or continuous venovenous hemofiltration (CVVH)
catheter and a mean arterial pressure of 60 mm Hg. 
Other types of CRRT include:
■ Continuous arteriovenous hemodialysis (CAVHD)
■ Continuous venovenous hemodialysis (CVVHD)
■ Slow continuous ultrafiltration (SCUF)
■ Continuous arteriovenous hemodiafiltration (CAVHDF)
■ Continuous venovenous hemodiafiltration (CVVHDF)
Because it is difficult to obtain and maintain arterial access, CVVH or
venous access is preferred.
CRRT provides for the removal of fluid, electrolytes, and solutes.
CRRT differs from hemodialysis in the following ways:
■ It is continuous rather than intermittent, and large fluid volumes can
be removed over days instead of hours.
■ Solute removal can occur by convection (no dialysate required) in
addition to osmosis and diffusion.
■ It causes less hemodynamic instability.
→
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■ It requires a trained ICU RN to care for patient but does not require
constant monitoring by a specialized hemodialysis nurse.
■ It does not require hemodialysis equipment, but a modified blood
pump is required.
■ It is the ideal treatment for someone who needs fluid and solute con-
trol but cannot tolerate rapid fluid removal.
■ It can be administered continuously, for as long as 30–40 days. The
hemofilter is changed every 24–48 hours.
Nursing Care
■ Monitor fluid and electrolyte balance.
■ Monitor intake and output every hour.
■ Weigh daily.
■ Monitor vital signs every hour.
■ Assess and provide care of vascular access site every shift.
Renal Transplant
A renal transplant is the surgical placement of a cadaveric kidney or live
donor kidney (including all arterial and venous vessels and long piece of
ureter) into a patient with end-stage renal disease (ESRD).
Operative Procedure
The surgery takes 4–5 hours. The transplanted kidney is usually placed in the
right iliac fossa to allow for easier access to the renal artery, vein, and ureter
attachment. The patient’s nonfunctioning kidney usually stays in place
unless there is a concern about chronic infection in one or both kidneys.
Postoperative Care 
■ Admit to ICU.
■ Monitor vital signs frequently as per ICU policy.
■ Monitor hourly urine output for first 48 hours.
■ Assess urine color.
■ Obtain daily urinalysis, urine electrolytes, urine for acetones, and
urine culture and sensitivity.
■ Administer immunosuppressive drug therapy ( risk of infection).
■ Provide Foley catheter care.
■ Maintain continuous bladder irrigation as needed.
■ Strict intake and output.
■ Monitor daily weight.
→
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■ Administer diuretics.
■ Obtain daily basic metabolic panel (BMP).
Complications 
■ Rejection (most common and serious complication): A reaction
between the antigens in the transplanted kidney and the antibodies in
the recipient’s blood → tissue destruction → kidney necrosis.
■ Thrombosis to the major renal artery, may occur up to 2–3 days
postop → may be indicated by sudden ↓ in urine output → emergent
surgery is required to prevent ischemia to the kidney.
■ Renal artery stenosis → HTN is the manifestation of this complication
→ a bruit over the graft site or ↓ in renal function may be other indi-
cators → may be repaired surgically or by balloon angioplasty.
■ Vascular leakage or thrombosis → requires emergent nephrectomy
surgery.
■ Wound complications: Hematomas, abscesses → risk of infection
→ exertion on new kidney. Infection is major cause of death in trans-
plant recipient. These patients are on immunosuppressive therapy →
signs and symptoms of infection may not manifest in its usual way.
Watch for low-grade fevers, mental status changes, and vague com-
plaints of discomfort.
Nephrectomy
Radical nephrectomy is the removal of the kidney, the ipsilateral adrenal
gland, surrounding tissue, and, at times, surrounding lymph nodes. Due
to the increased risk of reoccurrence in the ureteral stump, a ureterecto-
my may be performed as well.
Pathophysiology 
Primary indication is for treatment of renal cell carcinoma (adenocarcino-
ma of the kidney), in which the healthy tissue of the kidney is destroyed
and replaced by cancer cells.
Secondary indication is for treatment of renal trauma → penetrating
wounds or blunt injuries to back, flank, or abdomen injuring the kidney;
injury or laceration to the renal artery → hemorrhage.
Clinical Presentation
■ Flank pain (dull, aching)
■ Gross hematuria
→
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■ Palpable renal mass
■ Abdominal discomfort (present in 5%–10% of cases)
■ Hematuria (late sign)
■ Muscle wasting, weakness, poor nutritional status, weight loss 
(late signs)
Diagnostic Tests 
■ Urinalysis (may show RBCs)
■ Complete blood count
■ Complete metabolic panel (CMP)
■ Erythrocyte sedimentation rate (ESR or sed rate)
■ Human chorionic gonadotropin (hCG) level
■ Cortisol level
■ Adrenocorticotropic hormone level
■ Renin level
■ Parathyroid hormone level
■ Surgical exploration
■ IV urogram
■ Nephrogram
■ Sonogram
■ CT of abdomen/pelvis with contrast
■ MRI
Postop Management
■ Monitor vital signs frequently.
■ Provide pain management.
■ Encourage patient to cough and deep breathe, and to use incentive
spirometer every hour.
■ Encourage early mobilization.
■ Monitor intake and output strictly.
■ Assess for bleeding.
■ Administer IV fluids.
■ May require blood transfusion.
■ Obtain CBC every 6 hours x 24 hours, then every 12 hours for 24
hours early postop.
■ Monitor daily weight.
■ Monitor for adrenal insufficiency.
■ If drain in place, monitor and record color and amount of drainage.
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Cystectomy
A radical cystectomy is the removal of the bladder, prostate, and seminal
vesicles in men; and the bladder, ureters, cervix, urethra, and ovaries in
women. The ureters are diverted into collection reservoirs → urinary diver-
sion (ileal conduit, continent pouch, bladder reconstruction [neobladder],
ureterosigmoidostomy).
Pathophysiology 
Primary indication is for treatment of carcinoma of the bladder (transition-
al cell, squamous cell, or adenocarcinoma). Once the cancer spreads
beyond the transitional cell layer, the risk of metastasis greatly.
Secondary indication is as part of pelvic exoneration for sarcomas or
tumors of the GI tract or GYN system.
Clinical Presentation 
■ Gross painless hematuria (chronic or intermittent)
■ Bladder irritability with dysuria, urgency, and frequency
■ Urine cytology positive for neoplastic or atypical cells
■ Urine tests positive for bladder tumor antigens
Diagnostic Tests 
■ Urine cytology
■ Urine for bladder tumor antigens
■ IV pyelogram
■ Ultrasound of bladder, kidneys, and ureters
■ CT of abdomen and pelvis
■ MRI of abdomen and pelvis
■ Cystoscopy and biopsy (confirmation of bladder carcinoma)
Postop Management
■ Monitor vital signs frequently, as per hospital policy immediately
postoperatively.
■ Encourage patient to cough and deep breathe, and to use incentive
spirometer every hour.
■ Monitor and record amount of bleeding from incision and in urine.
■ Monitor and record intake and output.
■ If patient has a cutaneous urinary diversion, assess stoma for warmth
and color every 8 hours in early postop period (ostomy appliance will
collect urine).
→
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■ Collaborate with enteral stoma nurse regarding stoma, skin, and 
urinary drainage.
■ If Penrose drain or plastic catheters in place, monitor and record
drainage.
■ Monitor hemoglobin and hematocrit levels. 
■ Provide pain management.
■ Encourage early ambulation.
■ Provide patient and family support.
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Increased Intracranial Pressure 
Increased ICP is an increase in pressure on the brain within the cranium
or skull caused by an increase in cerebrospinal fluid pressure. Normal ICP
is 1–15 mm Hg.
Cerebral perfusion pressure is a function of the mean arterial pressure
and intracranial pressure. If the CPP drops below 80 mm Hg, ischemia
may occur.
CPP should be maintained at 70–80 mm Hg and the ICP at <15 mm Hg.
Cerebral perfusion pressure (CPP) = mean arterial pressure (MAP) – ICP.
MAP = systolic blood pressure + 2 (diastolic blood pressure) ÷ 3.
Pathophysiology
■ Risk factor → intracranial volume of cerebrospinal fluid (CSF) →
ICP → ↓ cerebral perfusion, brain swelling → a shift in brain tissue
through the dura → herniation → death. Increased ICP also leads to
brain tissue ischemia/infarction and brain death.
■ Herniation results in a downward shifting of brain tissue from an area
of high pressure to low pressure, usually into the brainstem → coma
and death.
Clinical Presentation
■ Slow, bounding pulse and irregular respirations
■ Headache and changes in level of consciousness, slow speech, rest-
lessness, confusion, drowsiness
■ Stupor, coma, decortication, decerebration, and flaccidity
■ Fixed and dilated pupils
■ Respiratory impairment (Cheyne-Stokes), irregular or absence of
breathing → death
■ Cushing’s response/reflex: ↓↓ cerebral blood flow → cerebral
ischemia → arterial pressure and systolic BP, bradypnea, widen-
ing pulse pressure and reflex bradycardia (late sign).
→→
→
→
→→
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Decerebrate Position
Decorticate Position 
Complications
■ Brainstem herniation, brain anoxia, death
■ Diabetes insipidus
■ Syndrome of inappropriate antidiuretic hormone (SIADH)
Diagnostic Tests
■ Serum electrolytes and serum osmolarity
■ Cerebral angiography, CT scan, MRI, PET to rule out physiological cause
■ Transcranial Doppler studies
■ Avoid lumbar puncture, can lead to brain herniation
■ ICP monitoring devices: Ventricular drainage, intracranial bolts, intra-
parenchymal fiber-optic catheter
Management
■ Treatment is based on trends and sustained elevations of ICP and low
CPP.
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■ Administer osmotic diuretic (mannitol [Osmitrol] 0.25–1 g/kg). Restrict
fluids if necessary.
■ Administer diuretics such as furosemide (Lasix).
■ Administer IV hypertonic saline (>0.9% NaCl).
■ Institute mechanical ventilation according to arterial blood gases
(ABGs). 
■ Administer IV sedation cautiously.
■ Assess neurological and mental status by Glasgow Coma Scale,
including reflexes, pupils, motor and sensory function, and cranial
nerve function (extraocular movements, peripheral facial droop,
tongue deviation, gag reflex, corneal reflex, cough reflex, doll’s eyes). 
■ Assess for meningeal signs (headache, nuchal [neck] rigidity, photo-
phobia).
■ Assess response to verbal and painful stimuli.
■ Institute seizure precautions; administer anticonvulsants as necessary.
■ Monitor vital signs, CPP, and ICP, and control fever; hypothermia use
is controversial.
■ Keep head in midline position (head of bed [HOB] 30°–60°).
■ Avoid extreme rotation of neck and neck flexion.
■ Avoid extreme hip flexion.
■ Maintain patent airway, suction cautiously (can ICP), oxygenate,
and avoid positive end-expiratory pressure (PEEP).
■ Monitor ABGs and oxygenation.
■ Maintain cardiac output using inotropes such as dobutamine
(Dobutrex) and norepinephrine (Levophed).
■ Administer high doses of barbiturates to ↓ ICP (pentobarbital
[Nembutal], thiopental [Pentothal], and propofol [Diprivan] to ↓
metabolic demands).
■ Administer anticonvulsants.
■ Induce therapeutic hypothermia.
■ Provide DVT and peptic ulcer prophylaxis.
■ The following can intracranial pressure and should be avoided:
hypercapnia, hypoxemia, Valsalva maneuver, isometric muscle 
contractions, REM sleep, and noxious stimuli.
→
→
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ICP Monitoring
Devices placed inside the head that sense the pressure inside the brain
cavity and send measurement to a recording device include:
■ Intraventricular catheter (ventriculostomy), which allows CSF to drain
and allows for intraventricular administration of medications
■ Subarachnoid bolt or screw
■ Epidural or subdural catheter or sensor
Calibrate transducer 1 inch above ear with patient in supine position.
Glasgow Coma Scale
Response Patient Response Score Patient A Patient B
Eye opening Spontaneous 4
response To voice 3
To pain 2
None 1
Best verbal Oriented 5
response Confused 4
Inappropriate words 3
Incomprehensible 2
sounds
None 1
Best motor Obeys command 6
response Localizes pain 5
Withdraws 4
Flexion 3
Extension 2
None 1
Total 3–15
Reprinted from The Lancet, Vol. 304, Teasdale G and Jennett B, Assessment of Coma and
Impaired Consciousness: A Practical Scale, Page 4, Copyright (1994), with permission from
Elsevier. 
A score of 8 or less indicates severe head injury.
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Risks
■ Infection and bleeding
■ Damage to the brain tissue → neurological effects
■ Inability to accurately place catheter
Troubleshooting ICP Monitoring Problems
■ Check all connections; reposition catheter.
■ Check for air in the system.
■ Check monitor cable.
■ Calibrate or reposition transducer.
ICP Catheter Waveforms
■ A (plateau) waves → cerebral ischemia
■ B waves → intracranial hypertension (HTN) and change in vascular
volume
■ C waves → variations in systemic arterial pressure and respirations
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Brain Monitoring
Cerebral or jugular venous oxygen saturation (SjvO2) (virtually all blood
from the brain drains into internal jugular veins): 
■ 60%–80% is normal 
■ <50% indicates cerebral hypoxia
■ Brain tissue O2 monitoring (partial pressure of brain tissue O2 [PbtO2]
using LICOX catheter): >25 mm Hg is normal; <20 mm Hg needs to be
treated
■ Brain temperature monitoring: 0.5°–1.0° C > core body temperature is
normal
■ Bispectral index (BIS): EEG of critically ill patients with a decreased
level of consciousness is continually analyzed
Traumatic Brain Injury 
Traumatic brain injury refers to trauma to the scalp and skull that may or
may not include injury to the brain. There are several types of acute head
injuries:
■ Closed head injury: The skull is not broken
■ Penetrating head injury: Object pierces the skull and breaches the
dura mater
■ May also be diffuse or focal
Pathophysiology
Trauma → intracranial hemorrhage and hematoma → brain swelling →
intracranial volume and ICP → displacement or herniation of the
brain. Pressure on cerebral blood vessels → ↓ blood flow to brain → ↓ O2
to brain → cerebral hypoxia → cerebral ischemia, infarction, and irre-
versible brain damage → brain death.
Clinical Presentation
■ Persistent, localized pain; headache
■ Loss of consciousness, confusion, drowsiness, personality change,
restlessness
→
→
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■ Sudden onset of neurological deficits
■ Bruising over mastoid (Battle’s sign)
■ Nausea and vomiting
■ CSF otorrhea (ears) or rhinorrhea (nose)
■ Halo sign: Blood stain surrounded by a yellowish stain on bed linens
or head dressing that may indicate CSF leak
■ Abnormal pupillary response
■ Altered or absent gag reflex
■ Absent corneal reflex
■ Change in vital signs: altered respiratory pattern, widened pulse pres-
sure, bradycardia, or tachycardia
■ Seizures
Complicating Factors
■ Skull fracture, scalp lacerations
■ Cerebral contusion, concussion
■ Subarachnoid hemorrhage
■ Subdural, extra/epidural hematoma
■ Cerebral edema
■ ICP ↓ cerebral perfusion
■ Seizures
■ Impaired oxygenation/ventilation
■ Herniation, coma, or death
Diagnostic Tests 
■ Check for cerebrospinal fluid leak
■ X-ray, CT of the head, MRI, or PET to assess hematoma, swelling, and
injury
■ Cerebral angiography
■ CBC, chemistry panel, and blood coagulation studies
■ Urinalysis for specific gravity
Management
■ Stabilize cardiac and respiratory function to ensure adequate cerebral
perfusion. Maintain optimum ABGs or O2 saturation. Assess oxygena-
tion and respiratory status.
→
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■ Assess and monitor neurological status and ICP; calculate CPP to
maintain >70 mm Hg.
■ Perform frequent neurological checks, including Glasgow Coma
Scale. See pg. 124.
■ Provide light sedation as necessary to ↓ agitation. Administer anal-
gesics for pain. Induce barbiturate coma if necessary.
■ Administer hypertonic saline and osmotic diuretics as needed.
■ Monitor and control for elevations in ICP.
■ Induce therapeutic hypothermia.
■ Prepare patient for craniotomy to lessen the pressure in the brain if
necessary.
■ Assess for vision and hearing impairment and sensory function.
■ Assess for hypothermia and hyperthermia. Control fever.
■ Institute seizure precautions. Minimize stimuli and excessive suctioning.
■ Monitor ECG for cardiac arrhythmias. Institute deep vein thrombosis
(DVT) precautions.
■ Assess fluid and electrolyte balance. Control hemorrhage and hypo-
volemia.
■ Administer stool softeners to prevent Valsalva maneuver.
■ Keep head and neck in neutral alignment; no twisting or flexing of
neck.
■ Keep head of bed elevated.
■ Maintain adequate nutrition orally or enterally. Assess and maintain
skin integrity.
■ Provide DVT and peptic ulcer prophylaxis.
Subarachnoid Hemorrhage or Hemorrhagic Stroke
SAH is bleeding into the subarachnoid space between the arachnoid
membrane and the pia mater of the brain primarily. SAH is a medical
emergency.
Pathophysiology
■ SAH is caused by cerebral aneurysm (usually in the area of circle of
Willis), cerebral/head trauma, HTN, or arteriovenous malformation.
■ Blood rapidly passes into the subarachnoid space and then spreads over
the brain and to the spinal cord leading to ICP → coma → death.→
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Clinical Presentation
■ Sudden, severe “thunderclap” headache developing over seconds to
minutes
■ ↓ level of consciousness (LOC); confusion and agitation
■ Nuchal rigidity (stiff neck)
■ Nausea and vomiting
■ Photophobia, diplopia, visual loss, blurred vision, and oculomotor
nerve abnormalities (affected eye looking downward and outward,
pupil widened and less responsive to light)
■ Paralysis; positive Brudzinski’s sign and Kernig’s sign
■ Tinnitus, dizziness, vertigo, and hemiparesis
■ Fatigue, fever, and HTN
■ Cardiac arrhythmias (can progress to cardiac arrest)
Complications
■ Increased ICP
■ Coma and brainstem herniation
■ Rebleeding
■ Cerebral vasospasm
■ Hyponatremia due to SIADH or cerebral salt-wasting syndrome
■ Cardiac arrhythmias and myocardial damage
■ Acute hydrocephalus
■ Pneumonia, pulmonary embolus, and respiratory failure
■ Neurogenic cardiac stunning (reduction of function of heart 
contraction) and pulmonary edema
Diagnostic Tests
■ CT scan of brain or MRI of brain
■ Transcranial Doppler studies
■ ECG (changes in ST segment and T wave, prominent U wave)
■ Lumbar puncture if CT inconclusive and no ICP present
■ CSF is clear and colorless, with no organisms present; it will test 
positive for protein and glucose
■ Cerebral angiography
→
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Management
■ Neurological assessment: LOC, papillary reaction, motor and sensory
function, cranial nerve deficits, and speech and visual disturbances.
■ Assess for headache and nuchal rigidity.
■ Provide intubation and mechanical ventilation as needed; assess
ABGs.
■ Assess BP, HR, RR, and Glasgow Coma Scale frequently.
■ Control BP via antihypertensives. Monitor and control ICP.
■ Institute aneurysm precautions: Bed rest; dark, quiet room with mini-
mal stimulation and nonstressful environment; pain control; HOB
15°–30°; stool softeners (avoid enemas). Restrict visitors.
■ Avoid Valsalva maneuver, straining, forceful sneezing, and acute flex-
ion of head and neck. Eliminate caffeine from diet.
■ Administer analgesia for pain control; use nonsedating agents.
Control anxiety.
■ Give nimodipine (Nimotop) for cerebral vasodilation. Therapy should
start within 96 hours of subarachnoid hemorrhage.
■ Provide DVT and peptic ulcer prophylaxis.
Triple-H Therapy to Prevent Vasospasms 
■ Hypovolemia treated with colloids and crystalloids to keep central
venous pressure (CVP) 10–12 mm Hg and pulmonary capillary wedge
pressure (PCWP) 15–18 mm Hg
■ Hemodilution to keep hematocrit level at 33%–38%
■ Hypertensive therapy to keep systolic BP 110–160 mm Hg
Prepare patient for surgery:
■ Surgical aneurysm repair: Surgical clipping
■ Endovascular treatment: Occlusion of parent artery
■ Endovascular (aneurysm) coiling: Obstruction of aneurysm site with coil
Cerebral Vascular Accident–Ischemic Stroke
CVA is a sudden disruption of blood flow to a part of the brain. It may be
hemorrhagic (see subarachnoid hemorrhage) or ischemic and may result
in brain tissue damage and neurological deficits. CVA is also called brain
attack. 
→
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Pathophysiology
■ Causes of CVA include thrombosis, embolism, systemic hypoperfu-
sion, and hemorrhage. Cocaine use doubles the risk of CVA.
■ In CVA there is a disruption of blood flow to the brain → ↓ O2 and 
glucose to the brain → ischemic cascade → neurons unable to main-
tain aerobic respiration → switch to anaerobic respiration → build-up
of lactic acid → change in blood pH → influx of intracellular calcium
and increase in glutamate → destroys cell membrane → cell mem-
brane and proteins break down, forming free radicals → cell injury
and death → neurological dysfunction.
■ Low cerebral blood flow → ↓ O2 to the brain → extraction of O2 by
the brain.
■ Ischemia penumbra (zone of ischemic area) forms around an infarct
in stroke lesions. This penumbra may be reversible.
→
Clinical Presentation
■ Sudden neurological deficits such as muscle weakness (hemiplegia)
of face, arm, or leg (especially if confined to one side of body); con-
fusion or trouble speaking or understanding speech; trouble seeing
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in one or both eyes; trouble walking; dizziness; loss of balance or
coordination; and severe headache with no known cause
■ Other neurological assessments: Ptosis (drooping of eyelids), weak-
ness of ocular muscles, ↓ gag and swallow reflex, slow papillary 
reactivity to light, visual field defects, memory defects, confusion, and
hypersexual gestures
■ Numbness; ↓ sensory or vibratory sensation; altered sense of small,
taste, hearing; ↓ sensation and muscle weakness to face (facial pare-
sis); nystagmus; and dysphagia
■ Altered breathing and heart rate
■ Inability to turn head to one side (weak sternocleidomastoid muscle)
■ Inability to protrude tongue and/or move from side to side
■ Aphasia (difficulty to speak or understand language)
■ Apraxia (altered voluntary movements)
■ Vertigo and disequilibrium, with difficulty walking, altered movement
coordination, and arm drift
■ Urinary and fecal incontinence
Complications
■ Physical: Pressure sores, incontinence, pneumonia, seizures, coma,
and death
■ Emotional: Anxiety, panic attacks, flat affect, depression, withdrawal,
sleep disturbances, lethargy, irritability, and emotional lability
Diagnostic Tests 
■ CBC, serum chemistry, coagulation studies, fibrinogen test
■ Drug screen and ETOH level if indicated
■ CT scan without contrast or MRI
■ Carotid Doppler ultrasound (carotid stenosis)
■ Transcranial Doppler flow studies
■ ECG, transthoracic of transesophageal echocardiogram, Holter moni-
tor (arrhythmias)
■ EEG, especially if seizure activity is present
■ ABGs if hypoxic
■ Cerebral angiography
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Management
■ Administer recombinant tissue plasminogen activator (rtPA) within 
3 hours of onset of symptoms (contraindicated if abnormal lab val-
ues, HTN, or recent surgery). Risk of intracranial bleeding. rtPA may
also be administered intra-arterially by the interventional radiologist
via the femoral artery within 6 hours of symptoms.
■ Administer aspirin (50–325 mg daily), clopidogrel (75 mg daily), or
dipyridamole extended release (25/200 mg twice daily) if no rtPA.
■ Assess for bleeding related to anticoagulant therapy.
■ Induce hypothermia within 12 hours of stroke symptoms by infusing
cold saline intravenously into the body until core temperature is 
92°F or 33°C.
■ Assess and monitor neurological and respiratory function; administer
O2 if necessary. Keep PaCO2 at 30–35 mm Hg and/or SpO2 at >95%.
Avoid hypoxia. Intubate if needed according to ABGs.
■ Monitor and manage ICP and cerebral edema. Give mannitol,
furosemide (Lasix), or 3% saline solution. Use nondextrose IV 
solutions. 
■ Monitor BP. Management of HTN may be deferred unless end-organ
damage, MAP >130 mm Hg, SBP >220 mm Hg, or DBP >120 mm Hg.
■ Administer sodium nitroprusside (Nipride) or labetalol (Normodyne,
Trandate) IV.
■ Ensure continuous cardiac monitoring of arrhythmias.
■ Provide DVT and peptic ulcer disease prophylaxis.
■ Maintain glycemic control (blood glucose at 80–110 mg/dL) with 
IV insulin.
■ Provide ECG monitoring to prevent bradycardia → ↓ CO and ↓ CPP.
■ Treat and control fever.
■ Avoid use of Foley catheter if possible. Monitor intake and output
closely.
■ Institute seizure precautions and administer anticonvulsants if neces-
sary. 
■ Provide enteral or PEG tube feedings, following aspiration precautions.
Elevate HOB 30°.
■ Provide DVT and peptic ulcer prophylaxis.
→
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Surgical Management
■ Carotid endarterectomy or carotid artery angioplasty and stenting
■ Mechanical thrombectomy to remove offending thrombus
Spinal Cord Injury 
SCI may be classified as complete (loss of conscious sensory and
motor function below the level of spinal cord injury due to transaction
of the spinal cord) or incomplete (preservation of some sensory and
motor function below the level of spinal cord injury due to partial
spinal cord transaction). The most common sites of SCI are C4–C7,
T12, and L1.
Causes of SCI include: 
■ Blunt force trauma 
■ Penetrating force trauma 
■ Ankylosing spondylitis 
■ Rheumatoid arthritis 
■ Spinal abscesses and tumors, especially lymphoma and multiple
myeloma
Pathophysiology
■ ↓ blood flow to gray matter of spinal cord with 8-hour delay of ↓
blood flow to white matter → thrombi form furthering ↓ blood flow to
spinal cord.
■ interstitial pressure related to edema → ↓ blood flow to spinal cord.
■ Inflammatory process → edema of injured area → ↓ blood flow to
spinal cord. Edema moves up and down the spinal cord rather than
laterally.
■ Release of norepinephrine, histamine, and prostaglandins → vasocon-
striction → ↓ cellular perfusion.
■ extracellular fluid concentrations of Na+ and K+ → osmotic 
pressure in area of injury → edema. 
■ Ischemia, hypoxia, and edema → tissue necrosis and cell membrane
damage → destruction of myelin and axons → neuronal death.
→→
→
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Clinical Presentation
■ Spinal shock initially: Flaccid paralysis with ↓ or absent reflex activity
■ Partial or total loss of motor function below the level of SCI (includes
voluntary movement and movement against gravity or resistance)
■ Partial or total loss of sensory function below the level of SCI
(includes touch, temperature, pain, proprioception [e.g., position])
■ HR initially → bradycardia; BP initially → ↓ BP
■ Acute pain in back or neck that may radiate along nerve
■ Abnormal deep tendon reflex and perianal reflex activity
■ Loss of sweating and vagomotor tone
■ Loss of sensory, motor, and deep tendon reflexes below the level of
injury
■ Retention of lung secretions, ↓ vital capacity, PaCO2, ↓ O2 → respi-
ratory failure and pulmonary edema
■ Bladder and bowel incontinence with urine retention and bladder 
distention
■ Paralytic ileus causing constipation and/or bowel impaction
■ Loss of temperature control → hyperthermia
■ Sweating above level of lesion
■ Priapism in males
Diagnostic Tests
■ Lateral, anterior-posterior (cervical, thoracic, lumbar, sacral), and
odontoid films
■ CT scan, MRI
■ Myelography
Management
■ Assess motor and sensory function, including deep tendon reflexes.
■ Assess neurological status, including LOC and papillary action.
■ Assess for closed head injury.
■ Maintain spinal and proper body alignment.
■ Assess respiratory status. Monitor ABGs or pulse oximetry. Administer
O2 by nasal cannula or mask. Provide mechanical ventilation as 
determined by ABGs.
→
→→
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■ Suction cautiously → stimulate vagus nerve → bradycardia → cardiac
arrest.
■ Monitor ECG for cardiac dysrhythmias, especially bradycardia (may
need pacemaker). Monitor BP for hypotension.
■ Provide intermittent bladder catheterization or temporary Foley
catheter.
■ Provide DVT and peptic ulcer prophylaxis.
■ Insert nasogastric tube initially to prevent vomiting and aspiration.
■ Start TPN or enteral feedings.
■ Follow skin care protocol to prevent decubitus ulcers.
■ Avoid and treat bladder spasms.
■ Avoid bowel impaction by administering stool softeners and establish
bowel control.
■ Prevent autonomic dysreflexia.
■ Provide IV fluids cautiously, because they can precipitate heart failure
due to poor heart rate response to ↓ circulating blood volume.
Administer methylprednisolone Na succinate within 8 hours of injury
(30 mg/kg IV over 15 minutes; infusion of 5.4 mg/kg/hr for 24–48
hours).
■ Administer vasodilators: nifedipine (Procardia), phenoxybenzamine
(Dibenzyline), or nitroprusside (Nipride).
■ Prevent sepsis and infections (respiratory, urinary tract, and wound).
■ Provide emotional support for patient and family.
■ Prepare patient for surgical management to reduce spinal fracture or
dislocation and decompression of the spinal cord:
■ Skeletal fracture reduction and traction with skeletal tongs or
calipers, skeletal traction device, and halo device.
Autonomic Dysreflexia
A stimulus causes sympathetic nervous system response below the
level of SCI and systemic vasoconstriction → bradycardia, HTN, facial
and neck flushing (reddening above the level of SCI) associated with
pale, cold skin on the trunk and extremities (below the SCI), sweating,
anxiety, pounding headache, nasal congestion, “goose bumps,” blurred
vision, difficulty breathing, increased spasticity, and chest pain. It may
lead to CVA, renal failure, atrial fibrillation, seizures, and acute pul-
monary edema.
→
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Autonomic dysreflexia is also known as hyperreflexia. It occurs in peo-
ple with SCI at or above the level of T6 (or rarely as low as T8).
Causes
■ Bladder distention or spasm (most common cause); urinary tract
infection
■ Bowel impaction
■ Stimulation of anal reflex (stimulation of skin around the anus pro-
duces contraction of the anal sphincter)
■ Labor in women
■ Temperature change
■ Acute pain
■ Decubitus ulcer
■ Tight, constrictive clothes
■ Ingrown toenails
Management
■ Place patient in sitting position and monitor vital signs every 
5 minutes.
■ Loosen constrictive clothing or devices.
■ If no indwelling catheter, palpate bladder for distention → insert Foley
catheter.
■ If indwelling catheter, check for kinks and obstruction and irrigate if
necessary.
■ Check for fecal impaction and administer laxative as needed. Use 
2% lidocaine jelly 10–15 minutes before removing impaction.
■ Assess skin for pressure or irritation.
■ If SBP >150 mm Hg, administer an antihypertensive such as
hydralazine (Apresoline).
■ The sweating will become less profuse or stop.
■ There will usually be an immediate lowering of the BP, although it
may take about 1 hour for BP to decrease if BP is very high.
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Neurogenic Shock
Neurogenic shock is caused by vasoconstriction and venous pooling
(veins dilated and filled with blood) → ↓ BP, ↓ systemic vascular resis-
tance, ↓ HR, ↓ CO, ↓ respiration rate, skin warm with pink mucous mem-
branes → ↓ blood flow to vital organs → organ damage and ischemia.
Treatment involves the administration of vasopressors.
Myasthenia Gravis
MG is a neuromuscular autoimmune disease causing muscle weakness
and fatigability of skeletal muscles.
Pathophysiology
Circulating antibodies block acetylcholine receptors at the postsynaptic
neuromuscular junction → inhibits acetylcholine → inhibits depolarization
of muscles → ↓ nerve impulse transmission → diminishes muscle con-
traction, including diaphragmatic muscle → ↓ vital capacity and respirato-
ry failure.
Causes include thymic hyperplasia and tumor of the thymus gland.
Clinical Presentation
■ Muscle weakness that increases during activity and improves after
rest; eye muscle weakness; possible ptosis, diplopia, and inability to
maintain upward gaze
■ Weakness of limb, axial, bulbar, and/or respiratory muscles, especially
those related to chewing, talking, swallowing (dysphagia), breathing,
and neck and limb movements; inability to close mouth and inability
to raise chin off chest
■ Slurred speech, neck muscle weakness with head bobbing
■ Diaphragmatic and intercostal weakness → dyspnea, difficulty 
coughing 
■ Crises that may be triggered by fever, infection, trauma, extreme tem-
peratures, adverse reaction to medication or emotional stress →
respiratory distress, dysphagia, dysarthria (difficulty speaking), eyelid
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ptosis, diplopia, prominent muscle weakness, neurologic changes,
absence of sweating, hyperthermia → respiratory failure
Diagnostic Tests
■ Muscle fatigability test
■ Antibodies against acetylcholine receptor (AChR Ab) ≤0.03 nmol/L or
negative
■ Edrophonium chloride (Tensilon) test: Administration of 1–2 mg IV
over 15–20 seconds; resolution of facial muscle weakness and ptosis
and improved muscle strength should be seen in 30 seconds; if no
response in 1 minute, may repeat dose; have atropine, ECG monitor-
ing, and advanced life-saving equipment available
■ Ice pack test: Placing ice over an eyelid if ptosis is present; clear reso-
lution of the ptosis is a positive test result; ptosis occurs in approxi-
mately 80% of patients with ocular myasthenia
■ Single-fiber electromyography and repetitive nerve stimulation
■ Blood test to identify antibodies against the acetylcholine receptor
(AChR Abs)
■ Thyroid function and pulmonary function tests
■ CT scan or MRI to detect thymomas
Management
■ Assess and monitor respiratory status and oxygenation (pulmonary
function tests, ABGs).
■ Provide mechanical ventilation if paralysis of respiratory muscles is
present.
■ Monitor risk for aspiration and pneumonia. Initiate enteral feedings if
dysphagic.
■ Avoid sedatives and tranquilizers.
■ Initiate plasmapheresis to treat exacerbations.
■ Administer IV immunoglobulin (IVIG).
■ Administer immunosuppressants such as: 
■ Prednisone 
■ Cyclosporine 
■ Mycophenolate mofetil 
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■ Azathioprine 
■ Corticosteroids
■ Administer cholinesterase inhibitors: neostigmine (Prostigmin), 
pyridostigmine (Mestinon).
■ Provide DVT and peptic ulcer prophylaxis.
■ Prepare patient for surgical thymectomy.
Guillain-Barré Syndrome 
GBS is an autoimmune acute inflammatory disease causing demyelina-
tion of the lower motor neurons of the peripheral nervous system.
Pathophysiology
■ Immune-mediated response → destruction of myelin sheath → inter-
feres with nerve signal transmission → slowing of nerve signals →
weakness of limbs → ascending paralysis → total paralysis.
■ Paralysis of the diaphragm → respiratory failure.
■ If mild, remyelination can occur.
Clinical Presentation
■ Infection of the respiratory or GI tract 10–14 days before onset of 
neurological symptoms
■ Flaccidity of muscle may progress to symmetric ascending paralysis
from the legs (hours or days) leading to upper limbs and face
with/without numbness or tingling
■ Loss of deep tendon reflexes (areflexia)
■ Difficulty with eye movements; double vision
■ Difficulty with swallowing; drooling
■ Loss of pain and temperature sensation
■ Loss of proprioception (position sense)
■ Sinus tachycardia or bradycardia and cardiac dysrhythmias
■ Orthostatic hypotension; HTN
■ Absence of fever
■ Excessive diaphoresis
■ Seizures
■ Bowel and bladder retention or incontinence
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■ Changes in vital capacity and negative inspiratory force → respiratory
arrest
■ pulmonary secretions
■ protein in CSF (100–1000 mg/dL)
■ SIADH
■ Residual damage possibly occurring after the acute phase
Diagnostic Tests
■ Lumbar puncture and CF analysis
■ EMG and nerve conduction velocity studies
■ CBC, PFTs, and ABGs
Management
■ Assess respiratory status and ABGs.
■ Provide early respiratory support, including mechanical ventilation or
tracheostomy.
■ Assess neurological function—start with lower extremities.
■ ECG and BP monitoring.
■ Administer antihypertensive or vasopressors to maintain BP within
normal limits.
■ Insert indwelling Foley catheter if incontinent.
■ Provide enteral feedings and nutritional support.
■ Active and passive range of motion, physical or occupational therapy.
■ Corticosteroids may be tried but generally not effective.
■ Provide DVT prophylaxis.
■ Administer IVIGs at 400 mg/kg for 5 days.
■ Plasmapheresis—40-50 mL/kg plasma exchange four times over a
week.
■ Provide DVT and peptic ulcer prophylaxis.
■ Provide short- and long-term rehabilitation, physical therapy, and
occupational therapy consultations.
→
→
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Bacterial Meningitis
Bacterial meningitis is an inflammation that involves the arachnoid and
pia mater of the brain, the subarachnoid space, and the CSF.
Pathophysiology
■ Bacteria enter the CNS through the bloodstream and crosses the
blood-brain barrier or directly enters the bloodstream via penetrating
trauma, invasive procedures, cancer, certain drugs, or ruptured cere-
bral abscess. An upper respiratory infection → bacteria in nasophar-
ynx → bloodstream → CSF subarachnoid space and pia-arachnoid
membrane → meninges.
■ Purulent exudate → clings to meningeal layers → clogs CSF → vascu-
lar congestion and obstruction → cranial nerve dysfunction, hyper-
emia of meningeal blood vessels, brain tissue edema, CSF, 
WBC in subarachnoid space → acute hydrocephalus and seizures.
■ Abnormal stimulation of hypothalamic area → inappropriate ADH
production → water retention.
Clinical Presentation
■ Symptoms of upper respiratory infection possibly preceding
meningeal irritation → severe and unrelenting headache, nausea,
vomiting, fever and chills, nuchal rigidity (stiff neck), irritability,
malaise, restlessness, myalgia, and tachycardia
■ Photophobia and signs of ICP
■ Problems with memory; ↓ LOC; disorientation to person, place, and
year; abnormal eye movements → coma, delirium, and seizures
■ Kernig’s sign: Inability to extend the leg at the knee when the thigh is
flexed
■ Brudzinski’s sign: Flexion of the hip and knee when the patient’s neck
is flexed
Complications
■ Septic emboli and septic shock with vascular dysfunction, or dissemi-
nated intravascular coagulation
■ Fluid and electrolyte imbalances
→
→→
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■ Seizures and hemiparesis
■ Cranial nerve (CN) dysfunction: CN III, IV, VI, VII, VIII
■ Hydrocephalus and cerebral edema
■ ICP → herniation of the brain
Diagnostic Tests
■ Lumbar puncture, culture, and assessment of CSF and pressure →
CSF pressure and protein, ↓ glucose (CSF pressure >180 mm Hg is
indicative of bacterial meningitis)
■ CBC, especially WBC
■ Blood cultures
■ Serum electrolytes, especially Na (dilutional hyponatremia)
■ CT scan or MRI if ICP, or brain abscess or hydrocephalus
Management
■ Maintain respiratory isolation until pathogen not cultured in
nasopharynx (usually 24 hours after antibiotic treatment).
■ Monitor neurological status, cranial nerve function, and vital signs
every 1–2 hours. Check pupils, LOC, and motor activity.
■ Assess vascular function for signs of septic emboli.
■ Ensure ↓ environmental stimuli, quiet environment, and ↓ exposure
to lights.
■ Administer corticosteroids to decrease inflammation.
■ Administer anticonvulsants for seizures.
■ Administer antipyretics for fever.
■ Administer analgesia for headache.
■ Administer hyperosmolar agents for cerebral edema.
■ Insert surgical shunt if hydrocephalus is present.
■ Consider the following antibiotic therapy: 
■ Cefotaxime (Claforan) 
■ Ceftazidime (Ceptaz, Fortaz) 
■ Ceftriaxone (Rocephin) 
■ Vancomycin 
■ Meropenem (Merrem)
Assess CSF analysis, gram stain, and cultures for antibiotic sensitivity.
→
→
→
→
133
NEURO
20841_Tab05_111-136.qxd  1/15/09  6:06 PM  Page 133
NEURO
134
Seizure Disorder
A seizure disorder is a temporary, abnormal, sudden, excessive, uncon-
trolled electrical discharge of neurons of the cerebral cortex. Status
epilepticus (SE), which denotes continuous seizure activity, is a medical
emergency.
Pathophysiology
Repetitive depolarization of hyperactive hypersensitive brain cells →
abnormal electrical activity in the brain.
Risk factors for seizure disorder include 
■ Epilepsy 
■ Drug or alcohol abuse 
■ Drug toxicity (aminophylline) 
■ Recent head injury 
■ Infection 
■ Headache 
■ Acute metabolic disturbances (hypoglycemia, hyponatremia, hypocal-
cemia, renal failure) 
■ CVA 
■ CNS infection (meningitis, encephalitis) 
■ CNS trauma or tumor 
■ Hypoxemia 
■ Fever (children) 
■ HTN 
■ Allergic reaction 
■ Eclampsia related to pregnancy
Clinical Presentation
■ From simple staring to prolonged convulsions 
■ Brief loss of memory, sparkling or flashes, and sensing of an unpleas-
ant odor
■ Classified as motor, sensory, autonomic, emotional, or cognitive
■ Aura occurring prior to the seizure along with tachycardia
■ Alternation in mental state; confusion or dazed state
■ Tonic or clonic movements
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■ Loss of consciousness
■ Déjà vu or jamais vu (any familiar situation that is not recognized by
the observer)
The clinical presentation of seizure disorder depends on the type of seizure.
Complications
■ Pulmonary edema
■ Pulmonary aspiration
■ Cardiac dysrhythmias
■ HTN or hypotension
■ Hyperthermia
■ Hyperglycemia/hypoglycemia
■ Hypoxia
■ Dehydration
■ Myoglobinuria
■ Oral or musculoskeletal injuries
Diagnostic Tests
■ Electroencephalogram (EEG)
■ CT scan, MRI, or PET to rule out cerebral lesions
■ Serum drug screen to rule out drug or alcohol intoxication
■ Serum electrolytes, BUN, calcium, magnesium, glucose
■ CBC
■ ECG to detect cardiac arrhythmias
■ ABGs or pulse oximetry
Management
■ Administer fast-acting anticonvulsants:
■ Lorazepam (Ativan) 0.1 mg/kg at <2 mg/min IV
■ Diazepam (Valium) 5–10 mg IV
■ Administer long-acting anticonvulsants:
■ Phenytoin (Dilantin): 20 mg/kg at <50 mg/min IV
■ Phenobarbital (Luminal): 100–320 mg IV
■ Fosphenytoin (Cerebyx): 20 mg/kg at 150 mg/min
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■ Propofol (Diprivan): dosage per anesthesiologist
■ Midazolam (Versed): dosage per anesthesiologist
■ Identify precipitating factors and preceding aura.
■ Ensure patient safety (pad side rails, bed at lowest position).
■ Prevent Wernicke-Korsakoff syndrome; administer thiamine 100 mg IV
and 50 mL of 50% glucose if chronic alcohol ingestion or hypo-
glycemia is present.
■ Keep oral or nasal airway or endotracheal tube (ETT) at bedside.
■ During seizure: 
■ Observe seizure type, point of origin, and spread of seizure activity
■ Note length of time of seizure 
■ Note automatisms, such as lip smacking and repeated swallowing 
■ Assess LOC, bowel and bladder incontinence, and tongue biting 
■ Avoid restraining patient 
■ Avoid forcing airway into patient’s mouth when jaws clenched 
■ Avoid use of tongue blade 
■ Maintain patent airway during seizure 
■ During postictal state (after seizure):
■ Assess vital signs closely; provide ECG monitoring
■ Monitor oxygenation and respiratory status (ABGs, SpO2, breath
sounds)
■ Turn patient to side-lying position; administer O2 therapy; suction
prn
■ Check level of orientation and ability to speak (patient usually
sleeps afterward)
■ Note headache and signs of increased intracranial pressure
■ Check pupil size, eye deviations, and response to auditory and 
tactile stimuli
■ Note paralysis or weakness of arms or legs
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Acute Gastrointestinal Bleeding
Causes of upper GI (UGI) bleeding include:
■ Gastric or duodenal ulcers including stress ulcers; may be nonsteroidal
anti-inflammatory drug (NSAIDs) related
■ Peptic ulcer disease, gastritis, or esophagitis
■ Esophagogastric varices
■ Mallory-Weiss tear
■ Neoplasms
■ Liver disorders
Causes of lower GI bleeding include:
■ Diverticulosis
■ Infectious colitis
■ Bowel disease or trauma
■ Neoplasm
■ Hemorrhoids or anorectal disorders
Pathophysiology
■ Constriction of peripheral arteries → ↓ blood flow to skin and kidneys
→ renal failure; ↓ blood flow to GI tract → mesenteric insufficiency →
bowel infarction and liver necrosis; ↓ blood flow to coronary arteries
→ myocardial infarction (MI), pulmonary edema, heart failure, and
dysrhythmias; ↓ blood flow to brain → confusion, anxiety, restless-
ness, stupor, and coma.
■ Acute massive GI bleed → ↓ blood volume → ↓ cardiac output → ↓
BP, HR → hypovolemic shock and multiple organ dysfunction.
■ Metabolic acidosis and lactic acid accumulation → anoxia and 
respiratory failure.
Clinical Presentation
■ Hematemesis: Bright red or brown, coffee-ground emesis
■ Melena: Black, tarry stools
■ Hematochezia: Maroon-colored stools or bright red blood
■ Hypotension: May be orthostatic, light headedness, fainting
→
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■ Tachycardia: ↓ pulse pressure, capillary refill sluggish
■ Cardiac dysrhythmias
■ Tachypnea, shortness of breath, chest pain
■ Pallor, apprehension, confusion, lethargy, weakness
■ ↓ urine output, urine concentration
■ bowel sounds, diarrhea
■ Stupor and coma if large blood loss
■ Multiple organ dysfunction if severe blood loss and hypovolemic
shock
Diagnostic Tests
■ CBC, platelets, and coagulation studies
■ Serum chemistries, liver function tests, and blood urea nitrogen/
creatinine ratio (if >36 → GI bleed if no renal insufficiency)
■ Arterial blood gases (ABGs) or pulse oximetry
■ UGI series
■ Abdominal x-ray or CT of abdomen
■ Barium enema
■ GI bleeding scan
■ Endoscopy
■ Colonoscopy or sigmoidoscopy
Management
■ Monitor vital signs and hemodynamics (central venous pressure
[CVP], pulmonary artery pressure [PAP]). Note ↓ BP, HR, ↓ CVP and
cardiac output.
■ Monitor for cardiac dysrhythmias.
■ Assess respiratory status and ABGs or pulse oximetry. Administer 
O2 via cannula, mask, or mechanical ventilation. Assess for signs of
hypoxia.
■ Insert nasogastric (NG) tube and set at low intermittent suction.
Lavage as necessary. Assess color and amount of drainage. Note
bright red to coffee-ground drainage. Keep patient NPO if active
bleeding. Start clear liquids when bleeding stops.
■ Assess bowel sounds; assess abdomen for distention and palpate for
pain.
■ Administer IV fluids, colloids, crystalloids, blood, and blood products.
→
→
→
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■ Note amount and color of feces. Hematest stool prn.
■ Insert Foley catheter. Monitor intake and output. Assess fluid and
electrolyte balance.
■ Administer histamine blockers or proton pump inhibitors. Consider
misoprostol (prostaglandin analog), anticholinergics, or mucosal 
protective agents.
■ Administer IV or intra-arterial vasopressin with caution.
■ If coagulopathy is present ( partial thromboplastin time [PTT]),
administer vitamin K and fresh frozen plasma.
■ Administer tranexamic acid (Cyklokapron) if excessive bleeding and
decreased fibrinolysis.
■ A specific protocol of medications is ordered if patient is Helicobacter
pylori positive. 
■ Provide emotional support to patient and family. Relieve anxiety and
pain.
■ Prepare patient for possible endoscopic or surgical procedures:
■ Laser phototherapy
■ Endoscopic thermal or injection therapy
■ Intra-arterial embolization
■ Vagotomy, pyloroplasty, or total or partial gastrectomy
Complications
■ Gastric perforation → sudden and severe generalized abdominal pain
with rebound tenderness and board-like abdominal rigidity 
■ Reduced cardiac output, including hypovolemic shock
■ Nausea, vomiting, and diarrhea
■ Altered nutritional status with nutritional deficits; aspiration
■ Infection; fever, WBC and HR
Esophageal Varices
Esophageal varices are dilated, distended, tortuous veins in the esoph-
agus. They may also occur in the proximal stomach. These varices are
most commonly due to portal hypertension (>10 mm Hg) secondary 
to hepatic cirrhosis caused by the consumption of large amounts of
alcohol.
→→
→
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Pathophysiology
Impaired liver structure and function → resistance to portal blood flow
at portal vena and inferior vena cava and pressure in the liver → por-
tal venous pressure (portal hypertension) → collateral circulation from the
liver to the veins of the esophagus, spleen, intestines, and stomach →
engorged and dilated blood vessels → esophagogastric varices → rupture
→ massive hemorrhage → death.
Clinical Presentation
■ Vomiting of blood (hematemesis) or massive bleeding (hematochezia)
■ Tachycardia; ↓ BP; cool, clammy skin; decreased urine output
■ Bright red to black stools, indicating blood in feces
■ Abdominal pain and weakness
■ Other signs of upper GI bleeding
Diagnostic Tests
■ CBC, serum chemistries, and liver enzymes
■ Platelet count, prothrombin time (PT)/PTT, and fibrinogen
■ Type and crossmatch for possible blood administration
■ Endoscopy
■ Liver biopsy
■ Splenoportography, hepatoportography, or celiac angiography
Management
■ Administer antibiotics to prevent/control infection.
■ Provide nutritional supplementation.
■ Administer octreotide (Sandostatin) infusion to ↓ portal pressure.
■ Initiate arterial or central line infusion of vasopressin (Pitressin). Use
with caution; → myocardial or mesenteric ischemia and infarction
due to vasoconstriction.
■ Insert esophagogastric balloon tamponade.
■ Prepare patient for endoscopic injection therapy (sclerotherapy).
■ Prepare patient endoscopic variceal ligation/banding or apply 
hemoclips.
→→
→
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■ Initiate treatment with heater probe, laser therapy, or electrocoagulation.
■ Prepare patient transjugular intrahepatic portosystemic shunt (TIPS).
■ Prepare patient portacaval shunt, mesocaval shunt, or splenorenal shunt.
■ Refer to assessment and management of patients with GI bleeding.
Esophagogastric Balloon Tamponade
■ Esophagogastric balloon tamponade is used to control esophageal
variceal bleeding through use of the Sengstaken-Blakemore tube or
Minnesota tube. A Linton-Nachlas tube is used for isolated gastric
hemorrhage, such as with gastric varices. The balloons apply direct
pressure to the varices → ↓ blood flow. 
■ The Sengstaken-Blakemore tube has 3 lumens: gastric aspiration,
esophageal balloon inflation, and gastric balloon inflation. The
Minnesota tube has a 4th lumen for esophageal aspiration. The infla-
tion of the balloons is as follows:
■ The esophageal balloon is inflated to 25–35 mm Hg pressure for a
maximum of 36 hours.
■ The gastric balloon is inflated to 500 mL of air or as specified by
manufacturer for a maximum of 72 hours.
■ 1 to 3 lbs of pressure is used for tension on the balloons. 
■ One port is connected to intermittent suction.
Postsurgical Management
■ Confirm placement by chest x-ray.
■ Assess airway patency.
■ Scissors should be placed at the bedside for cutting the balloons if
airway obstructed.
■ Position patient in high-Fowler’s position or on left side.
■ Provide frequent oral and nares care and oral suction.
■ Monitor gastric and esophageal output. The balloons may be deflated
every 8 to 12 hours to decompress the esophagus and stomach.
Assess for bleeding. 
■ The esophageal balloon must be deflated before the gastric balloon
to prevent upward migration of the esophageal balloon → airway
occlusion.
■ To discontinue tamponade therapy, gradually decrease esophageal
balloon pressure. Observe for bleeding. If no further bleeding, then
deflate the gastric balloon. If no further bleeding within the following
4 hours, the tube may be removed. Continue to monitor for bleeding.
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Complications
■ Esophageal erosion and rupture
■ Pulmonary aspiration
■ Balloon migration
■ Nasal necrosis
Institution Specific Care:
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
Hepatic Failure
Hepatic failure occurs when there is a loss of 60% of hepatocytes. It may
be chronic or acute and can lead to hepatic encephalopathy. Causes of
hepatic failure include:
■ Cirrhosis of the liver
■ Hepatitis A, hepatitis B, hepatitis C, and Epstein-Barr virus
■ IV drug use, cocaine use, and acetaminophen toxicity
■ Repeated environmental and hepatotoxin exposure
■ Malignancy
■ Hypoperfusion of the liver
■ Metabolic disorders: Reye’s syndrome, Wilson’s disease
■ Malnutrition, diabetes mellitus, chronic cholestatic disease, and
hypertriglyceridemia
■ Postoperatively: jejunoileal bypass, partial hepatectomy, liver 
transplant failure
Pathophysiology
■ Severe liver impairment such as necrosis or ↓ blood supply to liver →
toxic substances accumulating in the blood.
■ Impaired bilirubin conjugation, ↓ clotting factors, ↓ glucose synthesis,
↓ lactate clearance → jaundice, coagulopathies, hypoglycemia, and
metabolic acidosis.
■ Decreased macrophages in liver → risk of infection and spleen
enlargement.
→
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■ Hypoalbuminemia, fluid and electrolyte imbalances, acute portal
hypertension → development of ascites.
■ Ineffective fat metabolism → ↓ bile salt production.
■ Cirrhosis: Fibrotic tissue replaces healthy liver tissue.
■ Fatty liver disease: Fatty cells replace healthy liver tissue.
■ Hepatic failure may progress to hepatic encephalopathy.
Clinical Presentation
■ Jaundice, ascites, edema, and pruritus
■ Malnutrition, nausea, vomiting, and anorexia
■ Weakness, fatigue, and confusion
■ Hyperventilation, respiratory alkalosis, dyspnea, pleural effusion, and
hypoxemia
■ Hypokalemia and hypo- or hypernatremia
■ Palmar erythema, spider nevi, and bruising
■ Asterixis: Liver flap (patient extends arms → wrist dorsiflexes down-
ward involuntarily)
■ Metabolic acidosis, hypoglycemia, hypokalemia, and hyponatremia
■ Gallstones, malnutrition, light-colored stools, and dark urine
■ Diarrhea and steatorrhea (fatty, greasy, foul-smelling stools)
■ Hepatic encephalopathy: Drowsiness, confusion, delirium or coma,
inappropriate behavior, fetor hepaticus (breath odor), and day-night
reversal
Diagnostic Tests
■ CT scan or ultrasound
■ Serum chemistries, bilirubin, and albumin
■ AST, APT, ALT, and cholesterol
■ Ammonia levels
■ CBC and platelets
■ ABGs or pulse oximetry
■ PT, PTT, plasmin, plasminogen, fibrin, and fibrin-split products
■ Urinalysis, urine bilirubin, and urine urobilinogen
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Management
■ Administer lactulose orally or rectally. Administer Neomycin orally or
rectally if not contraindicated.
■ Administer diuretics such as furosemide (Lasix) if ascites present.
Monitor intake and output. Prepare patient for paracentesis.
■ Measure abdominal girth; weigh daily.
■ Monitor for cardiac dysrhythmias.
■ Provide stress ulcer prophylaxis. Elevate head of bed 20°–30°. Assess
for signs of GI bleeding.
■ Administer vitamin K and platelets. Avoid frequent venipunctures.
■ Treat fever and control BP.
■ Correct fluid and electrolyte imbalances. Prevent and correct
hypokalemia, which increases renal ammonia production → ammonia
across the blood-brain barrier.
■ Prevent infection. Administer prophylactic antibiotics. Consider rifax-
imin (Xifaxan).
■ Assess neurological status, level of consciousness, Glasgow Coma
Scale score, and response to verbal and noxious stimuli.
■ Assess for signs of increased intracranial pressure (ICP). Administer
mannitol.
■ Assess respiratory status, and monitor ABGs or pulse oximetry.
Correct hypercapnia and hypoxemia via O2 administration or
mechanical ventilation.
■ Provide continuous renal replacement therapy (CRRT) if renal failure
present.
■ Avoid benzodiazepines and other sedatives that may mask symp-
toms. Consider oxazepam (Serax), diazepam (Valium), or lorazepam
(Ativan) if sedation is required.
■ Use physical restraints as necessary. Provide reality orientation.
Institute measures for patient safety.
■ Administer medications with caution. Adjust dosage per liver function
tests.
■ Provide a low-protein, low-sodium diet. Restrict fluids as necessary.
Consider enteral feeding or total parenteral nutrition (TPN) if oral
intake insufficient. Assess for hypoglycemia. Monitor serum albumin,
electrolytes, and liver function tests.
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■ Prevent intravascular volume depletion through IV fluids, colloids,
and crystalloids. Avoid lactated Ringer’s solution.
■ Avoid hazards of immobility. Provide meticulous skin care.
■ Monitor ammonia levels (80–110 g/dl or 47–65 mol/L [SI units]).
■ Provide comfort measures and emotional support.
■ Prepare patient for TIPS to ↓ portal hypertension, prevent rebleeding
from varices, and ↓ formation of ascites.
■ Prepare patient for liver transplantation if necessary.
Complications
■ Cerebral edema and increased ICP, and low cerebral perfusion 
pressure
■ Cardiac dysrhythmias and coagulopathy
■ Respiratory depression, acute respiratory failure, and respiratory
arrest
■ Sepsis and circulatory failure
■ Acute renal failure
■ Hypoxemia, metabolic acidosis, and electrolyte imbalances
■ Hypoglycemia
■ GI bleeding
■ Hepatic failure may progress to hepatic encephalopathy → death.
Hepatic encephalopathy is divided into the following types:
■ Type A: hepatic encephalopathy associated with acute liver failure
■ Type B: hepatic encephalopathy caused by portal-systemic shunting
without associated intrinsic liver disease
■ Type C: hepatic encephalopathy associated with cirrhosis
■ The severity of hepatic encephalopathy is evaluated according to the
following grades:
■ Grade 1: Euphoria or anxiety, shortened attention span 
■ Grade 2: Lethargy, apathy, subtle personality change, inappropriate
behavior, minimal disorientation to time or place
■ Grade 3: Somnolence to semistupor, responds to verbal stimuli,
confusion
■ Grade 4: Coma, unresponsive to stimuli
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Pancreatitis
Pancreatitis is an inflammation of the pancreas that can be categorized
into edematous interstitial pancreatitis and acute necrotizing pancreatitis.
10%–20% of cases of pancreatitis are idiopathic and have no etiologic 
factor. Causes of pancreatitis include: 
■ Alcoholism
■ Gallstones, biliary disease, and hypertriglyceridemia
■ Infection (e.g., mumps, ischemia)
■ Blunt abdominal trauma and surgical trauma
■ Hyperparathyroidism, hypercalcemia, and hyperthyroidism
■ Systemic lupus erythematosus and vasculitis
■ Medications such as glucocoticoids, sulfanomides, tetracyclines,
NSAIDs, furosemide, hydrochlorothiazide, and estrogen
Pathophysiology
■ Trypsinogen is converted to trypsin (pancreatic enzymes) → destruc-
tion of ductal tissue and pancreatic cells → autodigestion and fibrosis
of the pancreas.
■ An increase in capillary permeability → leakage of fluid into the inter-
stitium → edema, hypovolemia, hemorrhage, pancreatic, and adipose
tissue necrosis → third spacing of fluids → systemic inflammatory
response syndrome (SIRS).
■ Obstruction of the pancreatic duct → reflux of bile into the pancreas
→ enzyme reaction.
■ Drugs and toxins → autodigestion and inflammation.
Clinical Presentation
■ Severe knife-like midepigastric or midabdominal pain that may radiate
to the back; onset of pain is frequently 24–48 hours after a heavy meal
or alcohol ingestion; pain may also be diffuse and difficult to localize
■ Nausea and vomiting
■ Fever, diaphoresis, and weakness
■ Tachypnea, ↓ BP, HR, and other symptoms of hypovolemic shock
■ Hypoactive or absent bowel sounds, and abdominal tenderness and
distention
→
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■ Ascites and jaundice if illness severe
■ Pancreatic hemorrhage → Grey Turner’s sign (gray-blue discoloration
of the flank) or Cullen’s sign (discoloration of the umbilical region)
■ Palpable abdominal mass if pseudocyst or abscess present
■ Hypocalcemia and hyperlipidemia
Diagnostic Tests
■ Serum amylase (30–220 U/L [SI units] normal) and/or lipase 
(0–160 U/L [SI units] normal) >3 times the upper limit of normal
■ Abdominal flat plate or ultrasound of abdomen, CT, MRI, and endo-
scopic cholangiopancreatography 
■ Chest x-ray to detect pleural effusions
■ Serum chemistries, including ↓ calcium, ↓ magnesium, bilirubin, 
glucose, ↓ potassium, liver enzymes, ↓ albumin, and triglycerides
■ Urinalysis and urinary amylase (6.5–48.1 U/hr [SI units])
■ CBC ( WBC, hematocrit and hemoglobin may be or ↓), PT/PTT, 
C-reactive protein
■ ABGs to assess for hypoxemia and metabolic acidosis
Management
■ Administer analgesics; position patient in knee-chest position.
■ Consider prophylactic antibiotics. For necrotizing pancreatitis, admin-
ister imipenem-cilastatin (Primaxin) for its high concentration of the
drug in the pancreas.
■ Assess fluid and electrolyte balance. Note hypokalemia or hypocal-
cemia. Administer IV fluids, crystalloids, and colloids. Monitor intake
and output. 
■ Assess nutritional status. Keep patient NPO initially. Consider TPN, or
gastric or jejunal enteral feedings. Stress ulcer prophylaxis.
■ Insert NG tube if vomiting, obstruction, or gastric distention is 
present. Provide frequent oral care.
■ Assess for metabolic acidosis.
■ Assess respiratory status and monitor ABGs or venous oxygen 
saturation. Administer O2 as needed.
■ Administer insulin if elevated blood glucose levels exist.
→
→→
→
→→
→→
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■ Assess abdomen for distention, rigidity, ascites, and increasing pain
or rebound tenderness; auscultate bowel sounds and measure
abdominal girth.
■ Treat fever and monitor WBC count.
■ Assess vital signs. Monitor for cardiac arrhythmias.
■ Prepare patient for surgical debridement or pancreatic resection for
necrotizing pancreatitis or drainage of pancreatic pseudocyst or
abscess.
Complications
■ Pancreatic abscess or pseudocyst formation, and bowel infarction
■ Acute lung injury (ALI), pleural effusion, atelectasis, pneumonia,
pneumonitis, hypoxemia, respiratory failure, and acute respiratory
distress syndrome 
■ Hypotension, pericardial effusion, myocardial depression, cardiac
dysrhythmias, and disseminated intravascular coagulation 
■ Acute renal failure, acute tubular necrosis, and azotemia
■ Hepatic dysfunction, obstructive jaundice, and paralytic ileus
■ Stress ulcers and esophageal varices → GI hemorrhage
■ Systemic inflammatory response syndrome
■ Severe hemorrhage and shock
■ Multiorgan failure, sepsis, and death
Peritonitis
Peritonitis is the inflammation of the peritoneum, the serous membrane
lining the abdominal cavity and covering the viscera. It may be localized
or generalized. Peritonitis is an example of acute abdomen.
Pathophysiology
Inflammation, bacterial infection, ischemia, tumor, and trauma → leakage
of contents from the abdominal organs into the abdominal cavity →
tissue edema → fluid in peritoneal cavity.
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Clinical Presentation
■ Abdominal pain that increases with movement such as coughing and
flexing the hips; rebound tenderness, guarding, and abdominal rigidi-
ty (washboard abdomen); Blumberg’s sign: Pressing a hand on the
abdomen elicits pain, but pain increases when releasing the hand as
the peritoneum moves back into place
■ Air and fluid in the bowel
■ Abdominal distention, hyperactive → hypoactive bowel sounds 
→ paralytic ileus
■ Nausea and vomiting
■ Fever and HR
■ Cloudy effluent if on peritoneal dialysis
Diagnostic Tests
■ CBC: assess for leukocytosis, and ↓ hemoglobin and hematocrit
■ Serum chemistries
■ Abdominal x-ray
■ Peritoneal lavage or peritoneal aspiration, and culture and sensitivity
studies of peritoneal fluid or peritoneal effluent
Complications
■ Fluid and electrolyte imbalance, ↓ CVP, hypovolemia → shock → acute
renal failure
■ Intestinal obstruction due to bowel adhesions
■ Peritoneal abscess
■ Sepsis
Management
■ Administer antibiotics. Obtain blood cultures to assess for sepsis.
■ Obtain peritoneal effluent cultures.
■ Provide fluid and electrolyte replacement. Monitor intake and output.
■ Administer analgesics and antiemetics. Place patient on side with
knees flexed. 
→
149
GI
20841_Tab06_137-158.qxd  1/15/09  6:07 PM  Page 149
GI
150
■ Monitor vital signs. Assess for ↓ BP and HR. Provide cardiac 
monitoring.
■ Assess respiratory status. Administer O2 as indicated by ABGs or
pulse oximetry.
■ Assess abdomen for pain and distention. Auscultate bowel sounds.
■ Perform surgery to remove infected material and correct the cause.
Crohn’s Disease
Crohn’s disease is an inflammatory bowel disease that may occur any-
where along the GI tract. The terminal ileum and proximal large intestine
are usually involved.
Pathophysiology
Chronic inflammation → edema and thickening of intestinal mucosa →
ulcers forming in the intestines → fistulas, fissures, and abscesses →
thickening of bowel wall → narrowing of intestinal lumen → scar tissue
and granulomas → weepy edematous intestines.
Clinical Presentation
■ Lower right quadrant abdominal pain that usually occurs after meals
■ Abdominal tenderness and spasm
■ Chronic diarrhea and steatorrhea (excessive fat in stool)
■ Weight loss, anorexia, malnutrition, and anemia
Diagnostic Tests
■ Sigmoidoscopy, colonoscopy, intestinal biopsies, and testing for
Clostridium difficile
■ Stool analysis for occult blood and steatorrhea, and stool culture and
sensitivity (C&S)
■ UGI series or endoscopy, and barium enema
■ Abdominal x-rays and CT, MRI, or ultrasound of the abdomen
■ CBC, erythrocyte sedimentation rate (ESR), and C-reactive protein
■ Serum chemistries, including albumin, protein, and calcium, and liver
function tests
→
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Management
■ Administer aminosalicylates:
■ Sulfasalazine (Azulfidine)
■ Mesalamine or mesalazine (5-ASA, Asacol, Pentasa)
■ Balsalazide (Colazal)
■ Olsalazine (Dipentum)
■ Administer corticosteroids:
■ Prednisone or hydrocortisone
■ Prednisolone or methylprednisolone
■ Beclomethasone or budesonide
■ Consider administration of antibiotics.
■ Administer analgesics for pain.
■ Assess vital signs for HR and fever, and assess for pallor.
■ Assess bowel sounds, and examine abdomen for distention and 
tenderness.
■ Assess number and frequency of stools, and test stool for occult
blood and parasites.
■ Administer IV fluids to correct fluid and electrolyte imbalance.
■ Maintain NPO with TPN, or provide diet high in protein and calories
with vitamins and iron.
■ Administer bulk hydrophilic agents.
■ Prepare patient for surgery as needed (partial or complete colectomy
with ileostomy of anastomosis).
Ulcerative Colitis
Ulcerative colitis is an inflammatory autoimmune disease of the bowel. It
is characterized by ulcers or open sores in the colon that affect the mucos-
al layer. The patient experiences remissions and exacerbations with an
increased risk of colorectal cancer.
Pathophysiology
Multiple ulcerations of the colon → bleeding → mucosa becomes edema-
tous and inflamed → abscesses → narrowing, shortening and thickening
of the bowel.
→
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Clinical Presentation
■ Diarrhea mixed with blood and mucus (as many as 10–20 liquid
stools/day) and an urgent need to defecate
■ Crampy abdominal pain in the left lower quadrant and rebound 
tenderness in the right lower quadrant
■ Intermittent tenesmus: Constant feeling of the need to defecate with
little or no fecal output
■ Rectal bleeding
■ Pallor, anemia, and fatigue
■ Anorexia, weight loss, vomiting, and dehydration
■ Fever and tachycardia
Diagnostic Tests
■ Sigmoidoscopy, colonoscopy, intestinal biopsies, and testing for
Clostridium difficile
■ Stool analysis for occult blood and steatorrhea, and stool C&S
■ UGI series or endoscopy, and barium enema
■ Abdominal x-rays and CT, MRI, or ultrasound of the abdomen
■ CBC, ESR, and C-reactive protein
■ Serum chemistries, including albumin, protein, and calcium, and liver
function tests
Management
■ Assess vital signs for HR, ↓ BP, RR, and fever, and assess for 
pallor.
■ Assess skin in the perianal area for redness and skin breakdown.
■ Assess bowel sounds, and examine abdomen for distention and 
tenderness.
■ Assess number and frequency of stools, and test stool for occult
blood and parasites.
■ Administer IV fluids to correct fluid and electrolyte imbalance.
■ Maintain NPO with TPN, or provide diet high in protein and calories
with vitamins and iron.
■ Administer bulk hydrophilic agents.
■ Administer antibiotics, such as metronidazole (Flagyl).
→→
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■ Administer aminosalicylates:
■ Sulfasalazine (Azulfidine)
■ Mesalamine or mesalazine (5-ASA, Asacol, Pentasa)
■ Balsalazide (Colazal)
■ Olsalazine (Dipentum)
■ Administer corticosteroids:
■ Prednisone or hydrocortisone
■ Prednisolone or methylprednisolone
■ Beclomethasone or budesonide
■ Administer GI anti-inflammatories/monoclonal antibodies:
■ Infliximab (Remicade)
■ Visilizumab (Nuvion)
■ Administer immunosuppressants:
■ Mercaptopurine (6-MP)
■ Azathioprine (Imuran, Azasan)
■ Methotrexate (Amethopterin)
■ Tacrolimus (Prograf)
■ Administer analgesics, sedatives, and antidiarrheals as needed.
■ Prepare patient for surgery as needed (total colectomy with ileostomy,
continent ileostomy, or bowel resection).
Complications
■ Toxic megacolon → colonic distention → fever, abdominal pain and
distention, vomiting, and fatigue (does not respond to medical man-
agement within 24–72 hours)
■ Intestinal perforation and bleeding
■ Pyelonephritis and nephrolithiasis
■ Malignant neoplasms
Small Bowel Obstruction
SBO is a mechanical or functional obstruction of the small intestines. The
normal transit of the products of digestion through the intestines is
blocked.
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Causes
■ Adhesions and hernias
■ Crohn’s disease
■ Benign or malignant tumors
■ Foreign bodies
Pathophysiology
■ Intestinal contents, gas, and fluid accumulate above the obstruction
→ abdominal distention and fluid retention → ↓ venous and arteriolar
capillary pressure → edema, congestion, and necrosis of the intestine
→ rupture or perforation of the intestinal wall → peritonitis.
■ SBO may also lead to intestinal strangulation.
■ Reflex vomiting also occurs → ↓ H+ and K+ → metabolic acidosis, and
↓ H2O and ↓ Na+ → dehydration → hypovolemic shock.
■ Obstruction may resolve spontaneously.
Clinical Presentation
■ Crampy, colicky, wave-like central or midabdominal pain
■ No bowel movement and absence of flatus → abdominal distention
→ bowel ischemia or perforation
■ Nausea and vomiting → dehydration (drowsiness, malaise, and
parched tongue and mucous membranes) and electrolyte imbalances
→ hypovolemic shock
■ Possible aspiration of vomitus (vomitus may be fecal in nature)
Diagnostic Tests
■ Abdominal x-ray; CT scan and ultrasound of the abdomen
■ Contrast enema or small bowel series
■ Colonoscopy and laparoscopy
■ CBC and serum chemistries
Management
■ Insert NG tube and connect to low intermittent suction; assess color
and amount of drainage.
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■ Administer IV fluids, and assess fluid and electrolyte balance.
■ Monitor nutritional status. Monitor intake and output.
■ Assess abdomen for bowel sounds, pain, and distention.
■ Administer analgesics for pain.
■ Prepare patient for surgery as indicated to relieve the obstruction.
Morbid Obesity
Morbid obesity is defined as a body mass index (BMI) >30–40 kg/m2, a
body weight twice the person’s ideal body weight, or a body weight more
than 100 lbs. greater than the ideal body weight.
Persons who are morbidly obese are at a higher risk for: 
■ Diabetes mellitus 
■ Cardiovascular disease, including stroke and hypertension 
■ Hypertrophic cardiomyopathy 
■ Hyperlipidemia 
■ Gallbladder disease 
■ Osteoarthritis 
■ Obstructive sleep apnea 
■ Obesity hypoventilation syndrome 
■ Certain cancers (uterine, breast, colorectal, kidney, and gallbladder)
Psychosocial problems may also co-exist:
■ Low self-esteem 
■ Impaired body image 
■ Depression 
■ Social anxiety/isolation
Management
Pharmacological Management
■ Sibutramine HCL (Meridia).
■ Orlistat (Xenical).
Surgical Management
■ Bariatric surgical techniques include those based on gastric restriction
and those combining gastric restriction and malabsorption. They
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include gastric bypass (Roux-en-Y), gastric banding, vertical-banded
gastroplasty, and biliopancreatic diversion (BPD).
■ Gastric restriction surgeries use staples or banding to reduce the
stomach size to 15 mL.
■ Vertical-banded gastroplasty (Mason procedure or stomach stapling)
creates a pouch, and a band is placed at the lower end of the pouch
→ creation of a stoma → emptying into the small intestine.
■ Circumgastric (adjustable) banding limits the stomach size through
the placement of an inflatable band around the fundus of the stom-
ach. This may be done laparoscopically.
■ BPD (Scopinaro procedure) has been replaced by duodenal switch
(BPD/DS). In BPD/DS, part of the stomach is resected and the distal
part of the small intestine is connected to the stomach pouch,
bypassing the duodenum and jejunum.
■ Gastric bypass surgery (most commonly performed operation for
weight loss) creates a stomach pouch that is connected to the distal
small intestine. 
Postoperative Management
Standard postoperative care should be provided, with the following 
special attention:
■ Administer analgesics for pain.
■ Vigilantly assess respiratory status. Patient may need long-term 
ventilatory support with use of tracheostomy.
■ Elevate head of bed 30° to reduce weight of adipose tissue on the
diaphragm.
■ Encourage early ambulation; turn and position frequently with use of
trapeze on the bed.
■ Assess for skin breakdown especially within skin folds.
■ When starting diet, provide 6 small feedings/day (totaling 600–800
calories); encourage fluids to prevent dehydration.
■ Provide deep vein thrombosis (DVT) prophylaxis.
Complications may include:
■ Bleeding from surgical site or internally
■ Thromboembolism and pulmonary embolism
■ Atelectasis and pneumonia
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■ Bowel obstruction, incisional or ventral hernias, wound dehiscence,
and slow wound healing
■ Infection: Respiratory, urinary, wound, or sepsis
■ Anastomosis leak → peritonitis
■ Abdominal compartment syndrome
■ Nausea, vomiting, gastric dumping syndrome ( HR, nausea, tremor,
dizziness, fatigue, abdominal cramps, and diarrhea), and diarrhea or
constipation
■ Fluid and electrolyte imbalances
■ Gallstones, nutritional deficiencies, electrolyte imbalance, anemia,
and weight gain (long-term complications)
Gastrointestinal Surgery
Esophagectomy is the removal of the entire esophagus and part of the
stomach and lymph nodes in the surrounding area.
Whipple procedure or pancreaticoduodenectomy is the removal of the
head of the pancreas, duodenum, part of the jejunum, common bile duct,
gallbladder, and part of the stomach.
Complications
■ Atelectasis, pneumonia, and respiratory failure
■ DVT and pulmonary embolism
■ UGI bleeding
■ Gastritis, esophagitis, and dumping syndrome
■ Anastomotic leak: Tachycardia, tachypnea, fever, abdominal pain, anxi-
ety and restlessness, subcutaneous emphysema (crepitus), and sepsis
Management
■ Provide standard postoperative care, including administration of anal-
gesics and provision of pulmonary care.
■ Assess for GI bleeding.
■ Provide DVT prophylaxis. Encourage early ambulation.
→
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Percutaneous transjugular intrahepatic portosystemic shunt (TIPS ) is an
interventional procedure to decrease portal hypertension and reduce
complications from high hepatic pressures. A catheter is placed in a
hepatic vein, and a stent is placed in the liver parenchyma.
Postprocedure, observe for bleeding due to hepatic or portal vein punc-
ture, puncture of the biliary tree, bile duct trauma, and stent migration
or thrombosis.
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Hematologic and Oncologic Disorders
Disseminated Intravascular Coagulation
DIC is a disorder characterized by massive systemic intravascular activa-
tion of coagulation caused by a variety of clinical conditions, including
sepsis (Gram + and Gram – infections), severe trauma or burns, and solid
or hematologic cancers. It can also be caused by some obstetric condi-
tions, such as placental abruption, amniotic fluid embolism, and placenta
previa.
Pathophysiology
■ Activation of thrombus → fibrinogen fibrin formation and deposition
of fibrin in the microvasculature → an in platelet aggregation or
adhesions → formation of fibrin clots to form → diffuse obstruction of
the smaller vessels → progressive organ dysfunction (i.e., renal insuf-
ficiency, ARDS, hypotension, circulatory failure, skin necrosis). 
■ Concurrent with these events, platelets, prothrombin, and fibrinogen
are used up → a deficiency of these factors compromising coagula-
tion and predisposing to bleeding. 
■ The excessive clotting at the microvasculature level activates the 
fibrinolytic system → production of fibrin degradation products
(FDPs) (i.e., fibrin split products) → an anticoagulation effect of FDP
with fibrinogen and thrombin → interference with the formation of
fibrin clot and decreased platelet function → bleeding → hemorrhagic
bleeding.
Clinical Presentation
■ Bleeding (purpura, petechiae, eccymosis) 
■ GI bleeding (hematemesis, melena, tarry stools)
■ GU/GYN bleeding (hematuria, menorrhagia in women)
■ Wound bleeding
■ Bleeding and oozing from puncture sites and around invasive
catheters and lines
■ Hematoma formation
■ Pulmonary hemorrhage
■ Large foci of skin necrosis (resulting from tissue injury and necrosis
associated with compromised circulation)
■ Acrocyonosis (cyanosis of hands and feet)
→
159
HEMA/
ONCO
20841_Tab07_159-175.qxd  1/15/09  6:08 PM  Page 159
HEMA/
ONCO
160
■ Acute multiorgan dysfunction (characterized by hypotension, oliguria,
dyspnea, confusion, convulsions, coma, abdominal pain, diarrhea,
and other GI symptoms)
■ Angina
■ Malaise
■ Dyspnea
■ Fatigue and weakness
■ Headache
■ Nausea and vomiting
■ Palpitations
■ Severe pain in abdomen, back, muscles, joints, and bones
■ Sudden vision changes
■ Vertigo
■ Confusion and anxiety/irritability
■ Convulsions
■ Coma
Diagnostic Tests
■ CBC
■ Prothrombin time (PT)/partial thromboplastin time (PTT)
■ Fibrinogen level
■ Fibrin degradation/ split products
■ D-dimer
■ Thrombin time
■ Anti-thrombin III (AT III)
Management
■ Be aware of early signs of impaired tissue perfusion in patients at high
risk for DIC (subtle mental status change, hypotension [especially
orthostatic]), dyspnea, tachypnea, syncope, decreased urine output.
■ Start heparin infusion.
■ Replace deficient clotting factors.
■ Administer vitamin K and folate.
■ Administer platelet infusion.
■ Administer fresh frozen plasma (FFP) infusion.
■ Administer cryoprecipitate infusion.
■ Provide blood transfusion.
■ Administer O2 as needed.
■ Provide support to patient and family.
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Heparin-Induced Thrombocytopenia
Heparin-induced thrombocytopenia is a transient disorder in which throm-
bocytopenia (>50% ↓ in platelet count) appears approximately 1 week 
after exposure to heparin. There is a strong association with venous and
arterial blood clot formation.
Pathophysiology 
After heparin is administered, an immune complex can form between
heparin and specific blood factor (platelet factor 4 [PF4]) that is released
by platelets → body viewing this “heparin-PF4” as a foreign body → for-
mation of antibodies against the heparin PF4 complex → antibodies
binding to the complex → platelet destruction → disruption of platelets
→ formation of new blood clot → deep vein thrombosis (DVT), pul-
monary embolism (PE), myocardial infarction (MI) or cerebrovascular
accident (CVA).
Clinical Presentation
■ Signs and symptoms of DVT (pain or tenderness, sudden swelling,
discoloration of visible leg veins)
■ Signs and symptoms of PE (SOB, change in HR, sharp chest pain,
dizziness, anxiety, excessive sweating)
■ Severe indicators: 
■ Skin changes (bruising or blackening around injection site as well
as on fingers and toes, and nipples) gangrene
Diagnostic Tests
■ CBC
■ PT/PTT
■ PF4 assay
■ Platelet activation assay (C-SRA; heparin- induced platelet activation
assay)
Management
■ Discontinue all heparin products.
■ Administer IV direct thrombin inhibitor for anticoagulation: 
■ Lepirudin (Refludan)
■ Argatroban (Acova)
■ Bivalirudin (Angiomax)
■ CBC: monitor platelet count. 
→
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■ Once platelet count is normal, initiate Coumadin therapy.
■ Provide a complete skin and neurovascular assessment.
■ Provide support to patient and family.
Neutropenia
Neutropenia is an abnormally low absolute neutrophil count.
Pathophysiology
■ Neutropenia is caused by problems with neutrophil production and/or
problems with neutrophil distribution due to infection, treatment, or
drugs:
■ Decreased production of neutrophils due to aplastic anemia, med-
ications or toxins, metastatic cancer, lymphoma or leukemia,
myelodysolastic syndrome, chemotherapy, or radiation.
■ Increased destruction of neutrophils (medication induced), due to
immunologic disease (e.g., systemic lupus erythematosus), viral
disease (e.g., infectious hepatitis, mononucleosis), or bacterial
infection.
■ Interruption of neutrophil production or neutrophil distribution 
→ decrease in neutrophil count.
Clinical Presentation 
When a patient is neutropenic, the following usual signs of infection may
not be present because of the lack of sufficient number of neutrophils
needed to produce common infectious signs:
■ Fever
■ Shaking chills
■ Sore throat
■ Cough
■ SOB
■ Nasal congestion
■ Diarrhea or loose stools
■ Burning during urination
■ Unusual redness
■ Swelling warmth
Diagnostic Tests 
■ Blood cultures
■ CBC
20841_Tab07_159-175.qxd  1/15/09  6:08 PM  Page 162
■ Basic metabolic panel (BMP)
■ Kidney and liver functions
■ Urinalysis and urine culture
■ Site-specific cultures, such as stool, skin, and vascular access devices
■ Chest x-ray
Management
■ Treat with broad-spectrum antibiotics until an organism is identified.
■ Check temperature every 4 hours.
■ Monitor for signs of infection.
■ Assess and monitor CBC with differential.
■ Discontinue any medications that could be the cause.
■ Educate patient’s family members to avoiding visiting if they have
cold or flu-like symptoms.
■ Maintain good hand washing procedures.
Coagulopathy
Abnormalities in blood coagulation may comprise a large number of dis-
orders, including deficiency (or single-factor) abnormalities and acquired
forms associated with multiple coagulation abnormalities. The disorders
are discussed here.
Vitamin K Deficiency
Vitamin K deficiency occurs when stores of this vitamin are deficient or
abnormal, causing inhibition of normal coagulation.
Pathophysiology
■ Prothrombin; factors VII, IX, and X (FVII, FIX, and FX); and proteins 
C and S are synthesized by the liver through a process that depends
on vitamin K.
■ Vitamin K deficiency → synthesized hypofunctional by-products →
inhibition of normal coagulation. These by-products do not bind to
cellular phospholipid surfaces and therefore do not participate in 
cell-associated coagulation reactions. Coumadin produces a similar
coagulation abnormality that antagonizes the action of vitamin K. 
■ Because the vitamin K is fat soluble, the absorption from the GI 
tract is decreased in biliary obstruction and in fat malabsorption 
syndromes. 
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■ Antibiotics that inhibit gut flora decrease amount of vitamin K 
ordinarily supplied by these organisms.
Clinical Presentation
■ Epistaxis and/or bleeding from puncture sites or invasive lines,
wounds
■ Prolonged PT and elevated international normalized ratio (INR)
Diagnostic Tests
■ PT (most sensitive early indicator)
Management
■ Administer FFP (treatment of choice for acute hemorrhage or to
reverse for a procedure).
■ Administer vitamin K (1–10 mg x 3 days).
■ Continue to monitor PT.
■ Assess for bleeding.
■ Provide emotional support to patient and family.
Liver Disease 
Coagulation disorder caused by liver disease is multifactoral and involves
decreased synthesis of coagulation proteins, decreased clearance of
FDPs, and increased fibrinolysis.
Pathophysiology
■ In cirrhosis, FVII and protein C are the first to fall → a low FVII level,
resulting in a prolonged PT. The remaining vitamin K dependent 
factors decrease → prolonged aPTT. The fibrinogen level is usually
maintained until end-stage disease. Because of impaired synthetic
function → factors and fibrinogen may be functionally abnormal.
■ In acute toxic or infectious hepatitis, impairment of coagulation 
correlates with the severity of cell damage. 
Unlike the situation with other types of coagulopathy → coagulation 
factors and fibrinogen may be dysfunctional → because of abnormal
hepatic synthetic function platelets may be dysfunctional by circulating
FDPs that the liver fails to clear.
Clinical Presentation
■ Bleeding
■ Prolonged PT, activated PTT (aPTT)
■ Elevated FDPs
■ Low platelet count
20841_Tab07_159-175.qxd  1/15/09  6:08 PM  Page 164
Diagnostic Tests
■ PT/PTT
■ D-dimer
■ Fibrin degradation/split products
■ CBC
■ Liver function tests
Management
■ Administer FFP.
■ Administer platelets.
■ Administer desmopressin acetate (DDAVP) at 0.3 mcg/kg over 20 minutes
(may improve platelet function).
Massive Transfusion 
Coagulopathy can be caused by massive transfusion when the replace-
ment of 1 or more blood volumes occurs in a 24-hour period (1 blood vol-
ume in a 70-kg adult is about a 5-L blood loss or transfusion volume of 
10 units of packed red blood cells [PRBCs]). Common complications of
massive transfusion are dilutional coagulopathy, DIC and fibrinolysis,
hypothermia, citrate toxicity, hypokalemia, hyperkalemia, and infection.
Pathophysiology
Dilutional thrombocytopenia is the most common cause of bleeding after
massive transfusion. If ongoing blood loss is replaced with only PRBCs →
fall in platelet count → splenic pool mobilizing and counteracting loss 
during hemorrhage. If patient’s count was high prior to transfusion →
remainder may be adequate to prevent bleeding. If pretransfusion count
was low or normal → the count may be 50,000–100,000 per microliter →
bleeding. Repletion of platelets → enhanced function of the coagulation
factors and platelet plug formation. Platelets provide the surface on which
many of the factors are activated and fibrin strands are formed.
Clinical Presentation
■ Bleeding from areas other than the area of hemorrhage
■ Low platelet count
■ Prolonged PT, aPTT, and thrombin time
■ Decreased fibrinogen
Diagnostic Tests
■ PT/PTT
■ CBC
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■ D-dimer
■ Fibrin degradation/split products
Management
■ Administer platelets.
■ Administer cryoprecipitate.
■ Replace electrolytes as needed.
■ Provide support to patient and family members.
For disseminated intravascular coagulation and heparin-induced throm-
bocytopenia, see pages 159 to 162. 
Oncologic Emergencies
Oncologic emergencies are complications or conditions of cancer and/or
its treatments requiring urgent or emergent interventions to avoid life-
threatening situations.
Sepsis
Sepsis is a condition in which organisms enter into the blood stream,
causing activation of the host inflammation defense mechanism →
release of cytokines and the activation of plasma protein cascade systems
→ septic shock → multisystem organ failure. Cancer patients are at an
increased risk for sepsis due to ↓ WBC and poor immune systems.
Clinical Presentation 
■ WBC
■ Fever
■ Hypotension
■ Tachycardia
■ Lethargy
■ Agitation and confusion
Diagnostic Tests 
■ Blood cultures
■ Urine cultures and urinalysis
■ CBC with differential
■ PT/PTT
→
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Management
■ Administer broad-spectrum antibiotics until organism identified.
■ Support BP with vasopressors, such as vasopressin, Levophed, and
dopamine.
■ Administer IV fluids.
■ Provide emotional support to patient and family members.
Disseminated Intravascular Coagulation
See DIC as previously mentioned on pages 159 to 160.
Syndrome of Inappropriate Antidiuretic Hormone
(SIADH)
SIADH is caused by malignant tumors that produce or secrete ADH or
tumors that stimulate the brain to make and secrete ADH. SIADH can also
be caused by medications frequently used by cancer patients (e.g., mor-
phine, cyclophosphamide). In SIADH, an excessive amount of water is
reabsorbed by the kidney → in excessive fluid in circulation → hypona-
tremia and fluid retention.
Clinical Presentation
■ Weakness
■ Muscle cramps
■ Loss of appetite
■ Fatigue
■ Hyponatremia (115–120 mEq/L)
■ Weight gain (water weight)
■ Nervous system changes
■ Personality changes
■ Confusion
■ Extreme muscle weakness
■ If Na+ <110, may cause possible seizures, coma, and death 
(if Na+ <110)
Diagnostic Tests
■ Urine electrolytes
■ Urinalysis
■ BMP (watch Na+ levels closely)
→
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Management
■ Restrict fluids.
■ Increase Na+ intake.
■ Drug therapy includes demeclocycline (an antibiotic taken orally that
works in opposition to ADH).
■ Radiation or chemotherapy may be given to reduce tumor progres-
sion causing SIADH → to normal ADH production.
Spinal Cord Compression
Compression of the spinal cord is caused by a tumor that directly enters
the spinal cord or by vertebrae collapsing due to deterioration of the
bone secondary to a tumor. The compression site can be from a primary
tumor but is usually due to metastases from the lung, prostate, breast,
or colon.
Clinical Presentation 
■ Back pain
■ Numbness
■ Tingling
■ Loss of urethral, vaginal, and rectal sensation
■ Muscle weakness (neurologic deficits are later signs)
■ Paralysis (usually permanent)
Diagnostic Tests 
■ CT scan of torso
■ MRI of spine
Management
■ Provide early recognition and treatment.
■ Perform comprehensive neurologic examination.
■ Administer high-dose corticosteroids to reduce swelling and relieve
symptoms.
■ Administer high-dose radiation to reduce tumor size and relieve
symptoms.
■ Surgery may be indicated in order to remove the tumor.
■ Apply external neck or back braces.
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Hypercalcemia
Cancer in the bone → bone releasing calcium into bloodstream →
serum calcium levels. Cancer in other parts of the body (especially lung,
head and neck, kidney, or lymph nodes) → secretion of parathyroid hor-
mone by the tumor → release of calcium by the bone → serum calci-
um levels. Decreased mobility and dehydration worsen hypercalcemia.
Clinical Presentation 
■ Fatigue
■ Loss of appetite
■ Nausea and vomiting
■ Constipation
■ Polyuria (early sign)
■ Severe muscle weakness
■ Loss of deep-tendon reflexes
■ Paralytic ileus
■ More severe changes: dehydration, ECG changes
Diagnostic Tests 
■ Parathyroid hormone levels
■ BMP q6h (every 6 hours)
■ Ionized calcium levels
Management
■ Provide oral hydration.
■ Provide IV hydration with normal saline.
■ Administer medications to decrease calcium levels temporarily.
■ Administer glucocorticoids.
■ Administer calcitonin.
■ Administer diphosphonate.
■ Administer mithramycin.
■ Dialysis may be indicated to decrease serum calcium levels in 
life-threatening situations or in those with renal impairment.
→
→
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Superior Vena Cava Syndrome
SVC syndrome occurs when the superior vena cava is compressed 
or obstructed by tumor growth → painful life-threatening emergency,
most often seen in lymphomas and lung cancer. SVC results in block-
age of blood flow in the venous system of the chest, neck, and upper
trunk.
Clinical Presentation
Early Symptoms
■ Edema of the face, especially around the eyes, when patient arises
from night’s sleep 
■ Tightness of shirt or collar (Stoke’s sign) as compression worsens
■ Edema in arms and hands, dyspnea, erythema of upper body, and
epistaxis
Late Symptoms
■ Hemorrhage
■ Cyanosis
■ Mental status changes
■ Decreased cardiac output → hypotension
■ Death (if compression not relieved)
Diagnostic Tests
■ CT of chest
■ ECG
Management 
■ Provide high-dose radiation to the mediastinal area (provides 
temporary relief).
■ Provide interventional radiology may place a metal stent in the vena
cava to relieve swelling.
■ Follow-up angioplasty may be needed to keep the stent open
longer.
■ Surgery is rarely performed, because the tumor may have caused
such an increase in intrathoracic pressure that closing the chest post-
operatively would be impossible.
■ Best treatment results occur in the early stages of SVC syndrome.
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Tumor Lysis Syndrome
TLS occurs when large numbers of tumor cells are destroyed rapidly →
the release of intracellular contents (potassium and purines) into the
bloodstream faster than the body can eliminate them → tissue damage
and death if severe or untreated potassium levels → severe hyper-
kalemia → severe cardiac dysfunction. An in purines (converted in the
liver to uric acid) released into bloodstream → hyperuricemia → precipi-
tation of these crystals in the kidney → sludge in the tubules → blockage
→ acute renal failure. TLS is most often seen in patients receiving
chemotherapy or radiation for the cancers highly responsive to this treat-
ment, including leukemia, lymphoma, small cell lung carcinoma, and
multiple myeloma. This oncologic emergency is a positive sign the treat-
ment is working.
Diagnostic Tests
■ CMP
■ CBC
■ ECG
■ Ultrasound of kidneys
■ Uric acid level
Management
■ Provide IV hydration, which ↓ serum K+ level and kidney filtration rate.
■ Instruct patient to drink at least 3–5 L of fluid the day before, the day
of, and 3 days after treatment (especially in patient with tumors high-
ly sensitive to treatment, as mentioned earlier).
■ Ensure that some fluids are alkaline (Na+).
■ Health teach importance of consistent fluid intake over 24 hours (help
patient draw up a schedule).
■ Health teach importance of taking antiemetics after treatment to 
prevent nausea and vomiting, which would hinder fluid intake.
■ Administer diuretics, especially osmotic types, to increase urine flow.
*Use with caution as diuretics may cause dehydration.
■ Administer medications that increase secretion of purines: allupurinol
(Zyloprim), rasburicase (Elitek).
■ Administer medications to decrease hyperkalemia: sodium poly-
styrene sulfonate (Kayexalate), either orally or rectally by enema. 
→
→
→
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■ Administer IV infusion containing dextrose and insulin if 
hyperglycemic.
■ Initiate dialysis as needed.
Leukemia
Leukemia is the uncontrolled neoplastic reproduction of white blood cells.
Causes include significant bone marrow damage that can result from radi-
ation or chemicals.
Pathophysiology 
Myeloid Leukemia
■ Acute: Malignant alterations in hematopoietic stem cells. Risk factors
include advanced age, therapeutic radiation, supportive care patients,
smoking, and exposure to chemicals. It is the more common form of
myeloid leukemia.
■ Chronic: Uncontrolled mutation of myeloid cells. This disease is rare in
children, and risk increases with age. There is an increased incidence of
this type of leukemia with radiation exposure.
Lymphocytic Leukemia
■ Acute: Large amount of bone marrow stem cells develop into 
lymphocytes. Most prevalent in young children.
■ Chronic: Only leukemia not related to radiation or chemicals. 
B lymphocytes do not go through apoptosis → excessive cells in
bone marrow and blood → enlarged nodes → hepatomegaly and
splenomegaly → anemia and thrombocytopenia. There is a slight
genetic predisposition with this type of leukemia.
Clinical Presentation 
Acute Myeloid Leukemia
■ Fatigue
■ Bruising or bleeding
■ Fever
■ Infection
■ Pain from enlargement of liver and spleen
■ Gum hyperplasia
■ Bone pain
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Chronic Myeloid Leukemia
■ Remain asymptomatic in many patients for long periods of time
■ Malaise
■ Loss of appetite
■ Weight loss
■ Spleen tenderness and enlargement
Acute Lymphocytic Leukemia
■ Reduced leukocytes, erythrocytes, and platelets
■ Pain from bone, liver, or spleen
■ Headache
■ Vomiting
Chronic Lymphocytic Leukemia
■ Asymptomatic in many cases
■ Elevated WBC 
■ Enlarged lymph nodes and spleen
■ Possible development of B-symptoms: fever, night sweats, weight
loss, bacterial infections, and viral infections
Diagnostic Tests 
■ CBC
Management 
■ Perform daily assessment of body systems and monitor for anemia
and infections.
■ Monitor CBC closely.
■ Maintain bleeding precautions.
■ Provide nutritional support.
■ Provide meticulous oral hygiene.
■ Provide perirectal hygiene.
■ Apply mask to patient when out of room.
■ Assess anxiety level.
■ Monitor intake and output, and assess hydration status.
■ Administer analgesic and antipyretics; provide comfort measures as
needed.
■ Provide emotional support to patient and family members.
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Bone Marrow Transplantation
Bone marrow transplantation is the aspiration of marrow from the poste-
rior iliac crest of a marrow donor under regional or general anesthesia
and the IV transfusion of the marrow into a donor-matched recipient.
Procedure
Before being ready to receive the transplant, the patient must:
■ Undergo high-dose chemotherapy with or without total body irradia-
tion in an effort to treat the underlying disease and overcome 
rejection. 
■ Be treated with immunosuppressive drugs to decrease the risk of
rejection. T Factors influencing the outcome of bone marrow 
transplantation include: 
■ Disease status at transplantation
■ Type of donor 
■ Recipient’s age 
■ Comorbid medical conditions
Early-Stage Complications 
The time of greatest risk is between 0 and 100 days. 
■ Rejection
■ Mucositis, pain issues secondary to oral ulcerations and reactive 
herpes virus; oral nutritional deficits secondary to oral pain
■ Hemorrhage, caused by chronic thrombocytopenia and tissue injury;
can be life threatening, but rare
■ Common minor bleeding, such as petechiae, epitaxis, or GI or GU
bleeding (not life threatening, but worrisome to patients)
■ Infections 
■ Bacterial; usually gram-positive, but can be gram-negative 
■ Fungal
■ Viral; can be life threatening to these patients
■ Acute graft-versus-host disease: One of the most serious and 
challenging complications; caused by immunologically competent
donor-derived T cells that react with recipient tissue antigens
■ Venoocclusive disease of the liver: One of the most feared complica-
tions; signs and symptoms include unexplained weight gain, 
jaundice, abdominal pain, and ascites
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■ Pulmonary complications: A common problem; causes of lung injury
or pneumonitis can be infection, chemical, bleeding, or idiopathic.
Management 
■ Provide emotional support to patient and family.
■ Perform good hand washing and asceptic technique.
■ Use reverse isolation procedures.
■ Monitor CBC and BMP laboratory tests frequently.
■ Provide frequent oral care.
■ Assess for signs and symptoms of bleeding.
■ Monitor vital signs every 4 hours or more frequently if needed.
■ Administer immunosuppressive drugs as ordered.
■ Consider IV or enteral nutritional support.
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Diabetic Ketoacidosis
DKA is a life-threatening metabolic complication caused by an absence or
inadequate amount of insulin. Affecting mostly type 1 diabetics, it is
marked by three concurrent abnormalities: hyperglycemia, dehydration
and electrolyte loss, and metabolic acidosis. 
Pathophysiology
DKA can be initiated by trauma or conditions such as new-onset diabetes,
heart failure, or stress. The body under stress → decrease in the amount
of insulin → reduction of glucose entering cells and increased glucose
production by the liver → hyperglycemia → liver attempting to get rid of
excess glucose by excreting glucose with water, Na+ and K+→ polyuria →
dehydration.
DKA can also be caused by a lack of insulin → increased breakdown of
fat → increased fatty acid and glycerol → fatty acids converted into
ketones → acidosis → increasing respiratory rate and abdominal pain,
and acetone breath.
Clinical Presentation
■ Hyperglycemia
■ Polyuria
■ Dehydration
■ Weakness
■ Headache
■ Polydipsia
■ Acetone or fruity breath
■ Poor appetite
■ Nausea and vomiting
■ Abdominal pain, usually generalized or epigastric
■ Rigid abdomen and irregular bowel sounds
■ Kussmaul’s respirations
■ Hypothermia
■ Tachycardia
■ Hypotension
■ Glycosuria
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■ Ketones in blood and urine 
■ Metabolic acidosis: pH <7.3, bicarbonate <15 mmol/L, blood glucose
>14 mmol/L, and ketonuria
Diagnostic Tests
■ Electrocardiogram
■ Chest x-ray
■ Urinalysis (note presence of ketones) 
■ CBC
■ Serum electrolytes, glucose and ketone levels, and blood urea nitrogen
■ Urine, sputum, and wound and blood cultures
■ Arterial blood gases (ABGs) and anion gap (8–16 mEq/L or 8–16 mmol/L
normal)
■ Plasma osmolarity
■ Cardiac enzymes
■ Amylase and lipase levels
Note: Serum and urine should be negative for ketones.
Management 
■ Provide airway support.
■ Administer O2 (3–6 L via nasal cannula). 
■ Monitor respiratory rate and rhythm and blood pH.
■ Monitor vital signs.
■ Assess for changes in mental status.
■ Assess for signs of hypokalemia.
■ Monitor serum glucose and ketone levels.
■ Provide insulin replacement (insulin drip).
■ Provide electrolyte replacement.
■ Provide fluid resuscitation and monitor intake and output.
Diabetes Insipidus 
DI is a disease manifested by the excretion of a large volume of urine
caused by ineffective production of antidiuretic hormone (ADH) at the
posterior pituitary.
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Pathophysiology
The four types of DI include: 
■ Central DI 
■ No ADH secretion
■ Cause can be congenital or idiopathic:
• Tumors in the central nervous system 
• Cerebrovascular disease or trauma
• Infection
• Granulomas
• Pregnancy
• Brain death
■ Nephrogenic DI
■ Secretion of ADH but no stimulation to the nephron’s collecting
tubules
■ Cause can be congenital or idiopathic:
• Obstruction that hinders normal urine excretion
• Chronic tubulointerstitial disease
• Medications
• Electrolyte imbalance
■ Dipsogenic DI
■ Caused by a defect or damage to the thirst mechanism in the hypo-
thalamus
■ Results in an abnormal increase in thirst with an increased fluid
intake that suppresses ADH secretion and increases urine output
■ Gestational DI
■ Occurs only during pregnancy
Clinical Presentation
■ Large volume of very diluted urine with a low specific gravity (volume
does not decrease even with restricted fluids)
■ Extreme thirst, especially for cold water and sometimes ice or ice
water
■ Craving for fluid
■ Dehydration
■ Symptoms of hypovolemic shock: Changes in level of consciousness
(LOC), tachycardia, tachypnea, and hypotension
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Diagnostic Tests
■ Fluid deprivation test
■ Desmopressin stimulation
■ ADH test
■ Plasma and urine osmolarity
■ Serum chemistries and electrolytes
■ Urinalysis
■ CT scan of head to detect cranial lesions
Management
■ Administer desmopressin; ineffective in nephrogenic DI.
■ Administer hydrochlorothiazide or indomethacin (Indocin) for nephro-
genic DI.
■ If surgery is needed, provide emotional support to patient and family.
■ Assess intake and output.
■ Monitor vital signs frequently.
■ Administer fluids as needed.
Adrenal Crisis
Acute crisis, also known as acute adrenal insufficiency, is a serious com-
plication of a dysfunctional adrenal gland causing difficulties producing
aldosterone and cortisol hormones.
Pathophysiology
Destruction of adrenal cortex → hindered secretion of aldosterone and
cortisol → Addison’s disease → hypoglycemia and hypovolemic shock.
Causes of adrenal crisis include:
■ Recently halted chronic corticosteroid therapy
■ Injury to or infection of the adrenal gland
■ Chronic adrenal insufficiency
■ Bilateral adrenalectomy
■ Medications that suppress adrenal hormones
■ Medications that enhance steroid metabolism
■ Sepsis
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Clinical Presentation
■ Serious weakness and fatigue
■ Hypoglycemia
■ Fever
■ Vomiting
■ Diarrhea
■ Altered mental status and confusion
■ Hypotension
■ Tachycardia
■ Dysrhythmias
■ Lack of response to vasopressors
Diagnostic Tests 
■ Cosyntropin (ACTH) stimulation test
■ CT scan or ultrasound of the adrenal glands
Management
■ Assess vital signs.
■ Weigh daily.
■ Strictly monitor intake and output.
■ Monitor serum glucose levels frequently.
■ Administer IV fluids.
■ Administer cortisol replacement medications (hydrocortisone IV).
■ Insert nasogastric tube if vomiting. 
■ Reorient and minimize stress.
■ Provide small frequent meals and nutritional supplements.
Thyroid Storm
Thyroid storm is a rare life-threatening complication of a severe form of
hyperthyroidism that is characterized by high fever, extreme tachycardia,
and altered mental status, and is precipitated by stress.
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Pathophysiology 
Thyrotropin-releasing hormone (TRH) is released from the hypothalamus
after exposure to stress → the pituitary gland releasing thyroid-stimulating
hormone (TSH) → causes the release of thyroid hormone (T3 and T4) from
the thyroid gland → T3 active form of thyroid hormone → increased levels
of thyroid hormone leading to hyperthyroidism or thyrotoxicosis → if 
precipitated by stress (surgery, infection, trauma, DKA, heart failure, pul-
monary embolism, toxemia of pregnancy, thyroid hormone ingestion,
radioiodine therapy, discontinuation of antithyroid), further increase in
serum TH → thyroid storm.
Clinical Presentation
■ High fever and hyperthermia
■ Severe tachycardia (>200 bpm) with heart failure and shock
■ Restlessness and agitation
■ Abdominal pain
■ Goiter
■ Nausea and vomiting
■ Nervousness
■ Tremor
■ Confusion
■ Delirium
■ Coma
Exaggerated symptoms of hyperthyroidism with disturbances of major
systems:
■ GI:
■ Weight loss
■ Diarrhea
■ Abdominal pain
■ CV: 
■ Edema
■ Chest pain
■ Dyspnea
■ Palpitations
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Diagnostic Tests
■ Serum thyroid panel
■ Liver function tests
Management
“Triangle of Treatment”:
■ Decrease sympathetic outflow (beta blockers: esmolol–drug of
choice).
■ Decrease production of TH (propylthiouracil [PTU] or methimazole).
■ Decrease peripheral conversion of T4 to T3 (PTU, beta blockers, and
steroids).
■ Prevent cardiac collapse.
■ Administer humidified O2.
■ Monitor ABGs and provide continuous pulse oximetry monitoring.
■ Monitor vital signs frequently.
■ Administer IV fluids containing dextrose to replace liver glycogen.
■ Give beta blockers; if contraindicated, give calcium channel blockers
to prevent excessive hyperthermia.
■ Give acetaminophen; salicylates are contraindicated.
■ Monitor intake and output.
Syndrome of Inappropriate Antidiuretic Hormone 
SIADH is the continuous production of ADH from the pituitary gland
despite low osmolarity. It is frequently manifested by hyponatremia.
Pathophysiology
Malignant tumors, disorders of CNS and medications → increased secre-
tion of ADH → hyponatremia → increased water retention → stimulation
of renin-angiotensin system → increased excretion of sodium in urine.
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Clinical Presentation
■ Concentrated urine
■ Water retention
■ Lethargy
■ Dilutional hyponatremia
■ Signs and symptoms of hyponatremia:
■ Poor skin turgor and dry mucosa
■ Headache
■ Decreased saliva
■ Orthostatic hypotension
■ Anorexia, nausea, and vomiting
■ Abdominal cramps
■ Irritability, confusion, and disorientation
■ Seizures
Diagnostic Tests
■ Comprehensive metabolic panel 
■ Urine Na+ and electrolytes
■ Serum and urine osmolarity
■ Ultrasound of kidneys
■ CT scan of head
Management
■ Monitor intake and output.
■ Weigh daily.
■ Monitor for CNS changes.
■ Assess for edema of extremities.
■ Institute fluid restrictions.
■ Closely monitor electrolytes.
■ Administer demeclocycline (Declomycin, Declostatin, Ledermycin) to
treat hyponatremia by inhibiting the action of ADH.
■ Administer conivaptan (Vaprisol) to treat hyponatremia.
■ Provide emotional support.
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Shock
The 3 types of shock include:
■ Hypovolemic shock: Due to decreased circulating or intravascular vol-
ume
■ Cardiogenic shock: Due to the inability of the heart to pump 
effectively
■ Distributive shock: Due to maldistribution of circulating blood 
volume. Examples include:
■ Septic shock (caused by an infectious process)
■ Anaphylactic shock (a hypersensitivity reaction)
■ Neurogenic shock (due to alterations in vascular smooth muscle tone)
Pathophysiology
The pathophysiology of shock is complex and not fully understood.
■ Blood volume displaced in the vasculature → ↓ cardiac output (CO) →
↓ tissue perfusion → HR and contractility with shunting of blood to
the vital organs (brain).
■ Renin-angiotensin response → angiotensin II (vasoconstriction) →
release of aldosterone and antidiuretic hormone → Na+ and H2O
retention → preload.
■ Stimulation of the anterior pituitary gland → secretion of adrenocorti-
cotropic hormone → stimulation of adrenal cortex → release of gluco-
corticoids → blood glucose.
■ Stimulation of the adrenal medulla → release of epinephrine and nor-
epinephrine → cell metabolism changes from aerobic to anaerobic →
lactic acidosis.
■ Cardiac hypoperfusion → ventricular failure.
■ Cerebral hypoperfusion → failure of sympathetic nervous system, 
cardiac and respiratory depression, and thermoregulatory failure.
■ Respiratory depression → pulmonary capillary membrane perme-
ability → pulmonary vasoconstriction, → acute respiratory failure, and
acute respiratory distress syndrome (ARDS).
■ Renal hypoperfusion → acute tubular necrosis → acute renal failure.
■ GI hypoperfusion → failure of GI organs.
■ Multiple organ dysfunction syndrome (MODS): the failure of 2 or
more body systems → death.
→
→
→
→
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Clinical Presentation
■ Systolic BP <90 mm Hg
■ HR, narrowing of pulse pressure, dysrhythmias, absent peripheral
pulses
■ Delayed capillary refill and flat jugular veins
■ Altered mental status, confusion, altered level of consciousness (LOC)
→ lethargy and unconsciousness
■ Hypoxemia and respiratory alkalosis initially due to respiratory
rate (RR) and depth of respirations → respiratory
distress → respiratory failure → respiratory and metabolic acidosis
■ Oliguria progressing to anuria, and urine osmolarity and specific
gravity
■ blood urea nitrogen (BUN) and creatinine
■ Pale and cool skin progressing to ashen, cold-clammy to cyanotic,
mottled, and diaphoretic skin
Diagnostic Tests
■ Serum chemistries, including electrolytes, BUN, and creatinine
■ CBC and coagulation profile
■ Arterial blood gases (ABGs) or pulse oximetry
■ Cardiac output studies → ↓ cardiac index (CI), ↓ cardiac output, 
↓ preload, ↓ right atrial pressure (RAP), afterload, and systemic 
vascular resistance
■ Serum lactate
■ Urinalysis with specific gravity, osmolarity, and urine electrolytes
■ Electrocardiogram (ECG)
Management
■ Monitor vital signs and hemodynamics via arterial line and pul-
monary artery catheter.
■ Institute cardiac monitoring for dysrhythmias.
■ Assess respiratory status and ABGs or pulse oximetry.
■ Administer O2 via cannula, mask, or mechanical ventilation. Assess
for signs of hypoxia.
■ Note skin color and temperature. Control fever.
→→
→
→
→
→
→
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■ Assess neurological status and LOC.
■ Administer IV fluids, colloids (.9NS, LR), and crystalloids.
■ Insert Foley catheter. Monitor intake and output. 
■ Assess fluid and electrolyte balance.
■ Administer IV vasopressors as indicated by hemodynamic 
parameters.
■ Administer IV vasodilators and diuretic to ↓ preload or afterload.
■ Administer sympathomimetics and digoxin to contractility.
■ Administer antiarrhythmics if cardiac dysrhythmias present.
■ Provide nutritional support, either enterally or parenterally.
■ Institute intra-aortic balloon pump counterpulsation for cardiogenic
shock or ventricular assist device.
■ Monitor serum lactic acid level. Administer sodium bicarbonate 
(not recommended in the treatment of shock-related lactic acidosis).
■ Provide stress ulcer and deep vein thrombosis (DVT) prophylaxis 
per institution policy and protocols.
■ Provide analgesics for pain. Sedate as necessary.
■ Provide emotional support to patient and family. Relieve anxiety.
Medications
Sympathomimetics are administered to improve contractility, SV, and 
CO:
■ Dobutamine (Dobutrex)
■ Dopamine (Intropin)
■ Inamrinone (Amrinone) 
■ Milrinone (Primacor)
■ Epinephrine (Adrenalin)
Vasodilators are administered to ↓ preload and afterload, and to ↓ O2
demand on the heart:
■ Nitroglycerine (Tridil)
■ Nitroprusside (Nipride)
Vasoconstrictors are administered to BP:
■ Norepinephrine (Levophed)
■ Phenylephrine (Neo-synephrine)
Caution must be used in titrating medications to the patient’s 
hemodynamic response.
→
→
→
→
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Sepsis
In sepsis, microorganisms invade the body, resulting in a systemic inflam-
matory response syndrome (SIRS) that may lead to septic shock, multiple
organ dysfunction syndrome (MODS), and eventually death. Causes are
gram (+) and gram (–) aerobes, anaerobes, fungi, and viruses.
Pathophysiology
Sepsis is a condition in which organisms enter into the bloodstream,
causing activation of the host inflammation defense mechanism →
release of cytokines and the activation of plasma protein cascade systems
→ septic shock → multisystem organ failure. Cancer patients are at an
increased risk for sepsis due to ↓ WBC and poor immune systems.
Clinical Presentation
■ T >38°C (100.4°F) or <36°C (96.8°F)
■ HR >90 bpm
■ RR >20 bpm or partial pressure of arterial carbon dioxide (PaCO2) 
<32 mm Hg
■ WBC >12,000/mm3, <4,000/mm3, or >10% immature (band) forms
The presence of 2 or more of the above symptoms indicates SIRS.
■ Fever and chills
■ Fatigue and malaise
■ Warm and pink skin, progressing to cold, clammy, and mottled skin
■ Hypotension or normal BP
■ Widening pulse pressure
■ ↓ RAP and left ventricular stroke work index
■ Partial arterial oxygen tension (PaO2)/fractional concentration of oxy-
gen in inspired gas (FIO2) ratio <300
■ lactate levels and lactic acidosis
■ Decreased urine output progressing to oliguria
■ Acute changes in mental status, such as anxiety, apprehension, 
delirium, disorientation, confusion, combativeness, agitation, 
lethargy, or coma
→
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■ Increased RR, SOB, crackles, hypoxemia progressing to pulmonary
edema, acute lung injury, hypoxemia, and respiratory failure
■ Nausea, vomiting, jaundice, ↓ GI motility, and ileus
■ Changes in carbohydrate, fat, and glucose metabolism
■ Signs of thrombocytopenia and coagulopathies (possibly progressing
to disseminated intravascular coagulation)
■ Possible development of signs of septic shock
Diagnostic Tests
■ CBC with differential ( or ↓ WBC)
■ Serum chemistries, bilirubin, serum lactate (increased), liver function
tests (abnormal), and protein C (decreased)
■ Insulin resistance with elevated blood glucose
■ ABGs (hypoxemia, lactic acidosis)
■ Urine, sputum, wound, and blood cultures
■ Activated partial thromboplastin time (increased), international nor-
malized ratio (increased), and D-dimer (increased)
Management
Management is dependent on degree of sepsis and whether or not septic
shock is present.
Sepsis Resuscitation Bundle
Within 6 hours of diagnosis of severe sepsis:
■ Measure serum lactate.
■ Obtain blood cultures prior to antibiotic administration.
■ Administer broad-spectrum antibiotic within 3 hours of ED admission
and within 1 hour of non-ED admission.
■ If hypotension is present and/or serum lactate is >4 mmol/L, 
deliver an initial minimum of 20 mL/kg of crystalloid or equivalent
and administer vasopressors for hypotension not responding to
fluid resuscitation to maintain mean arterial pressure (MAP) at 
>65 mm Hg.
■ In the case of persistent hypertension and/or elevated lactate levels,
achieve a central venous pressure (CVP) of >8 mm Hg, and a central
venous oxygen saturation of >70% or a mixed venous oxygen 
saturation of >65%.
→
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Sepsis Management Bundle
Within 24 hours of presentation with severe sepsis or septic shock:
■ Administer low-dose steroids for septic shock.
■ Administer drotrecogin alpha (activated).
■ Maintain glucose control at >70 but <150 mg/dL.
■ Maintain a median inspiratory plateau pressure of <30 cm H2O for
mechanically ventilated patients.
Other Nursing Care
■ Assess vital signs and consider arterial line placement. Monitor mean
arterial pressure and maintain at >65 mm Hg.
■ Support BP by administering vasopressors (e.g., vasopressin,
Levophed, dopamine).
■ Assess hemodynamic status. Consider pulmonary artery catheter
placement. Maintain CVP at 8–12 mm Hg.
■ Assess respiratory status.
■ Monitor ABGs and note ↓ pH, ↓ PaO2, and PaCO2.
■ Administer O2 via nasal cannula, mask, or mechanical ventilation. Use
minimum positive end-respiratory pressure to achieve tidal volume
and end-inspiratory plateau pressure goals.
■ Position patient to promote optimal O2 exchange. Reposition every 
2 hours.
■ Institute skin care protocols.
■ Keep head of bed (HOB) elevated 45°.
■ Institute ventilator-associated pneumonia precautions if patient is on
mechanical ventilation.
■ Treat fever if present.
■ Assess neurologic status for changes in mentation.
■ Insert Foley catheter and monitor intake and output. Maintain urine
output at >0.5 mL/kg/hr.
■ Administer IV colloids and crystalloids, and fluid challenge as 
necessary. Assess fluid and electrolyte balance.
■ Assess nutritional status. Provide enteral feeding or total parenteral
nutrition (TPN) and lipids.
■ Perform cortisol stimulation test. Start continuous low-dose steroid
infusion.
→
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■ Administer antibiotics within 1 hour of sepsis diagnosis, and 
re-evaluate 48–72 hours afterward.
■ Administer vasopressors and inotropes. Consider Vasopressin for
refractory shock.
■ Monitor blood glucose levels and maintain tight glucose control at
80–110 mg/dL. Consider insulin infusion.
■ Administer platelets if platelet count is <5,000/mm3.
■ Institute stress ulcer and DVT prophylaxis.
■ Prevent nosocomial infections.
■ Sedate patient as necessary.
■ Administer drotrecogin alfa (Xigris): An anticoagulant, profibrinolytic,
anti-inflammatory agent.
Systemic Inflammatory Response Syndrome 
SIRS is a widespread inflammation that may progress to acute lung injury,
acute renal failure, MODS, and eventually death.
SIRS is diagnosed if one or more of the following signs are present:
■ T >38°C (100.4°F) or <36°C (96.8°F)
■ HR >90 bpm
■ Tachypnea with RR >20 bpm or PaCO2 <32 mm Hg
■ WBC count >12,000 cells/mm3 or <4,000 cells/mm3, or >10% immature
neutrophils
Signs, symptoms, and management are similar to those for sepsis, severe
sepsis, and septic shock.
Multiple Organ Dysfunction Syndrome 
MODS is defined as the physiologic failure of two or more separate organ
systems. With MODS, homeostasis can not be maintained without specif-
ic interventions due to the body’s inability to sufficiently activate its own
defense mechanisms.
Those at high risk for developing MODS include patients with:
■ Multiple trauma
■ Massive infection or sepsis
■ Hemorrhage or shock
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■ Surgical complications
■ Acute pancreatitis
■ Burns, extensive tissue damage, and/or necrotic tissue
■ Aspiration
■ Multiple blood transfusions
■ Inadequate fluid resuscitation 
Signs, symptoms, and management are similar to those for sepsis, severe
sepsis, and septic shock. The need for dialysis is an early warning sign of
MODS.
Trauma
Pathophysiology
■ Blunt trauma: Due to motor vehicle crashes (MVCs), falls, blows,
explosions, contact sports, and blunt force injuries, such as from a
baseball bat.
■ Estimating the amount of force a person sustains in an 
MVC = person’s weight  miles per hour of speed.
■ During an MVC, the body stops but the tissues and organs continue
to move forward and then backward (acceleration-deceleration force).
■ Penetrating trauma: Due to gunshot wounds, stabbings, and firearms
or implement (missile, shrapnel) injuries. 
■ There is direct damage to internal structures, with damage 
occurring along the path of penetration.
■ Penetrating trauma usually requires surgery.
■ Traumatic brain injury (TBI): Results from a skull fracture, concussion,
contusion, cerebral hematoma, and diffuse axonal injury.
■ Chest or thoracic injuries: Result from either blunt trauma or a pene-
trating injury. 
■ Common injuries include rib fractures, flail chest, ruptured
diaphragm, aortic disruption, pulmonary contusion, tension or
open pneumothorax, hemothorax, penetrating or blunt cardiac
injuries, and cardiac tamponade.
■ Abdominal injuries: Caused by blunt trauma or penetrating injury. 
■ Common injuries include liver and spleen damage, renal trauma,
bladder trauma, and pelvic fractures.
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■ Musculoskeletal injuries: Include spinal cord injury, fracture, disloca-
tion, amputation, and tissue trauma. 
■ Fat embolism may occur secondary to fractures of the long bones.
Diagnostic Tests
■ CBC
■ Serum chemistry panel, including electrolytes, glucose, BUN, and 
creatinine
■ Liver function tests
■ Serum amylase if pancreatic injury suspected or GI perforation is
present
■ Serum lactate level
■ Prothrombin time (PT) and PTT
■ Urinalysis
■ ABGs or pulse oximetry
■ ECG
■ Type and crossmatch for possible blood transfusion
■ Drug and alcohol toxicology screens
■ Pregnancy test for females of childbearing age
■ X-rays specific to injury (e.g., chest, abdomen and pelvis, extremity)
■ CT scan of the abdomen (ultrasound if indicated)
■ Diagnostic peritoneal lavage if internal abdominal bleeding suspected
■ Rectal or vaginal exam if indicated
Management
Management is dependent on type of trauma.
■ Maintain patent airway. Assess respiratory status for signs of trauma,
tachypnea, accessory muscle use, tracheal shift, stridor, hyperreso-
nance, dullness to percussion, rate depth, and symmetry. 
■ Monitor ABGs or pulse oximetry. 
■ Observe for respiratory distress. 
■ Assess chest wall integrity for flail chest or pneumothorax.
■ Administer O2 via nasal cannula, mask, or mechanical ventilation. Use
oropharyngeal or nasopharyngeal airway or endotracheal tube.
■ Insert chest tube if pneumothorax is present.
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■ Assess for signs of bleeding. Control hemorrhage. Transfuse as 
needed. Consider autotransfusion of shed blood, autologous blood,
unmatched type-specific blood, or type O (universal donor) blood.
■ Consider pneumatic antishock garment to control hemorrhage.
■ Replace each mL of blood loss with 3 mL of crystalloid (3:1 rule).
■ Monitor vital signs frequently, and assess for signs of hypovolemic
shock. Maintain BP within acceptable parameters.
■ Provide continuous cardiac monitoring.
■ Provide peripheral IV access or insert a central venous catheter for 
IV fluids. Use rapid infuser devices as needed.
■ Assess neurological status for confusion and disorientation. Use
Glasgow Coma Scale.
■ Immobilize the spine and cervical area until assessment is made of
spinal cord injury, and head and neck injuries.
■ Prevent hypothermia through the use of blankets, warming blankets,
or warming lights.
■ Insert Foley catheter. Monitor intake and output. Assess fluid and
electrolyte balance. Assess urine for bleeding.
■ Assess abdomen. Note bowel sounds, guarding, bruising, tenderness,
pain, rigidity, and rebound tenderness.
■ Perform peritoneal lavage if abdominal injury is present.
■ Insert nasogastric tube (NG) tube to prevent gastric distention,
decrease risk for aspiration, and assess for GI bleeding.
■ Provide nutritional support orally, enterally (gastric, duodenal, or 
jejunal route), or parenterally (TPN and lipids).
■ Note skin color, pallor, bruising, distended neck veins, and edema.
■ Inspect for soft tissue injury, deformities, wounds, ecchymosis, and
tenderness. Palpate for crepitus and subcutaneous emphysema.
■ Administer broad-spectrum antibiotics to prevent and treat infection.
Observe for sepsis. Avoid nosocomial infections.
■ Provide analgesics for pain. Sedate as necessary.
■ Provide DVT and stress ulcer prophylaxis.
■ Administer tetanus prophylaxis.
Complications
■ Hypermetabolism; occurs 24 to 48 hours after traumatic injury
■ Infection and sepsis; SIRS
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■ Acute respiratory failure or ARDS
■ DVT; pulmonary or fat embolism
■ Acute renal failure
■ Compartment syndrome
■ Dilutional coagulopathy
■ MODS
Induced or Therapeutic Hypothermia
In order to reduce the damage to brain cells through reduction of the
brain’s metabolic activity, hypothermia is intentionally induced by bring-
ing the core body temperature down to 32°–34°C (89.6º–93.2°F)
Indications for medically induced hypothermia include:
■ Ischemic cerebral or spinal injury, including stroke recovery
■ Cerebral edema and increased intracranial pressure
■ Heart surgery
■ Cardiac arrest due to ventricular fibrillation (VF) or ventricular tachy-
cardia; this is most effective within 6 hours of cardiac arrest
Hypothermia may be accomplished by several methods:
■ Rapid infusion of ice-cold IV fluids
■ NG lavage with ice water
■ Evaporative cooling of the external body surface
■ External cooling with ice packs or special cooling blankets
■ Prevention of shivering and fever
The patient may be rewarmed through the use of:
■ Cardiopulmonary bypass
■ Warm IV fluid administration
■ Warm humidified O2 administration via ventilator
■ Warm peritoneal lavage
■ Warming blankets and over-the-bed heaters
Caution should be taken with active core rewarming, because VF can
occur as the patient’s temperature increases.
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Burns
Burns may be thermal, electrical, or chemical. 
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Extent of Burn Injury
• Epidermis destroyed
• Portion of dermis
injured
• Epidermis and upper
layer of dermis
destroyed
• Injury to deeper 
portions of dermis
• Epidermis and der-
mis destroyed
• Underlying tissue
may be destroyed
Description of Burn
Injury
• Red and dry
• May be blistered
• Blanching with pres-
sure
• Little or no edema
• Tingling
• Supersensitivity
• Pain soothed by
cooling
• Painful wound
• Red or pale, mottled 
• Blistered, edema
• Fluid exudate
• Hair follicles intact
• ↓ blanching with
pressure
• Sensitive to cold air
• Pale white, cherry
red, brown, or black
leathery eschar
• Broken skin with fat
exposed
• Edema
• No blanching with
pressure
• Painless
• Hair follicles and
sweat glands
destroyed
Type of Burn
First-degree burn 
or superficial partial-
thickness burn
Second-degree burn 
or deep partial-
thickness burn
Third-degree or 
full-thickness burn
Continued
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A cold burn may occur when the skin is in contact with cold bodies, such
as snow or cold air, as in cases of frostbite, or is exposed to dry ice or
canned air. The treatment is the same for this type of burn.
Pathophysiology
Burns of <25% total body surface area (TBSA) → local response to injury.
Burns of >25% TBSA → local and systemic response to injury.
There are three zones of thermal injury:
■ Zone of coagulation where there is irreversible tissue necrosis.
■ Zone of stasis surrounding the zone of coagulation. 
■ There is ↓ blood flow to the area and vascular damage. 
■ Tissue damage may potentially be reversed with adequate care and
treatment.
■ Zone of hyperemia surrounding the zone of stasis. 
■ There is minimal injury to the area and evidence of early recovery.
Burn Stages
The two burn stages are the resuscitative phase and the acute phase.
Resuscitative Phase
■ The resuscitative phase begins at the time of injury and continues
during the first 48–72 hours, until fluid and protein shifts are 
stabilized.
■ Burn tissue injury occurs → loss of capillary integrity → permeabil-
ity of capillary membrane → fluid shifts from the vascular to the inter-
stitial spaces → ↓ CO, ↓ BP, and HR and peripheral vasoconstric-
tion → ↓ renal blood flow → ↓ renal function → acute renal failure.
■ Na+ and fluid pass through the burn areas → blisters, local edema,
and fluid exudate → compartment syndrome.
→
→
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Extent of Burn Injury
• Skin, fascia, muscle,
and bone are irre-
versibly destroyed.
Description of Burn
Injury
• Hard, leather-like
eschar
• No sensation
• Charred bones
Type of Burn
Fourth-degree or 
full-thickness burn
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■ K+ is released from the tissue injury and there is ↓ renal excretion of
K+ → hyperkalemia.
■ Lysis of red blood cells (RBCs) occurs → hematuria, myoglobin in the
urine, and anemia.
■ Coagulation abnormalities occur → prolonged clotting and prothrom-
bin times.
■ Metabolic acidosis occurs.
■ General tissue hypoperfusion occurs due to ↓ circulating blood 
volume → burn shock → ↓ BP and tachycardia.
■ Hypothermia occurs due to loss of skin barrier → thermoregulation
problems.
Acute Phase
■ The acute phase of burn injury is characterized by the onset of diure-
sis. It generally begins approximately 48–72 hours after the burn
injury.
■ Capillary membrane integrity returns → fluid shifts from interstitial to
intravascular space → in blood volume → diuresis if good renal
function exists. 
■ Fluid overload can occur.
■ Hemodilution causes a ↓ in serum electrolytes and hematocrit.
■ Na+ deficit may continue.
■ K+ moves back into the cells → hypokalemia.
■ Protein continues to be lost from the wound.
→
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Diagnostic Tests
■ Calculation of TBSA injured according to the rule of nines:
■ CBC
■ Serum chemistry panel, including electrolytes, glucose, BUN, and 
creatinine
■ Liver function tests
■ Serum lactate level
■ PT and PTT
■ Urinalysis (especially specific gravity, pH, glucose, acetone, protein,
and myoglobin)
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■ ABGs or pulse oximetry, and carboxyhemoglobin (COHgb)
■ ECG
■ Type and crossmatch for blood
■ Drug and alcohol toxicology screens
■ Pregnancy test for women of childbearing age
■ X-rays specific to injury (e.g., chest, abdomen and pelvis, extremity)
■ CT scan of abdomen (ultrasound if indicated)
■ Bronchoscopy if inhalation injury is present
Management
Management of burns depends on the location of the burn and the extent
of the burn injury. 
■ Maintain patent airway. Intubate or perform tracheostomy as needed.
Administer 100% humidified O2 by nasal cannula, mask, or mechani-
cal ventilation/continuous positive airway pressure.
■ Assess respiratory status. Encourage the use of incentive spirometer,
coughing and deep breathing, suctioning, or bronchodilators. Note
respiratory distress.
■ Monitor ABGs or pulse oximetry for hypoxemia. Monitor COHgb 
levels.
■ Monitor for and prevent pneumonia.
■ Immobilize the spine until assessment can be made of injury.
■ Irrigate chemical burns immediately.
■ Assess TBSA burned and depth of burn injuries.
■ Provide analgesics for pain. Maintain good pain control.
■ Initiate IV fluid resuscitation to replace fluid and electrolytes: 
■ Consensus Formula recommendation is to give 2 mL/kg per 
percentage burn of lactated Ringer’s solution
■ One half of the calculated total is given over the 1st 8 hours 
postburn injury, and the other half is given over the next 16 hours.
■ Provide IV fluid boluses if ↓ BP
■ Consider insertion of pulmonary artery catheter to monitor 
hemodynamics.
■ Insert arterial line to monitor BP and obtain blood specimens.
■ Palpate peripheral pulses. Use Doppler if necessary.
■ Provide continuous ECG monitoring.
■ Insert NG tube if burn is >25% of the TBSA. Note GI bleeding.
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■ Assess GI status, noting bowel sounds, abdominal distention, and
nausea. Administer antiemetics if nausea and vomiting present.
■ Keep patient NPO initially. Assess nutritional status and provide feed-
ings orally, enterally, or parenterally. Maintain aspiration precautions. 
■ Insert Foley catheter. Monitor intake and output with goal of 30–50 mL
of urine/hr. Note hematuria. Burgundy colored urine is composed of
hemochromogen and myoglobin. 
■ Weigh patient daily. Note height on admission to unit.
■ Monitor electrolyte balance.
■ Assess neurological status for restlessness, confusion, difficulty con-
centrating, and changes in LOC.
■ Assess warmth, capillary refill time, sensation, and movement of
extremities.
■ Keep HOB elevated 30°–45°. Elevate burned extremities.
■ Provide tetanus prophylaxis.
■ Monitor for infection and sepsis. Prevent nosocomial infection.
Provide aseptic management of burn areas and invasive lines.
■ Provide DVT and stress ulcer prophylaxis.
■ Provide active and passive range-of-motion exercises.
■ Treat anemia. Consider blood transfusions. Monitor coagulation factors.
■ Provide warm environment through the use of clean sheets and 
blankets, or warm IV fluids.
■ Monitor temperature, and prevent chills and shivering. 
■ Provide psychosocial support to patient and family. Be alert for signs
of depression. Provide antianxiety medications.
■ In the elderly, balance the risk of hypovolemia and fluid overload.
■ In circumferential burns (burn completely surrounds body part),
assess need for escharotomy, in which an incision is made through a
full-thickness chest wound to decrease constriction, relieve pressure,
and restore ventilation (chest) and/or improve blood flow and tissue
perfusion.
Wound Care
■ Cleanse wound as per protocol.
■ Prepare patient for wound debridement (natural, mechanical, or 
surgical).
■ Initiate topical antibacterial therapy:
■ Silver sulfadiazine (Silvadene) 1%
■ Silver nitrate aqueous solution (AgNO3) 0.5%
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■ Mafenide acetate (Sulfamylon) 5%–10%
■ Acticoat (silver-coated dressing)
■ Aquacel Ag (silver-coated dressing)
■ Silverlon (silver-coated dressing)
■ Clotrimazole cream or nystatin (Mycostatin) if fungal infection is
present
■ Diluted Dakin’s solution
■ Petroleum-based ointments (bacitracin, gentamycin)
■ A vacuum-assisted closure (VAC) device may be used for wound 
healing along with a variety of dressings.
Patient/Hospital Specific Wound and Dressing
Protocol
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
Wound Grafting
A variety of biological and synthetic skin grafts may be used for wound
grafting:
■ Hemografts or allografts: Skin from another human, such as a 
cadaver
■ Heterografts or xenografts: Skin from another animal, such as pigskin
■ Autografts: Skin from oneself that is transferred from one part of the
body to another
■ Temporary biosynthetic skin substitutes: Biobrane and TransCyte
■ Permanent biosynthetic skin substitutes: Integra and Alloderm
Complications
■ Hypovolemia
■ Decreased renal function, possibly leading to acute renal failure
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■ Infection and sepsis
■ Paralytic ileus (↓ bowel sounds, distention, and nausea and vomiting)
■ Curling’s ulcer (stress ulcer or duodenal erosion)
■ Metabolic acidosis
■ Tissue necrosis
■ Hypothermia
■ Acute respiratory failure and ARDS
■ VAP
■ Scarring
■ Compromised immunity
■ Changes in functional status, appearance, and body image, with asso-
ciated depression
■ Compartment syndrome occurring due to increased pressure in the
fascial compartments of an extremity → compression and occlusion
of blood vessels and nerves to the extremity. Symptoms include
delayed capillary refill, tense skin, progressively diminishing or
absent pulse to the extremity, intense pain, paresthesia, and paralysis
of the extremity → ischemia and necrosis → loss of limb.
Escharotomy is the treatment of choice.
■ Abdominal compartment syndrome with symptoms including an
increase in intra-abdominal pressure, decreased urine output, and dif-
ficulty with ventilation. This condition is treated by laparotomy, trunk
escharotomies, and diuretics.
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Commonly Used Critical Care Medications 
adenosine, Adenocard: antidysrhythmic. Uses: SVT, as a diagnostic 
aid to assess myocardial perfusion defects in CAD. Usual dosages: 
IV Bolus 6 mg, if conversion to NSR does not occur within 1–2 
minutes, give 12 mg by rapid IV Bolus, may repeat 12–mg dose again
in 1–2 min.
alteplase, Activase: Thrombolytic enzyme. Uses: Lysis of obstructing
thrombi associated with AMI, ischemic conditions requiring thrombol-
ysis (i.e., PE, DVT, unclotting arteriovenous shunts, acute ischemic
CVA). Dosages: >65 kg IV a total of 100 mg; 6–10 mg given IV Bolus
over 1–2 min, 60 mg given over 1st hour, 20 mg given over 2nd hour,
20 mg given over 3rd hour, 1.25 mg/kg given over 3 hr for patients 
<65 kg.
amiodarone, Cordarone: Antidysrhythmic. Uses: Severe VT, SVT, atrial
fibrillation, VF not controlled by first line agents, cardiac arrest.
Dosages: PO loading dose 800–1600 mg/day for 1–3 weeks; then
600–800 mg/day for 1 month; maintenance 400 mg/day; IV loading
dose (first rapid) 150 mg over the first 10 min, then slow 360 mg over
the next 6 hours; maintenance 540 mg given over the remaining 
18 hours, decrease rate of the slow infusion to 0.5 mg/min.
argatroban, Argatroban: Anticoagulant. Uses: Thrombosis, prophylaxis
or treatment; percutaneous coronary intervention (PCI), anticoagula-
tion prevention/treatment of thrombosis in heparin-induced thrombo-
cytopenia. Dosages: Heparin-induced thrombocytopenia/thrombosis
syndrome (HIT or HITTS)—IV: 2 mcg/kg/min (1 mg/mL) give at 6 mL/hr
for 50 kg, at 8 mL/hr for 70 kg, at 11 mL/hr for 90 kg, at 13 mL/hr 
for 110 kg, at 16 mL/hr for 130 kg. Hepatic dose—continue infusion 
0.5 mcg/kg/min, adjust rate based on aPTT. PCI in HIT IV infusion 
25 mcg/kg/min and a bolus of 350 mcg/kg given over 3–5 min, check
ACT 5–10 min after bolus is completed; proceed if ACT >300 sec.
atracurium, Tracrium: Neuromuscular blocker. Uses: Facilitation of tra-
cheal intubation, skeletal muscle relaxation during mechanical 
ventilation, surgery, or general anesthesia. Dosages: IV Bolus 
0.3–0.5 mg/kg, then 0.8–0.10 mg/kg 20–45 min after first dose if 
needed for prolonged procedures.
Atropine: Antidysrhythmic, anticholinergic, antimuscarinic. Parasympatholytic
Uses: Bradycardia, 40–50 bpm, bradydysrhythmia, reversal of 
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anticholinesterase agents, insecticide poisoning, blocking cardiac
vagal reflexes, decreasing secretions before surgery, antispasmodic
with GU, biliary surgery, bronchodilator. Dosages: bradycardia/
bradydysrhythmias IV bolus 0.5–1 mg given every 3–5 min, not to
exceed 2 mg. Organophosphate poisoning IM/IV 2 mg every hour
until muscarinic symptoms disappear, may need 6 mg every hour.
Presurgery SC/IM/IV 0.4–0.6 mg before anesthesia.
cosyntropin, Cortrosyn: Pituitary hormone. Uses: Testing adrenalcortical
function. Dosage: IM/IV 0.25–1 mg between blood sampling.
dexmedetomidine, Precedex: Sedative, alpha-2 adrenoceptor agonist.
Uses: Sedation in mechanically ventilated, intubated patients ICU.
Dosages: IV loading dose of 1 mcg/kg over 10 min then 0.2–0.7
mcg/kg/hr, do not use for more than 24 hr.
diltiazem, Cardizem: Uses: Calcium channel blocker. IV: Atrial fibrillation,
flutter, paroxysmal supraventricular tachycardia. Dosages: IV Bolus
0.25 mg/kg over 2 min initially, then 0.35 mg/kg may be given after 
15 min; if no response, may give Continuous Infusion 5–15 mg/hr for
up to 24 hr.
dobutamine, Dobutrex: Adrenergic direct-acting Beta 1-agonist, cardiac
stimulant. Uses: Cardiac decompensation due to organic heart disease
or cardiac surgery. Dosages: IV infusion 2.5–10 mcg/kg/min; may
increase to 40 mcg/kg/min if needed.
dopamine, Intropin: Adrenergic. Uses: Shock, increased perfusion,
hypotension. Dosages: Shock IV infusion 2–5 mcg/kg/min, not to
exceed 50 mcg/kg/min, titrate to patient’s response. 
drotrecogin alfa, Xigris: Thrombolytic agent. Uses: Severe sepsis 
associated with organ dysfunction. Dosages: IV infusion 24 mcg/kg/hr
over 96 hr.
epinephrine: Bronchodilator nonselective adrenergic agonist, vasopres-
sor. Uses: Acute asthmatic attacks, hemostasis, bronchospasm, ana-
phylaxis, allergic reactions, cardiac arrest, adjunction in anesthesia,
shock. Dosages: Asthma Inhaler 1–2 puffs of 1:100 or 2.25% racemic
every 15 min. Bronchodilator SC/IM 0.1–0.5 mg (1:1000 sol) every
10–15 min–4 hr, max 1 mg/dose. Anaphylactic reaction/asthma SC/IM
0.1–0.5 mg, repeat every 10–15 min, max 1 mg/dose; epinephrine sus-
pension 0.5 mg SC, may repeat 0.5–1.5 mg every 6 hr. Cardiac arrest
(ACLS) IV 1 mg every 3–5 min; Endotracheal 2–2.5 mg IC 0.3–0.5 mg. 
eptifibatide, Integrilin: Antiplatelet agent. Uses: Acute coronary syn-
drome including those undergoing PCI. Dosages: Acute coronary 
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syndrome IV Bolus 180 mcg/kg as soon as diagnosed, then IV
Contuous 2 mcg/kg/min until discharge or CABG up to 72 hr. PCI in
patient’s without acute coronary syndrome IV Bolus 180 mcg/kg given
immediately before PCI; then 2 mcg/kg/min for 18 hr and a second 
180 mcg/kg bolus, 10 min after 1st bolus; continue infusion for up to
18–24 hr. 
esmolol, Brevibloc: Beta-adrenergic blocker (antidysrhythmic II). Uses:
Supraventricular tachycardia, noncompensatory sinus tachycardia,
hypertensive crisis, intraoperative and postoperative tachycardia and
hypertension. Dosages: IV loading dose 500 mcg/kg/min over 1 min;
maintenance 50 mcg/kg/min for 4 min; if no response in 5 min, give
second loading dose; then increase infusion to 100 mcg/kg/min for 
4 min; if no response, repeat loading dose, then increase maintenance
infusion by 50 mcg/kg/min (max of 200 mcg/kg/min), titrate to patient
response.
etomidate, Amidate: General anesthetic. Induction of general anesthesia.
Dosages: IV 0.2–0.6 mg/kg over 1/2–1 min.
fenoldopam, Corlopam: Antihypertensive, vasodilator. Uses:
Hypertensive crisis, malignant hypertension. Dosages: IV 0.01–1.6
mcg/kg/min.
fentanyl, Fentanyl: Opiod analgesic. Uses: Preoperatively, postoperative-
ly; adjunct to general anesthetic, adjunct to regional anesthesia;
Fentanyl Oralet: Anesthesia as premedication, conscious sedation.
Dosages: Anesthetic IV 25–100 mcg (0.7–2 mcg/kg) every 2–3 min prn.
Anesthesia supplement IV 2–20 mcg/kg; IV Infusion 0.025–0.25
mcg/kg/min. Induction and maintenance IV Bolus 5–40 mcg/kg.
Preoperatively IM 0.05–0.1 mg every 30–60 min before surgery.
Postoperatively IM 0.05–0.1 mg every 1–2 hr prn. 
hetastarch, Hespan: Plasma expander. Uses: Plasma volume expander,
hypovolemia. Dosages: IV Infusion 500–1000 mL (30–60 g), total 
dose dose not to exceed 1500 mL/day, not to exceed 20 mL/kg/hr
(hemorrhagic shock).
isoproterenol, Isuprel: Beta-adrenergic agonist. Uses: Bronchospasm,
asthma, heart block, ventricular Dysrhythmias, shock. Dosages: Asthma,
Bronchospasms SL 10–20 mg every 6–8 hr, max 60 mg/day; INH 1 puff,
may repeat in 2–5 min, maintenance 1–2 puffs 4–6 times/day; IV 10–20
mcg during anesthesia. Shock IV Infusion 0.5–5 mcg/min. 1 mg/500 mL
D5W, titrate to BP, CVP, hourly urine output.
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labetalol, Normodyne: Antihypertensive, antianginal. Uses: Mild to 
moderate hypertension; treatment of severe hypertension. Dosages:
Hypertension PO 100 mg bid; may be given with a diuretic; may
increase to 200 mg bid after 2 days; may continue to increase every
1–3 days; maximum 2400 mg/day in divided doses. Hypertensive
Crisis IV Infusion 200 mg/160 mL D5W, infuse at 2 mL/min; stop 
infusion at desired response, repeat every 6–8 hr as needed; IV Bolus
20 mg over 2 min, may repeat 40–80 mg every 10 min, not to exceed
300 mg.
Lidocaine: Antidysrhythmic (Class Ib). Uses: Ventricular tachycardia, 
ventricular Dysrhythmias during cardiac surgery, MI, digitalis toxicity,
cardiac catheterization. Dosages: IV Bolus 50–100 mg (1 mg/kg) over
2–3 min, repeat every 3–5 min, not to exceed 300 mg in 1 hr; begin 
IV Infusion; IV infusion 20–50 mcg/kg/min; IM 200–300 mg (4.3 mg/kg)
in deltoid muscle, may repeat in 1–11⁄2 hr if needed.
midazolam, Versed: Sedative, hypnotic, antianxiety. Uses: Preoperative
sedation, general anesthesia induction, sedation for diagnostic endo-
scopic procedures, intubation. Dosages: Preoperative sedation IM
0.07–0.08 mg/kg 1⁄2–1 hr before general anesthesia. Induction of 
general anesthesia IV (unpremedicated patients) 0.3–0.35 mg/kg over 
30 sec, wait 2 min, follow with 25% of initial dose if needed; (premed-
icated patients) 0.15–0.35 mg/kg over 20–30 sec, allow 2 min for effect.
Continuous infusion for intubation (critical care) IV 0.01–0.05 mg/kg
over several min; repeat at 10–15 min intervals, until adequate 
sedation; then 0.02–0.10 mg/kg/hr by continuous infusion; adjust 
as needed.
milrinone, Primacor: Inotropic/vasodilator agent with phosphodiesterase
activity. Uses: Short-term management of advanced CHF that has not
responded to other medication; can be used with digitalis. Dosages: 
IV bolus 50 mcg/kg given over 10 min; start infusion of 0.375–0.75
mcg/kg/min; reduce dose in renal impairment.
naloxone, Narcan: opiod-agonist, antidote. Uses: Respiratory depression
induced by opiods, pentazocine, propoxyphene; refractory circulatory
shock, asphyxia neonatorum, coma, hypotension. Dosages: Opiod-
induced respiratory depression IV/SC/IM 0.4–2 mg; repeat every 
2–3 min if needed. Postoperative opiod-induced respiratory depres-
sion  IV 0.1–0.2 mg every 2–3 min prn. Opiod overdose IV/SC/IM 
0.4 mg (10 mcg/kg) (not opioid dependant) may repeat every 2–3 min
(opiod dependant).
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nesiritide, Natrecor: Vasodilator. Uses: Acutely decompensated CHF.
Dosages: IV Bolus 2 mcg/kg, then IV Infusion 0.01 mcg/kg/min nitro-
glycerine: Coronary vasodilator, antianginal. Uses: chronic stable 
angina pectoris prophylaxis of angina pain, CHF associated with AMI,
controlled hypotension in surgical procedures. Dosages: SL, transder-
mal, topical doses available. IV infusion uses listed only IV 5 mcg/min,
then increase by 5 mcg/min every 3–5 min; if no response after 20
mcg/min, increase by 10–20 mcg/min until desired response.
nitroprusside, Nitropress: Antihypertensive, vasodilator. Uses:
Hypertensive crisis, to decrease bleeding by creating hypotension dur-
ing surgery, acute heart failure. Dosages: IV infusion dissolve 50 mg in
2–3 mL of D5W, then dilute in 250–1000 mL of D5W; infuse at 0.5–8
mcg/min.
norepinephrine, Levophed: Adrenergic. Uses: Acute hypotension, shock.
Dosages: IV Infusion 8–12 mcg/min titrated to BP.
pancuronium, Pavulon: Neuromuscular blockade. Uses: Facilitation of
endotracheal intubation, skeletal muscle relaxation during mechanical
intubation, surgery or general anesthesia. Dosages: IV 0.04–0.1 mg/kg,
then 0.01 mg/kg every 1⁄2–1hr.
phenylephrine, Neo-Synephrine: adrenergic, direct acting. Uses:
Hypotension, paroxysmal supraventricular tachycardia, shock, main-
tain BP for spinal anesthesia. Dosages: Hypotension SC/IM 2–5 mg,
may repeat every 10–15 min if needed, do not exceed initial dose; 
IV 50–100 mcg, may repeat every 10–15 min if needed, do not exceed
initial dose. SVT IV Bolus 0.5–1 mg given rapidly, not to exceed prior
dose by >0.1 mg, total dose 1 mg. Shock IV Infusion 10 mg/500 mL
D5W given 100–180 mcg/min, then maintenance of 40–60 mcg/min.
procainamide, Pronestyl: Antidysrhythmic. Uses: Life-threatening 
ventricular dysrhythmias. Dosages: Atrial Fibrillation/PAT PO 1–1.25 g;
may give another 750 mg if needed; if no response, 500 mg–1 g every
2 hr until desired response; maintenance 50 mg/kg in divided doses
every 6 hr. Ventricular Tachycardia PO 1g; maintenance 50 mg/kg/day
given in 3-hour intervals; SUS Release 500 mg–1.25 g every 6 hr.
Other Dysrhythmias IV Bolus 100 mg every 5 min, given 25–50
mg/min, not to exceed 500 mg; or 17 mg/kg total, then IV Infusion 2–6
mg/min.
propofol, Diprivan: General anesthetic. Uses: Induction or maintenance
of anesthesia as part of balanced anesthetic technique; sedation in
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mechanically ventilated patients. Dosages: Induction IV 2–2.5 mg/kg,
approximately 40 mg every 10 sec until induction onset. Maintenance
IV 0.1–0.2 mg/kg/min (6–12 mg/kg/hr). ICU sedation IV 5 mcg/kg/min
over 5 min; may give 5–10 mcg/kg/min over 5–10 min until desired
response.
rocuronium, Zemuron: Neuromuscular blocker (nondepolarizing). Uses:
Facilitation of endotracheal intubation, skeletal muscle relaxation 
during mechanical ventilation, surgery or general anesthesia.
Dosages: Intubation IV 0.6 mg/kg.
streptokinase, Streptase: Thrombolytic enzyme. Uses: Deep vein throm-
bosis, pulmonary embolism, arterial thrombosis, arteriovenous 
cannula occlusion, lysis of coronary artery thrombi after MI, acute
evolving transmural MI. Dosages: Lysis of coronary artery thrombi IC
20,000 units, then 2,000 international units/min over 1 hour as IV
Infusion. Arteriovenous cannula occlusion IV Infusion 250,000 
international units/2 mL solution into occluded limb of cannula run
over 1⁄2 hour; clamp for 2 hours, aspirate contents; flush with NaCl
solution and reconnect. Thrombosis/embolism/DVT/pulmonary
embolism IV Infusion 250,000 international units over 1⁄2 hour, then
100,000 international units/hr for 72 hr for deep vein thrombosis;
100,000 international units/hr over 24–72 hr for pulmonary embolism;
100,000 international units/hr for 24–72 hr for arterial thrombosis or
embolism. Acute evolving transmural MI IV Infusion 1,500,000 inter-
national units diluted to a volume of 45 mL; give within 1 hr; intra-
coronary Infusion 20,000 international units by Bolus, then 2,000 
international units/min for 1 hr, total dose 140,000 international units.
succinylcholine, Anectine: Neuromuscular blocker (depolarizing—
ultra short). Uses: Facilitation of endotracheal intubation, skeletal
muscle relaxation during orthopedic manipulations. Dosages: 
IV 0.6 mg/kg, then 2.5 mg/min as needed; IM 2.5 mg/kg, not to
exceed 150 mg.
tenecteplase, TNKase: Thrombolytic enzyme. Uses: acute myocardial
infarction. Dosages: Adults <60 kg: IV Bolus 30 mg, give over 5 sec.
Adult <70 kg: IV Bolus 35 mg, give over 5 sec, Adult ≥70–<80 kg:
IV Bolus 40 mg, give over 5 sec, Adult ≥80–<90 kg: IV Bolus 45 mg,
over 5 sec, Adult ≥90 kg: IV Bolus 50 mg, give over 5 sec.
tirofiban, Aggrastat: Antiplatelet. Uses: Acute coronary syndrome in
combination with heparin. Dosages: IV 0.4 mcg/kg/min x 30 min, then
0.1 mcg/kg/min for 12–24 hr after angioplasty or atherectomy.
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tubocurarine, Tubarine: Neuromuscular blockade. Uses: Facilitation of
endotracheal intubation, skeletal muscle relaxation during mechanical
ventilation, surgery or general anesthesia. Dosages: IV Bolus 0.4–0.5
mg/kg, then 0.8–0.10 mg/kg 20–45 min after 1st dose if needed for
long procedures.
urokinase, Abbokinase: Thrombolytic enzyme. Uses: Venous thrombosis,
pulmonary embolism, arterial thrombosis, arterial embolism, arterio-
venous cannula occlusion, lysis of coronary artery thrombi after MI.
Dosages: Lysis of pulmonary emboli IV 4,400 international units/kg/hr
for 12–24 hr, not to exceed 200 mL; then IV heparin, then anticoagu-
lants. Coronary artery thrombosis  Instill 6,000 international units/min
into occluded artery for 1–2 hr after giving IV Bolus of heparin
2,500–10,000 units. May also give as IV Infusion 2 million–3 million
units over 45–90 min. Venous catheter occlusion Instill 5,000 interna-
tional units into line, wait 5 min, then aspirate, repeat aspiration
attempts every 5 min for 1⁄2 hr; if occlusion has not been removed, cap
line and wait 1⁄2–1 hr, then aspirate; may need 2nd dose if still occluded.
vasopressin, Pitressin: Pituitary hormone, vasoconstrictor. Uses:
Diabetes insipidus (nonnephrogenic/nonpsychogenic), abdominal 
distention postoperatively, bleeding esophageal varices, sepsis.
Dosages: Diabetes insipidus IM/SC 5–10 units twice a day–four times
a day as needed; IM/SC 2.5–10 units every 2–3 days for chronic thera-
py. Abdominal distention IM 5 units, then every 3–4 hr, increasing 
to 10 units if needed. Sepsis IV Infusion 0.03 units/hr, may titrate up 
to 0.04 units/hr for BP. 
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. . . . . . . . . . . . . . . . . . . . . . increase
. . . . . . . . . . . . greatly increased
↓ . . . . . . . . . . . . . . . . . . . . decrease
↓↓ . . . . . . . . . . . . . greatly decreased
→ . . . . . . . . . . . . . . . leads to, causes
<. . . . . . . . . . . . . . . . . . . . . . . less than
≥. . . . . . . . . . . . less than or equal to
>. . . . . . . . . . . . . . . . . . . . greater than
≥ . . . . . . . . greater than or equal to
/ . . . . . . . . . . . . . per, or, divided by
% . . . . . . . . . . . . . . . . . . . . percent
(–). . . . . . . . . . . . . . . . . . . . negative
(+) . . . . . . . . . . . . . . . . . . . . positive
° . . . . . . . . . . . . . . . . . . . . . degrees
µ . . . . . . . . . . . . . . . . . . . . . . micro
AAA. . . . . . . . . . . abdominal aortic 
aneurysm
AAD. . . . . . . . antibiotic-associated 
diarrhea
Ab. . . . . . . . . . . . . . . . . . antibodies
ABG . . . . . . . . . . arterial blood gas
AChr . . . . . . acetylcholine receptor
ACS. . . . . . . . . . . . . acute coronary 
syndrome
ACTH . . . . . . . adrenocorticotropic 
hormone
ACV . . . . . . . . . . . assist controlled 
ventilation
ADH . . . . . . . antidiuretic hormone
AgNO3 . . . . silver nitrate aqueous 
solution
AIS. . . . . . . . acute ischemic stroke
A-line . . . . . . . . . . . . . . arterial line
AMI . . . . . . . . . . . acute myocardial 
infarction
aPTT . . . . . . . . . . . activated partial 
thromboplastin
time
ARDS. . . adult respiratory distress 
syndrome
AV. . . . . . . . . . . . . atrial-ventricular
BCP . . . . . . . . . . . birth control pills
BE . . . . . . . . . . . . . . . . base excess
BiPAP . . . . . bilevel positive airway 
pressure
BM . . . . . . . . . . . bowel movement
BMI . . . . . . . . . . . body mass index
BNP. . . . . . . . . . . B-type natriuretic 
peptide
BP . . . . . . . . . . . . . . blood pressure
bpm . . . . . . . . . . . breaths or beats 
per minute
BSA . . . . . . . . . . body surface area
BSI. . . . . . . . . . . . . bispectral index 
monitoring
BUN . . . . . . . . blood urea nitrogen
C . . . . . . . . . . . . Celsius or cervical 
spine
CAD . . . . . . . . . . . . coronary artery 
disease
CAM-ICU. . Confusion Assessment 
Method for the Inten-
sive Care Unit
CAP. . . . . . . . community acquired 
pneumonia
CAPP . . . . . . . . . . . coronary artery 
perfusion pres-
sure
CASS . . . continuous aspiration of 
subglottic secretions
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CAVH . . continuous arteriovenous 
hemofiltration
CBC . . . . . . . . . . . . complete blood 
count
C&DB . . . . . . . . . . cough and deep 
breathe
CDC. . . . . . . . . Centers for Disease 
Control
CEMRI. . . . . . . . contrast enhanced 
magnetic reso-
nance imaging
CHF . . . . . congestive heart failure
CHO . . . . . . . . . . . . . carbohydrates
CI . . . . . . . . . . . . . . . . cardiac index
CK . . . . . . . . . . . . . . creatine kinase
CK MB . . . . . . . . . . creatine kinase 
myocardial
band
CLRT . . . . . . . . . continuous lateral 
rotation therapy
cm . . . . . . . . . . . . . . . . centimeters
CMP . . . . . . . . complete metabolic 
panel
CMV . . . . . . controlled mechanical 
ventilation
CNS . . . . . . . . . . . . central nervous 
system
CO . . . . . . . cardiac output, carbon 
monoxide
CO2 . . . . . . . . . . . . carbon dioxide
COHgb . . . . . . carboxyhemoglobin
COPD. . . . . . . . chronic obstructive 
pulmonary disease
CPAP. . . . . . . . continuous positive 
airway pressure
CPIS . . . . . . . . . clinical pulmonary 
infection score
CPOT. . . . . . . . . . Critical Care Pain 
Observation Tool
CPP . . . . . . . . . . cerebral perfusion 
pressure
CPR . . . . . . . . . . cardio-pulmonary 
resuscitation
CSF. . . . . . . . . cerebral spinal fluid
CT . . . . computerized tomography
CVA . . . cerebral vascular accident
CVP . . . . . central venous pressure
CXR . . . . . . . . . . . . . . . . chest x-ray
DBP . . . . . diastolic blood pressure
DI . . . . . . . . . . . . diabetes insipidus
DIC . . . disseminated intravascular 
clotting
DKA . . . . . . . diabetic ketoacidosis
dL . . . . . . . . . . . . . . . . . . . . deciliter
DNI. . . . . . . . . . . . . do not intubate
DNR . . . . . . . . . . do not resuscitate
Do2 . . . . . . . . . . . . oxygen delivery
DTR . . . . . . . deep tendon reflexes
DVT . . . . . . . deep vein thrombosis
D/W . . . . . . . . . . dextrose in water
EBCT . . . . . . . . . . . . electron beam 
computed
tomography
ECG. . . . . . . . . . electrocardiogram
ECMO . . . . . . . . . . . extracorporeal 
membrane
oxygenator
ED. . . . . . . emergency department
EEG . . . . . . electroencephalogram
e.g. . . . . . . . . . . . . . . . for example
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ESR . . . erythrocyte sedimentation 
rate
ETCO2 . . . . . . . . . end-tidal carbon 
dioxide
ETOH . . . . . . . . . . . . . . . . . . alcohol
ETT . . . . . . . . . . endotracheal tube
F . . . . . . . . . . . . . . . . . . . Fahrenheit
FIO2 . . . . . . . . . fraction of inspired 
oxygen
E jFx or EF . . . . . . ejection fraction
FRC. . . . . . . . . . functional residual 
capacity
GCS . . . . . . . Glasgow Coma Scale
GI . . . . . . . . . . . . . . gastrointestinal
Gms. . . . . . . . . . . . . . . . . . . . grams
GU. . . . . . . . . . . . . . . genitourinary
HCO3 . . . . . . . . . . . bicarbonate ion
Hct . . . . . . . . . . . . . . . . . hematocrit
HCTZ . . . . . . . hydrochlorothiazide
HF . . . . . . . . . . . . . . . . heart failure
HFJV . . . . . . . . . high frequency jet 
ventilation
Hgb . . . . . . . . . . . . . . . hemoglobin
H2O. . . . . . . . . . . . . . . . . . . . . water
HOB . . . . . . . . . . . . . . . head of bed
HR . . . . . . . . . . . . . . . . . . heart rate
hr . . . . . . . . . . . . . . . . . . . . . hour(s)
HRT . . . . . . hormone replacement 
therapy
HTN . . . . . . . . . . . . . . hypertension
Hx . . . . . . . . . . . . . . . . . . . . . history
IAA . . . . intra-arterial angiography
IABP . . . intra-aortic balloon pump
ICD . . . . . implantable cardioverter 
defibrillator
ICP. . . . . . . . . intracranial pressure
ICU . . . . . . . . . . intensive care unit 
IMV. . . . . . intermittent mandatory 
ventilation
INR . . . . . international normalized 
ratio
IO . . . . . . . . . . . . . . . . intraosseous
IPP . . . . . . . . . . inspiratory plateau 
pressure
IRV . . . . . . inverse ratio ventilation
IV . . . . . . . . . . . . . . . . . intravenous
IVIG. . . . . . . . intravenous immune 
globulin
J . . . . . . . . . . . . . . . . . . . . . . . joules
JVD. . . . . . . . . . . . . jugular venous 
distention
K+ . . . . . . . . . . . . . . . . . . potassium
kg . . . . . . . . . . . . . . . . . . . kilogram
L. . . . . . . . . . . liter or lumbar spine
LAP . . . . . . . . . . left atrial pressure
LOC . . . . . . level of consciousness
LPGD. . . . low-profile gastrostomy 
device
LR . . . . . lactated Ringer’s solution
LV . . . . . . . . . . . . . . . . left ventricle
LVEDP . . . . . . . . . . . left ventricular 
end-diastolic
pressure
LVF. . . . . . . . . . . . . . left ventricular 
failure
LVSWI . . . . . left ventricular stroke 
work index
m . . . . . . . . . . . . . . . . . . . . . . meter
MAP. . . . . . mean arterial pressure
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mcg . . . . . . . . . . . . . . . . microgram
mEq . . . . . . . . . . . . milliequivalent
mg . . . . . . . . . . . . . . . . . . milligram
MI. . . . . . . . . myocardial infarction
min. . . . . . . . . . . . . . . . . . . . minute
mL . . . . . . . . . . . . . . . . . . . milliliter
mm . . . . . . . . . . . . . . . . . millimeter
mm Hg . . . . . . . . . . . millimeters of 
mercury
mmol . . . . . . . . . . . . . . . . millimole
MODS . . . . . . . . . . . multiple organ 
dysfunction
syndrome
MRA. . . . . . . . magnetic resonance 
angiography
MRI . . . . . . . . magnetic resonance 
imaging
MRSA . . . . . . . methicillin-resistant
staphylococcus
aureus
MS . . . . . . . . . . . . musculoskeletal
MVC . . . . . . . . motor vehicle crash
Na+ . . . . . . . . . . . . . . . . . . . sodium
NaCl . . . . . . . . . . . sodium chloride
NaHCO3 . . . . . sodium bicarbonate
NCV . . . . . . . . . . nerve conduction 
velocity
NDT. . . . . . . . . nasoduodenal tube
NGT . . . . . . . . . . . nasogastric tube
NJT . . . . . . . . . . . nasojejunal tube
nmol . . . . . . . . . . . . . . . . nanomole
NPO. . . . . . . . . . nothing by mouth
NTG . . . . . . . . . . . . . . nitroglycerin
N/V. . . . . . . . . . . . nausea/vomiting
O2. . . . . . . . . . . . . . . . . . . . . oxygen
OD . . . . . . . . . . . . . . . . . . overdose
PAC. . . . . . . . . . . . premature atrial 
contraction
PaCO2 . . . . . . . . partial pressure of 
carbon dioxide in
arterial blood
PAD. . . . . . . . . . . pulmonary artery 
diastolic pressure
PAH. . . . . . . . . . pulmonary arterial 
hypertension
PaO2 . . . . . . . . . partial pressure of 
oxygen in arterial
blood
PAO2 . . . . . . . . . partial pressure of 
alveolar oxygen
PAP . . . . . . . . . . . pulmonary artery 
pressure
PAPm. . . . . . . . . . mean pulmonary 
artery pressure
PAS. . . . . . . . . . . pulmonary artery 
systolic pressure
PASG . . . . . . pneumatic antishock 
garment
PbtO2 . . . . . . . . partial pressure of 
brain tissue 
oxygen
PCI . . . . . . percutaneous coronary 
intervention
PCO2 . . . . . . . . . partial pressure of 
carbon dioxide
PCWP. . . . . . . pulmonary capillary 
wedge pressure
PEA . . . . . . . . . pulseless electrical 
activity
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PEEP . . . . . positive end-expiratory 
pressure
PEG. . . . percutaneous endoscopic 
gastrostomy
PEJ . . . . percutaneous endoscopic 
jejunostomy
PET . . . . . . . . . . positron emission 
tomography
PFT . . . . pulmonary function tests
PETCO2 . . . . . . . partial pressure of 
carbon dioxide at
the end of expira-
tion
P/F ratio. . . . . . . . . . . . . . PaO2/FIO2
pH . . . . . . . . potential of hydrogen
po. . . . . . . . . . . . . by mouth, orally
PO2 . . . partial pressure of oxygen
PQRST. . . . . . palliative/provoking, 
quality, radiation,
severity, timing
prn . . . . . . . . . . . . . . . . . as needed
PSV . . . . . . . . . . . pressure support 
ventilation
PT/PTT . . . . . . . prothrombin time/
partial thrombo-
plastin time
PVC . . . . . . . premature ventricular 
contraction
PVR. . . . . . . . . pulmonary vascular 
resistance
PVRI . . . . . . . . pulmonary vascular 
resistance index
RA . . . . . . . . . . . . . . . . right atrium
RAP. . . . . . . . . right atrial pressure
RASS . . . . . . . Richmond Agitation 
Sedation Scale
REM . . . . . . . rapid eye movement
RBBB . . . . . . . right bundle branch 
block
RR . . . . . . . . . . . . . respiratory rate
RSWI . . . . . right ventricular stroke 
work index
rtPA . . . . . . . . . recombinant tissue 
plasminogen acti-
vator
RV . . . . . . . . . . . . . . . right ventricle
RVF . . . . . . right ventricular failure
SAH. . . subarachnoid hemorrhage
SaO2 . . . . . . . . . oxygen saturation
SAS . . . . Sedation Agitation Scale
SBP. . . . . . systolic blood pressure
SCI . . . . . . . . . . . spinal cord injury
ScvO2 . . . . central venous oxygen 
saturation
sec(s) . . . . . . . . . . . . . . . . second(s)
SGOT. . . . . . . . . . . serum glutamic 
oxaloacetic 
transaminase
SGPT . . . . serum glutamic pyruvic 
transaminase
SI . . . . . . . . . . . . . . . . . stroke index
SIADH. . . . . . . . syndrome of inap-
propriate anti-
diuretic hormone
SIMV . . . synchronous intermittent 
mandatory ventilation
SIRS . . . . . systemic inflammatory 
response syndrome
Symbols and Abbreviations—Cont’d
Continued
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Troubleshooting ECG Problems
■ Place leads in the correct position. Incorrect placement can give false
readings.
■ Avoid placing leads over bony areas.
■ In patients with large breasts, place the electrodes under the breast.
Accurate tracings are obtained through the least amount of fat tissue.
■ Apply tincture of benzoin to the electrode sites if the patient is
diaphoretic. The electrodes will adhere to the skin better. 
SjvO2 . . . . . . . . cerebral or jugular 
venous oxygen
saturation
SL . . . . . . . . . . . . . . . . . . sublingual
SNS . . . . . . . sympathetic nervous 
system
SOB. . . . . . . . . shortness of breath
SpO2 . . . . saturation of peripheral 
oxygen via pulse
oximetry
Stat . . . . . . . . . . . . . . . immediately
SV . . . . . . . . . . . . . . stroke volume
SvO2. . . . systemic venous oxygen 
saturation
SVR . . . . . . . . . . systemic vascular 
resistance
SVT. . . . . . . . . . . . supraventricular 
tachycardia
T . . . . . . . . . . . . . . . . thoracic spine
TBI. . . . . . . . traumatic brain injury
TBSA. . . . . total body surface area
TEE. . . . . . . . . . . . transesophageal 
echocardiogram
Temp . . . . . . . . . . . . . . temperature
TIA . . . . . transient ischemic attack
TnI . . . . . . . . . . . . . . . . . . troponin I
TPA . . . . . . . . . tissue plasminogen 
activator
TPN . . . . total parenteral nutrition
TSH . . . . . . . . . thyroid-stimulating 
hormone
UA . . . . . . . . . . . . . . . . . . urinalysis
UTI. . . . . . . . urinary tract infection
VAC . . . . vacuum-assisted closure
VAP . . . . . . . . ventilator-associated 
pneumonia
VAS . . . . . . . . Visual Analog Scale
VF . . . . . . . . ventricular fibrillation
VO2. . . . . . . . oxygen consumption
vol . . . . . . . . . . . . . . . . . . . . volume
V/Q . . . . . . . . ventilation:perfusion
VS . . . . . . . . . . . . . . . . . . vital signs
VT . . . . . . . ventricular tachycardia
V–V. . . . . . . . . . . . . venous-venous
WBC . . . . . . white blood cell count
Symbols and Abbreviations—Cont’d
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■ Shave hair at the electrode site if it interferes with contact between
the electrode and skin.
■ Discard old electrodes and use new ones if the gel on the back of the
electrode dries.
Cable Connections
It is important to know if you are using an American or European cable for
ECG monitoring. The colors of the wires differ as shown below.
Patient Cable
Monitoring cables contain varying numbers of wires.
■ 3- and 4-wire cables: Allow a choice of limb and augmented leads.
■ 5-wire cable: Allows a choice of limb and augmented leads plus a
chest lead.
■ 10-wire cable: Records a 12-lead ECG.
Monitoring Cable Connections
USA Connect To Europe
White Right arm Red
Black Left arm Yellow
Red Left leg Green
Green Right leg Black
Brown Chest White
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Patient ECG Record
Patient name:
Sex F M
Heart rate: __________ bpm
• Normal (60–100 bpm) Y N
• Bradycardia (<60 bpm) Y N
• Tachycardia (>100 bpm) Y N
Rhythm
• Regular Y N
• Irregular Y N
• P waves Y N
P Waves (form)
• Normal (upright and uniform) Y N
• Inverted Y N
P wave associated with QRS Y N
PR interval normal (0.12–0.20 sec) Y N
P waves and QRS complexes associated with one another Y N
QRS Interval
• Normal (0.6–0.10 sec) Y N
• Wide (>0.10 sec) Y N
Are the QRS complex grouped or not grouped?
Are there any dropped beats?
Is there a compensatory or noncompensatory pause?
QT interval: 
Interpretation: 
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Frequently Used Phone Numbers
Overhead Code: 99/Blue:
Security: Emergency ext:
Admitting:
Blood Bank:
Burn Unit:
CICU (CCU):
Chaplain-Pastor:
Computer Help (IS, IT):
CT (Computed Tomography): 
Dietary—Dietician:
ECG—12 Lead:
ICU:
Interpreter Services:
Laboratory:
Maintenance—Engineering:
Med-Surg:
MRI (Magnetic Resonance Imaging):
Nutrition—Food Services:
OT (Occupational Therapy): 
PACU (Recovery):
Pediatrics:
Pharmacy (Rx):
Poison Control: USA – 1-800-222-1222
PT (Physical Therapy):
Respiratory (RT):
Social Services:
Speech Language Pathology (SLP):
Supervisor—Manager:
Surgery—Inpatient (OR):
Continued
20841_Tab11_210-226.qxd  1/15/09  6:28 PM  Page 218
219
TOOLS
Community Resources
Surgery—Day/Outpatient:
Telemetry Unit:
X-ray:
Abuse/Assault—Physical/Sexual
■ Children
■ Women
■ Rape/Sexual
■ Men
■ Elderly
Abuse—Substance
■ Alcohol
■ Drug
Communicable Disease Programs
■ AIDS
■ Hepatitis
■ TB
Food/Clothing
■ Food Kitchen
■ Meals on Wheels
■ Salvation Army
Shelters/Homeless
Mental Health
■ Suicide
Continued
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Basic English-to-Spanish Translation
Medical/Hospitals
■ State Program
■ Dept. of Health
■ Free Clinics
Teen/Children
■ Immunization
■ Pregnancy
■ Runaway
Other
English Phrase Pronunciation Spanish Phrase
Introductions—Greetings
Hello oh-lah Hola
Good morning bweh-nohs dee-ahs Buenos días
Good afternoon bweh-nohs tahr-dehs Buenos tardes
Good evening bweh-nahs noh-chehs Buenas noches
My name is meh yah-moh Me llamo
I am a nurse soy lah oon en-fehr-meh-ra Soy la enfermera
What is your name? koh-moh seh yah-mah ¿ Cómo se llama 
oo-sted? usted?
Continued
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English Phrase Pronunciation Spanish Phrase
How are you? koh-moh eh-stah ¿Como esta usted?
oo-stehd?
Very well mwee b’ yehn Muy bien
Thank you grah-s’yahs Gracias
Yes, No see, noh Sí, No
Please pohr fah-vohr Por favor
You’re welcome deh nah-dah De nada
Assessment—Areas of the Body
Head kah-beh-sah Cabeza
Eye oh-hoh Ojo
Ear oh-ee-doh Oído
Nose nah-reez Nariz
Throat gahr-gahn-tah Garganta
Neck kweh-yoh Cuello
Chest, Heart peh-choh, kah-rah-sohn Pecho, corazón
Back eh-spahl-dah Espalda
Abdomen ahb-doh-mehn Abdomen
Stomach eh-stoh-mah-goh Estómago
Rectum rehk-toh Recto
Penis peh-neh Pene
Vagina vah-hee-nah Vagina
Arm, Hand brah-soh, mah-noh Brazo, Mano
Leg, Foot p’yehr-nah, p’yeh Pierna, Pie
Assessment—History
Do you have… T’yeh-neh oo-stehd… ¿Tiene usted…
■ Difficulty di-fi-kul-thad ¿Dificultad para 
breathing? par-rehspee-rahr respirar?
■ Chest pain? doh-lorh en el ¿Dolor en el 
peh-chow pecho?
■ Abdominal pain? doh-lorh ¿Dolor abdominal?
ab-doh-mee-nahl
■ Diabetes? dee-ah-beh-tehs ¿Diabetes?
Are you… ehs-tah ¿Esta…
Continued
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English Phrase Pronunciation Spanish Phrase
■ Dizzy? mar-eh-a-dho(dha) ¿Mareado(a)?
■ Nauseated? kahn now-say-as ¿Con nauseas?
■ Pregnant? ¿ehm-bah-rah-sah-dah? ¿Embarazada?
Are you allergic ¿ehs ah-lehr-hee-koh ah ¿Es alergico a 
to any medications? ahl-goo-nah meh-dee- alguna medicina?
see-nah?
Assessment—Pain
Do you have pain? T’yeh-neh oo-stehd ¿Tiene usted 
doh-lorh? dolor?
Where does it hurt? dohn-deh leh dweh-leh? ¿Donde le duele?
Is the pain… es oon doh-lor… ¿Es un dolor…
■ Dull? Leh-veh ¿Leve?
■ Aching? kans-tan-teh ¿constante?
■ Crushing? ah-plahs-than-teh? ¿Aplastante?
■ Sharp? ah-goo-doh? ¿Agudo?
■ Stabbing? ah-poo-nya-lawn-teh ¿Apuñalante?
■ Burning? Ahr-d’yen-the? ¿Ardiente?
Does it hurt when Leh dweh-leh ¿Le duele cuando 
I press here? kwahn-doh le aprieto aqui?
ah-pree-eh-toh ah-kee?
Does it hurt to S’yen-teh oo-sted ¿Siente usted dolor 
breathe deeply? doh-lor kwahn-doh cuando respira 
reh-spee-rah profundamente?
pro-foon-dah-men-teh?
Does it move to Lh doh-lor zeh ¿El dolor se mueve
another area? moo-eh-veh a a otra area?
oh-tra ah-ri-ah
Is the pain better S’yen tey al-goo-nah ¿Siente alguna 
now? me-horr-ee-ah mejoria?
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Communication with a Non-Verbal Patient
Pain 1 2 3 4 5 6 7 8 9 10
Yes No Thank You
Cold Hot Sick
Thirsty Hungry
Please Bring: Empty:
■ Blanket ■ Bed Pan
■ Eyeglasses ■ Urinal
■ Dentures ■ Trash
■ Hearing Aids Raise – Lower: 
■ Head
■ Legs
Oral 
Care Bath Shower
TV Lights On Off
Web Resources for Evidence-Based Practices in
Critical Care
Agency for Healthcare Research & Quality . . . . . . . . . . . . . www.ahrq.gov
Algorithms for the Medical ICU . . . . . . . . . . . www.clevelandclinicmeded.
com/micu
American Association of Critical-Care Nurses . . . . . . . . . . www.aacn.org
American College of Cardiology . . . . . . . . . . . . . . . . . . . . . . www.acc.org
American Heart Association . . . . . . . . . . . . . . . . www.americanheart.org
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American Thoracic Society . . . . . . . . . . . . . . . . . . . . . . . www.thoracic.org
Brain Dysfunction in 
Critically Ill Patients . . . . . . . . . . . . http://www.icudelirium.org/delirium/
Centers for Disease Control & Prevention . . . . . . . . . . . . . . www.cdc.gov
Emergency Nurses Association . . . . . . . . . . . . . . . . . . . . . . . www.ena.org
Healthcare Freeware (2005) . . . . . . www.healthcarefreeware.com/icu.htm
Institute for Healthcare Improvement 
Critical Care. . . . . . . . . . . . . . . . . . . . www.ihi.org/IHI/Topics/CriticalCare/
Internet Stroke Center . . . . . . . . . . . . . . . . . . . . . . . . www.strokecenter.org
Medscape . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . www.medscape.com
National Guideline Clearinghouse . . . . . . . . . . . . . . . www.guideline.gov
National Heart Lung & Blood Institute . . . . . . . . . . . . . www.nhlbi.nih.gov
National Spinal Cord Injury Association . . . . . . . . . . . www.spinalcord.org
Sedation, Analgesia, and Neuromuscular 
Blockade in the ICU . . . . . . . . . . . . . . . www.mc.vanderbilt.edu/surgery/
trauma/Protocols/SedationAnal-
gesiaGuidelines.pdf
Surviving Sepsis Campaign . . . . . . www.survivingsepsis.org/implement/
bundles
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A
Abbreviations and symbols list, 
210-215
Abdominal aortic aneurysm, 44-46
Abdominal trauma, 191
Absolute shunt, 83
Acid-base imbalances, 2-3
Acidosis, 2-4
ACLS cardiac/respiratory arrest 
algorithms, 62
Acute coronary syndrome, 37-41
Acute gastrointestinal bleeding, 
137-139
Acute lymphocytic leukemia, 173
Acute myeloid leukemia, 172
Acute myocardial infarction, 40-41
Acute renal failure, 101-103
Adenosine, 203
Adrenal crisis, 179-180
Adult respiratory distress syndrome,
81-83
Agitation, 32-36
Alkalosis, 2-3
Alteplase, 203
Amiodarone, 203
Analgesic withdrawal, 33-34
Anatomic shunt, 83
Angina, 38-39
Antianxiety medications, 33, 36
Anxiety response, 33
Aortic aneurysm, 44-46
Aortic dissection, 46-47
Aortic pressure, 13
Aortic valve replacement, 52-53
Argatroban, 203
Arterial blood gas values, 2
Artificial airways, 6
Assist controlled ventilation, 7
Asystole, 62
Atracurium, 203
Atrial dysrhythmias, 66, 72-73
Atrial fibrillation, 73
Atrial flutter, 72
Atrioventricular block, 77-80
Atropine, 203-204
Automatic implantable cardioverter
device, 60
Autonomic dysreflexia, 126-127
AV block, 77-80
B
Bacterial endocarditis, 57-58
Bacterial meningitis, 132-133
Bariatric surgery, 155-157
Bilevel positive airway pressure, 7-9
Bispectral index monitoring, 35
Blood gas values, 2-3
Blood transfusion-related coagu-
lopathy, 165-166
Blunt trauma, 191
Body mass index, 20-21, 155
Bone marrow transplantation, 
174-175
Brain death criteria, 31-32
Brain injury, 116-118, 191
Brain monitoring, 116
Burns, 195-202
C
Cancer-related emergencies, 166-172
Capnography, 4-5
Carbon monoxide poisoning, 95-97
Cardiac arrest, 62
Cardiac dysrhythmias, 66-68, 71-80.
See also specific dysrhythmias
Cardiac infections, 57-59
227
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Cardiac output, 14-15
Cardiac surgeries, 49-56
Cardiac tamponade, 60-62
Cardiac transplant, 54-55
Cardiac valve replacement, 52-53
Cardiogenic shock, 184
Carotid endarterectomy, 56
CDC infection prevention guidelines,
28
Cerebral perfusion pressure, 111
Cerebral vascular accident, 120-124
Chest tubes, 98-100
Chronic lymphocytic leukemia, 173
Chronic myeloid leukemia, 173
Chronic renal failure, 103-107
Cirrhosis, 142-145, 164-165
Clostridium difficile, 27-28
Coagulopathy, 163-166
Colitis, 150-153
Coma scale, 114
Community resource form, 219-220
Community-acquired pneumonia,
87-88
Complete heart block, 80
Congestive heart failure, 42-44
Continuous positive airway pressure,
7-9
Continuous renal replacement thera-
py, 105-106
Controlled mechanical ventilation, 7
Coronary artery bypass graft, 49-50
Coronary artery stenting, 50-51
Coronary heart disease, 37-41
Cosyntropin, 204
Critical care medication list, 203-209
Crohn’s disease, 150-151
Cystectomy, 109-110
D
Decerebrate and decorticate 
positions, 112
Delirium, 32-36
Dexmedetomidine, 204
Diabetes insipidus, 177-179
Diabetic ketoacidosis, 176-177
Diltiazem, 204
Disseminated intravascular coagula-
tion, 159-160
Distributive shock, 184
Dobutamine, 204
Dopamine, 204
Drotrecogin alfa, 204
Dysrhythmias, 66-67, 71-80. See also
specific dysrhythmias
E
ECGs, 65-80, 225-227
analysis of, 68-70
cable connections in, 216
dysrhythmic, 71-80
lead placement in, 65
normal, 69-70
patient record of, 217
problems in, 215-216
Endocarditis, 57-58
Endotracheal tube, 6
English-Spanish translation aid, 220-
222
Enteral tube feedings, 22-24
Epinephrine, 204
Eptifibatide, 204-205
Esmolol, 205
Esophageal varices, 139-142
Esophagectomy, 157
Etomidate, 205
Evidence-based practice Web
resources, 223-224
F
Family needs, 30
Fenoldopam, 205
Fentanyl, 205
INDEX
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First-degree AV block, 77
Fluid volume deficit and excess, 
21-22
G
Gastric banding, 156
Gastrointestinal bleeding, 137-139
Gastrointestinal surgery, 157-158
Glasgow Coma Scale, 114
Guillain-Barré syndrome, 130-131
H
Heart failure, 42-44
Heart infections, 57-59
Heart surgeries, 49-56
Heart transplant, 54-55
Heart valve replacement, 52-53
Hemodialysis, 103-105
Hemodynamic monitoring, 13-20
Hemodynamic parameters, 13-15
Hemorrhagic stroke, 118-120
Heparin-induced thrombocytopenia,
161-162
Hepatic failure, 142-145
Hetastarch, 205
Hospital-acquired pneumonia risk
index, 86-87
Hypercalcemia, 169
Hypertensive crisis, 41-42
Hyperthyroidism, 180-182
Hypervolemia, 21-22
Hypothermia, 194
Hypovolemia, 21
Hypovolemic shock, 184
I
Increased intracranial pressure, 
111-116
Induced hypothermia, 194
Infectious diseases, 26-28
cardiac, 57-59
meningitis as, 132-133
pneumonia as, 84-88
sepsis as, 166-167, 187-190
Inflammatory bowel disease, 
150-153
Intermittent mandatory ventilation,
7-8
Internet evidence-based practice
resources, 223-224
Intra-aortic balloon pump, 62-64
Intra-arterial monitoring, 18-20
Intracranial pressure monitoring,
114-115
Inverse ratio ventilation, 8
Ischemic stroke, 120-124
Isoproterenol, 205
K
Ketoacidosis, 176-177
Kidney failure, 101-107
Kidney transplant, 106-107
L
Labetalol, 2-6
Lactic acidosis, 4
Leukemia, 172-173
Lidocaine, 206
Liver disease-related coagulopathy,
164-165
Liver failure, 142-145
Lymphocytic leukemia, 173
M
Mechanical ventilation, 6-13
Medication list, 203-209
Meningitis, 132-133
Metabolic acidosis, 2-3
Metabolic alkalosis, 2-3
Methicillin-resistant Staphylococcus
aureus, 27
Midazolam, 206
229
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Milrinone, 206
Mitral valve replacement, 52-53
Mobitz AV block, 78-79
Morbid obesity, 155-157
Multiple organ dysfunction syn-
drome, 190-191
Musculoskeletal trauma, 192
Myasthenia gravis, 128-130
Myeloid leukemia, 172-173
Myocardial infarction, 40-41
N
Naloxone, 206
Near-death experience, 29
Negative pressure ventilation, 7
Nephrectomy, 107-108
Nesiritide, 207
Neurogenic shock, 128
Neutropenia, 162-163
Nitroprusside, 207
Nonverbal patient communication, 223
Norepinephrine, 207
Normal blood gas values, 2
Nutrition, 20-26
O
Obesity, 155-157
Oncologic emergencies, 166-172
Organ donation, 30-32
Out-of-body experience, 30
P
Pacemakers, 59-60
Pain medications, 33-34
Pain response, 33
Pain visual analog scale, 35
Pancreatitis, 146-148
Pancuronium, 207
Penetrating trauma, 191
Percutaneous coronary intervention,
50-51
Percutaneous transjugular portosys-
temic shunt, 158
Pericardial effusion, 48-49
Pericarditis, 58-59
Peritonitis, 148-150
Phenylephrine, 207
Phone number form, 218-219
Physical assessment form, 1
Physiologic shunt, 83
Pneumonia, 84-88
Pneumothorax, 88-90
Portal hypertension, 158
Positive end-expiratory pressure, 7
Positive pressure ventilation, 6-7
Premature ventricular contractions,
74
Pressure support ventilation, 7-8
Procainamide, 207
Propofol, 207-208
Psychosocial issues, 29-32
Pulmonary arterial hypertension, 
91-93
Pulmonary artery catheter, 15-18
Pulmonary artery pressure, 14
Pulmonary edema, 90-91
Pulmonary embolism, 93-95
Pulse oximetry, 4
Pulseless electrical activity, 62
Pulseless ventricular tachycardia, 62
R
Renal failure, 101-107
Renal replacement therapy, 103-106
Renal transplant, 106-107
Residuals monitoring, 24
Respiratory acidosis, 2-3
Respiratory alkalosis, 2-3
Respiratory arrest, 62
Right ventricular pressure, 14
Rocuronium, 208
Rule of nines, 198
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Second-degree AV block, 78-79
Sedation, 32-36
Sedation assessment scales, 34-35
Sedative medications, 33-34, 36
Sedative withdrawal, 33-34
Seizure disorder, 134-136
Sensory overload and deprivation, 29
Sepsis, 166-167, 187-190
Shock, 128, 184-186
Shunting, 83-84
Small bowel obstruction, 153-155
Spanish phrases, 220-222
Spinal cord compression, 168
Spinal cord injury, 124-126
Spontaneous pneumothorax, 88
Status epilepticus, 134
Streptokinase, 208
Stress and nutrition, 20
Stroke, 118-124
Subarachnoid hemorrhage, 118-120
Succinylcholine, 208
Superior vena cava syndrome, 170
Supraventricular tachycardia, 71
Symbols and abbreviations list, 
210-215
Synchronized intermittent manda-
tory ventilation, 7-8
Syndrome of inappropriate antidi-
uretic hormone, 167-168, 182-183
Systemic inflammatory response
syndrome, 190
T
Tachycardia, 67-68, 71, 75
Telephone number form, 218-219
Tenecteplase, 208
Tension pneumothorax, 89
Therapeutic hypothermia, 194
Third-degree AV block, 80
Thoracic procedures, 97-100
Thoracic trauma, 191
Thrombocytopenia, 161-162
Thyroid storm, 180-182
Tirofiban, 208
Total body surface area calculation,
198
Total parenteral nutrition, 24-26
Tracheostomy tube, 6
Transfusion-related coagulopathy,
165-166
Trauma, 191-194
Traumatic brain injury, 116-118, 191
Traumatic pneumothorax, 88-89
Tube feedings, 22-24
Tubocurarine, 209
Tumor lysis syndrome, 171-172
U
Ulcerative colitis, 151-153
Unstable angina, 38-39
Urokinase, 209
V
Vasopressin, 209
Venous blood gas values, 2
Ventilators, 6-13
alarms in, 9-10
classification of, 6-7
complications of, 10-13
modes of, 7-8
pneumonia related to, 84-85
weaning from, 8-9
Ventricular dysrhythmias, 62, 66-67,
74-76
Ventricular fibrillation, 62, 76
Ventricular tachycardia, 75
Vitamin K deficiency, 163-164
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W
Weaning from ventilator, 8-9
Web evidence-based practice
resources, 223-224
Wenckebach phenomenon, 78
Whipple procedure, 157
Wound care in burns, 200-201
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